Interactions between iron and fat in non-alcoholic fatty liver disease by Britton, Laurence
1 
 
 
 
 
 
 
 
Interactions between iron and fat in                                                                   
non-alcoholic fatty liver disease 
Laurence James Britton 
MBChB FRACP 
 
 
 
 
 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2018 
Faculty of Medicine 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Thesis Abstract 
 
Non-alcoholic fatty disease (NAFLD) is estimated to affect approximately one billion 
people worldwide. However, the pathogenesis of this common disease is not well 
understood. This has hampered the development of effective treatments that might 
prevent complications such as liver failure, liver cancer and cardiac disease. Iron and 
mutations of the haemochromatosis gene (HFE) have long been considered to have 
pathogenic roles in the development of NAFLD although their significance and 
mechanisms of effect remain controversial. Recent data indicate a role for modest 
increases in iron in the generation of insulin resistance and adipose tissue dysfunction, 
both hallmark features of NAFLD.  
Modest increases in iron have been shown to occur with heterozygous HFE gene 
mutations. Due to their high prevalence, heterozygous HFE gene mutations are frequently 
observed in individuals with co-existent NAFLD and such mutations have been 
hypothesised to have a co-toxic role in NAFLD pathogenesis. Homozygous deletion of Hfe 
has been shown to lead to dysregulated lipid metabolism and liver injury in a mouse model 
of NAFLD. Chapter 3 describes a model of heterozygous deletion of the Hfe gene in mice 
fed a high calorie diet. This led to impaired homeostasis of both iron and glucose, although 
there were no alterations in hepatic lipid metabolism or liver injury. 
Chapter 4 seeks to further examine the links between iron and insulin resistance. Hepatic 
iron concentration (HIC) was measured using MR Ferriscan and serum concentrations of 
six adipokines were determined using a multiplex ELISA array from a cohort of 60 adults 
with NAFLD. After patients were randomised to six months of venesection and dietary 
advice (n=23) versus dietary advice alone (n=28), no differences were seen between 
groups in change in serum concentrations of adiponectin, leptin, resistin, retinol binding 
protein-4 (RBP-4), tumour necrosis factor alpha (TNFα) and interleukin-6 (IL-6). However, 
unexpectedly, a significant positive correlation between baseline HIC and serum 
adiponectin was found. This strengthened further after correction for age, gender and body 
mass index (rho=0.36, p=0.007). Furthermore, significant inverse correlations were 
identified between HIC and six surrogate measures of insulin resistance; Adipo-IR, serum 
insulin, serum glucose, HOMA-IR, HbA1C and hepatic steatosis. A positive correlation was 
noted between HIC and insulin sensitivity index. These data indicate that HIC positively 
correlates with serum adiponectin concentration and insulin sensitivity in patients with 
NAFLD, although at present, causality cannot be established. 
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Adipose tissue dysfunction secondary to iron has been increasingly implicated in NAFLD 
pathogenesis. The remainder of the thesis focuses on adipose tissue iron homeostasis 
and its effects on adipose tissue biology. A model of adipocyte-specific ferroportin (Fpn1) 
knockout (FKO) was developed in order to selectively load in into adipocytes. This 
involved an Adipoq-Cre recombinase driven floxed deletion of Fpn1 in adipocytes (Chapter 
5). This model demonstrated successful selective deletion of Fpn1, however this did not 
result in increased adipocyte iron stores. Similarly, FKO mice did not demonstrate 
evidence of adipokine dysregulation, or altered insulin sensitivity in hyperinsulinaemic-
euglycaemic clamp studies. Likewise, there was no effect of adipocyte-specific ferroportin 
deletion on liver injury. This study has demonstrated that ferroportin is not a key 
determinant of adipocyte iron homeostasis in this model. Further studies are required in 
order to establish the key factors that regulate adipocyte iron homeostasis in animal 
models and humans. 
Finally, to test the hypothesis that iron modulates adipokine release, an in vitro model of 
adipocyte iron loading using differentiated Simpson-Golabi-Behmel Syndrome (SGBS) 
pre-adipocytes was developed (Chapter 6). Using a proteomic approach of stable isotope 
labelled amino acids in cell culture (SILAC), the effects of iron on the human adipocyte 
secretome were examined. This identified 60 proteins with a greater than two-fold change 
in secretome concentration and p<0.05 with iron treatment. Of these, it was found that 
secreted apolipoprotein E (ApoE) was reduced by 58% (p=0.001) and 76% (p=0.007) by 
SILAC and western blot respectively. Intracellular ApoE levels were increased more than 
11-fold (p=0.0005) with iron treatment. These findings suggest that secretion of ApoE from 
adipocytes is inhibited by iron. This may be highly relevant with regard to NAFLD 
pathogenesis given the observation that ApoE knockout leads to steatohepatitis in mice 
fed a Western diet. Moreover, the broad range of proteins with differential secretion 
secondary to iron provides a platform for multiple future studies. 
In conclusion, this thesis describes a number of novel links between iron, insulin sensitivity 
and adipokine regulation relevant to NAFLD pathogenesis. In particular, impaired glucose 
homeostasis in a mouse model of heterozygous Hfe deletion was observed. Notably 
consistent links between HIC and multiple measures of insulin sensitivity were seen in a 
human cohort of patients with NAFLD. Finally the effect of iron on the human adipocyte 
secretome was examined, identifying profound inhibition of ApoE secretion by iron. These 
findings may offer opportunities for the development of effective new therapies for the 
treatment of NAFLD. 
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Chapter 1 : Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) has emerged as a major 21st century public 
health problem, affecting around one billion people globally.[1] NAFLD increases the risk 
of death from liver failure, liver cancer and cardiac disease.[2] The epidemic of obesity and 
unhealthy lifestyles are undoubtedly major contributors to disease pathogenesis. However, 
a detailed understanding of the mechanisms leading to liver injury is lacking.[3, 4] A 
greater understanding of the pathogenesis of NAFLD will be hugely important in order to 
identify effective treatments for this disease. 
Although iron is an essential micronutrient, it is toxic in excess, such as seen in iron 
overload conditions such as hereditary haemochromatosis (HH).[5] It has been shown that 
the added insult of NAFLD in HH leads to a greater degree of liver injury.[6] However, the 
extent of adverse effects of lesser degrees of iron loading on NAFLD pathogenesis and 
disease progression are less certain. Iron has long been proposed as a co-factor in 
NAFLD pathogenesis, although a detailed understanding of the interactions between iron 
and NAFLD have remained elusive.[7, 8] Two particularly relevant aspects of the role of 
iron in NAFLD pathogenesis relate to the contribution of heterozygous HFE gene 
mutations and the emerging role of iron in the regulation of adipose tissue function.[7, 9] 
In this thesis, the effects on NAFLD pathogenesis of dysregulated iron homeostasis in 
several tissues is examined. This includes the role of dysregulated gut absorption of iron 
due to HFE and hepcidin deficiency. In addition, the relationships between hepatic iron 
and insulin resistance are studied. Finally, the effects of adipocyte iron on adipose tissue 
function are addressed in detail and form the major focus of the latter part of this thesis. 
Generally throughout this thesis, the term NAFLD is used rather than non-alcoholic 
steatohepatitis (NASH), despite steatohepatitis being the more significant lesion on liver 
histology. There are two reasons for this choice of term. Firstly, it is increasingly 
recognised that many of the insults previously referred to as “second hits” in Day and 
James’ two-hit hypothesis [10] have since been shown to drive steatosis itself, leading us 
to consider NAFLD as a disease of multiple concurrent and additive “hits”. [11] Secondly, 
much of the proposed effect of iron on NAFLD and NASH pathogenesis relates to insulin 
resistance, a near universal observation across the spectrum of NAFLD. [12] 
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Chapter 2 reports on a review of the literature regarding links between iron and NAFLD in 
humans as well as the proposed mechanisms of co-toxicity of iron and fat determined from 
animal and tissue culture models. 
One such mechanism of iron’s involvement in NAFLD pathogenesis relates to mutations in 
the HFE gene. Heterozygous p.C282Y mutations of the HFE gene are found in 
approximately 11% of Caucasian populations and are associated with increased iron 
stores.[13] Such mutations are very commonly seen in individuals with NAFLD and a role 
for these mutations in NAFLD pathogenesis has been postulated.[14] Previously it has 
been shown that homozygous deletion of Hfe in mice fed a high calorie diet leads to 
dysregulated hepatic lipid metabolism, steatohepatitis and early fibrosis, compared to 
simple steatosis alone in wild-type controls fed the same diet.[15] Chapter 3 examines a 
mouse model of Hfe heterozygous knockout fed a high calorie diet.  Effects on iron, 
glucose and lipid metabolism as well as liver injury are assessed. 
Continuing on the theme regarding the impact of modest alterations of iron homeostasis, 
Chapter 4 explores the relationships between iron and NAFLD in a cohort of human 
participants with NAFLD. This study focuses on the relationship between iron and multiple 
measures of insulin resistance, a hallmark feature of NAFLD.[2] In addition the 
relationships between hepatic iron concentration and polypeptides that undergo regulated 
secretion from adipose tissue, termed adipokines, are explored. Many adipokines have 
been shown to have significant roles in promoting insulin resistance and liver injury in 
NAFLD. [16] Serum concentrations of six such adipokines with established roles in NAFLD 
pathogenesis, namely adiponectin, leptin, resistin, retinol binding protein-4 (RBP-4), 
tumour necrosis factor-alpha (TNFα) and interleukin-6 (IL-6) are studied.[16] Adiponectin, 
leptin, resistin and RBP-4 have all been proposed to be regulated by iron, although 
substantial human data is lacking.[17-20]   
Chapters 5 and 6 continue to focus on adipose tissue as a site of iron-related 
dysregulation in NAFLD pathogenesis. It is increasingly recognised that adipose tissue 
function has an important role in metabolic health and also the pathogenesis of insulin 
resistance and NAFLD.[21] Recently it has been shown that adipocytes utilise much of the 
same iron handling apparatus as other cells such as hepcidin and transferrin receptor.[22, 
23] It has become increasingly recognised that adipose tissue rather than the liver itself, 
may be the key site at which iron mediates liver injury in NAFLD.[7] Indeed it has recently 
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been shown that mice fed a high fat diet undergo a repartitioning of iron from the liver to 
adipocytes, with a four-fold increase in adipocyte iron concentration.[24] 
In order to scrutinise the relationships between iron and adipose tissue function, in vivo 
(Chapter 5) and in vitro (Chapter 6) models of adipocyte iron overload were developed. 
Chapter 5 examines the effects of adipocyte specific deletion of the iron-exporter, 
ferroportin, using a Cre-lox mouse model (Adipoq-Cre:Fpn1fl/fl) in the setting of a dietary 
model of NASH (the fast food diet model[25]). Adipocyte specific deletion of ferroportin has 
been proposed as a method of generating adipocyte specific iron loading in mouse 
models.[17, 18] However the iron loading phenotype has not been well described and the 
hepatic effects are unknown. Also, models previously used have relied on an adipocyte 
protein-2 (AP2) Cre. AP2 has been shown to be expressed in other cell types, in particular 
macrophages and as such, the AP2-Cre: Fpn1fl/fl model may be regarded as insufficiently 
specific for its purpose.[26] Therefore, the more adipocyte specific Adipoq-Cre,[27] in 
which a bacterial artificial chromosome with a Cre recombinase in the promoter region of 
the adiponectin gene (Adipoq) is employed.  
In Chapter 6, differentiated human pre-adipocytes, Simpson-Golabi-Behmel Syndrome 
(SGBS) cells, are exposed to increased concentrations of iron. A proteomic approach is 
employed to describe the differential secretion of adipokines in response to iron. The 
technique of stable isotope labelled amino acids in cell culture (SILAC) has enabled a 
detailed characterisation of the human adipocyte secretome and the effects of iron upon it. 
This serves as broad platform for multiple funding studies investigating iron-related 
adipocyte dysfunction. 
In Chapter 7, a summary of the major findings from the thesis is made. The potential 
implications of these findings and future directions for research in this field are discussed 
in detail.  
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Chapter 2 : Iron and non-alcoholic fatty liver disease (Literature Review) 
 
In this literature review, the relationships between iron and NAFLD, based on data from 
tissue culture, animal models and human studies are explored. 
 
This review is published in the World Journal of Gastroenterology. 
 
Britton LJ, Subramaniam VN, Crawford DHG 
Iron and non-alcoholic fatty liver disease 
World J Gastroeneterol. 22(36): 8112-22, Sep 2016 
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Abstract 
 
The mechanisms that promote liver injury in non-alcoholic fatty liver disease (NAFLD) are 
yet to be thoroughly elucidated. As such, effective treatment strategies are lacking and 
novel therapeutic targets are required. Iron has been widely implicated in the pathogenesis 
of NAFLD and represents a potential target for treatment. Relationships between serum 
ferritin concentration and NAFLD are noted in a majority of studies, although serum ferritin 
is an imprecise measure of iron loading. Numerous mechanisms for a pathogenic role of 
hepatic iron in NAFLD have been demonstrated in animal and cell culture models. 
However, the human data linking hepatic iron to liver injury in NAFLD is less clear, with 
seemingly conflicting evidence, supporting either an effect of iron in hepatocytes or within 
reticulo-endothelial cells. Adipose tissue has emerged as a key site at which iron may 
have a pathogenic role in NAFLD. Evidence for this comes indirectly from studies that 
have evaluated the role of adipose tissue iron with respect to insulin resistance. Adding 
further complexity, multiple strands of evidence support an effect of NAFLD itself on iron 
metabolism. In this review, we summarize the human and basic science data that has 
evaluated the role of iron in NAFLD pathogenesis. 
Introduction 
 
The worldwide epidemic of obesity has led to a disturbing rise in the incidence of non-
alcoholic fatty liver disease (NAFLD) and its complications.[1, 28] NAFLD, regarded as the 
“hepatic manifestation of the metabolic syndrome”, is now estimated to affect one billion 
individuals worldwide.[1] Non-alcoholic steatohepatitis (NASH), the aggressive form of the 
disease, can lead to cirrhosis and liver failure.[2, 29] Indeed, NASH is predicted to soon 
become the predominant cause of advanced liver disease in the developed world [30] and 
the leading indication for liver transplantation.[29] NAFLD has also been increasingly 
recognized as an independent risk factor for the development of type II diabetes mellitus, 
cardiovascular disease and hepatocellular carcinoma, the latter of which may occur even 
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in non-cirrhotic individuals.[2, 31, 32] The factors that predispose patients to the 
development of steatohepatitis and fibrosis in NAFLD are not well understood and 
effective treatment strategies are lacking.[4] 
There is evidence that a modest degree of iron overload is associated with more advanced 
liver injury in NAFLD, although the mechanisms by which this might occur remain 
unclear.[7, 8] A syndrome of increased hepatic iron in conjunction with the metabolic 
syndrome is commonly observed and has been termed dysmetabolic iron overload 
syndrome (DIOS).[7, 33]  
To date, the majority of studies have focused mainly on the role of hepatic iron and 
mutations in the HFE gene, the gene mutated in type 1 hereditary hemochromatosis. 
Recently, however, it has become increasingly evident, that adipose tissue iron plays an 
important role in the pathogenesis of insulin resistance and therefore possibly NAFLD.[3, 
34] 
In this review, the potential involvement of iron in NAFLD pathogenesis is explored using 
the available data from human studies, as well as animal and cell culture models. In 
addition, the counterview that implicates NAFLD itself in the dysregulation of iron 
metabolism is outlined. 
Human iron homeostasis  
 
Iron is an essential nutrient required for erythropoiesis and multiple cellular metabolic 
functions.[35, 36] An excess of iron is also, however, a potent cause of cellular injury from 
oxidative stress due to the generation of reactive oxygen species by the Fenton 
reaction.[5] Under usual conditions, intracellular protection from iron-induced oxidative 
stress is facilitated by sequestration of iron within ferritin.[35]  
Total body iron homeostasis is achieved predominantly by regulation of iron release from 
duodenal enterocytes and macrophages by the hormone hepcidin.[36-38] Predominantly 
produced by hepatocytes, hepcidin binds the enterocyte basal membrane iron transporter, 
ferroportin, causing its internalization and eventual degradation, thus reducing iron release 
from duodenal enterocytes and other cells.[36, 38] Ferroportin has been shown to be 
highly expressed in enterocytes, reticuloendothelial cells, and more recently, in 
adipocytes.[17, 36] Thus, hepcidin regulates systemic iron balance by reducing intestinal 
iron absorption.[36] 
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An understanding of the regulation of hepcidin (HAMP) gene expression has come about 
from studying human subjects with various forms of hereditary hemochromatosis, and by 
analysis of gene knockout rodent models. Hepcidin is regulated by many factors, including 
erythropoiesis, iron status, intracellular oxygen tension and inflammation.[38] 
Pathologic states of iron overload often lead to saturation of serum iron transporter, 
transferrin. As a result, serum levels of toxic non-transferrin bound iron (NTBI) rise. NTBI is 
readily absorbed by tissues such as the liver and cardiac muscle.[38] Tissue iron overload 
with NTBI results in increased oxidative stress and lipid peroxidation, leading to organ 
dysfunction. The common causes of iron overload include hereditary hemochromatosis, 
iron loading anemias (such as thalassemia) and parenteral iron overload from multiple 
blood transfusions.[38] 
Insulin resistance and the pathogenesis of NAFLD 
 
It has become evident that insulin resistance is associated with a more subtle degree of 
iron overload than is seen in hereditary hemochromatosis and thalassemia.[7, 8, 34] This 
is important as insulin resistance is central to the pathogenesis of NAFLD.[2, 39] The 
presence of abdominal obesity and accompanying insulin resistance provide fertile 
conditions for the development of NAFLD. Indeed, NAFLD is often considered as the 
hepatic manifestation of insulin resistance and the metabolic syndrome.[2] Central obesity 
is associated with adipose tissue dysfunction, characterized by infiltration of adipose tissue 
with macrophages.[40] Dysfunctional adipose tissue produces adipokines that promote the 
development of insulin resistance.[34] The key sites of insulin action and resistance are 
the liver, skeletal muscle and adipose tissue.[41] In adipose tissue itself, insulin resistance 
potentiates lipolysis of triglycerides by hormone sensitive lipase.[42] This generates the 
majority of free fatty acid flux to the liver in NAFLD.[43] Insulin resistance in skeletal 
muscle leads to reduced uptake of glucose, whereas in the liver, insulin resistance 
enhances gluconeogenesis.[44] The resultant compensatory hyperinsulinemia and relative 
hyperglycemia promote hepatic de novo lipogenesis and cholesterol synthesis and 
reduced catabolism of free fatty acid by oxidation.[2] 
Increased hepatic free fatty acid flux resulting from this dysregulation of hepatic lipid 
metabolism and more importantly by adipose tissue lipolysis, appears to be central to the 
pathogenesis of steatohepatitis via direct lipotoxicity.[2, 45, 46]  A number of other 
mechanisms have been well demonstrated to be responsible for not only the development 
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of steatohepatitis, but also steatosis itself. These mechanisms include dysregulated 
adipokine production,[16, 21] abnormal bile acid signaling,[47] cytokine mediated 
effects[48], in particular as a result of increased gut cell permeability and TLR-4 receptor 
activation,[49] endoplasmic reticulum stress[50, 51] and oxidative stress[48, 52]. 
Hepatocellular injury promotes cell death and steatohepatitis through a combination of 
apoptosis and cell necrosis.[2] These mechanisms also contribute to hepatic stellate cell 
activation and resultant development of hepatic fibrosis.[53] 
Iron and insulin resistance 
 
The association between hyperferritinemia, insulin resistance and type II diabetes is 
compelling. There is an increased prevalence of type II diabetes associated with two 
common iron overload conditions, HFE-hereditary hemochromatosis (HH) and β-
thalassemia major.[34]  HH can lead to β-cell pancreatic loss and type I diabetes,  but 
whether HH causes type II diabetes by unmasking insulin resistance through pancreatic β-
cell loss or by causing insulin resistance itself remains controversial.[34] Animal data 
suggest that insulin sensitivity is enhanced in HH, but it has been difficult to tease out the 
relative contributions of β-cell loss and insulin resistance in human studies.[34, 54] The 
case of β-thalassemia major is more clear, with evidence suggesting that both β-cell loss 
and insulin resistance are at play.[34] 
In those who have neither hereditary hemochromatosis nor another cause of overt iron 
overload such as thalassemia, the evidence for a pathogenic role of iron is also strong. In 
the National Health and Nutritional Education Survey (NHANES), 9486 US adults were 
studied.[55] The odds ratios for developing diabetes in those with elevated serum ferritin 
levels were high at 3.61 for women and 4.94 for men.[55] A further analysis of the 
NHANES cohort revealed that even after accounting for other factors such as age, race, 
alcohol consumption and C-reactive protein (CRP) levels, elevated serum ferritin 
concentration still accounted for a two-fold increase in the risk of the metabolic 
syndrome.[55]  The risk of diabetes itself, has been shown to be strongly linked to serum 
ferritin concentration in healthy women, even within the normal range of ferritin.[56] In 
2012, the European Prospective Investigation in Cancer and Nutrition (EPIC)-Potsdam 
study followed 27,548 European adults for 7 years.[57] In this time, 849 subjects 
developed type II diabetes. Serum ferritin concentration in the highest vs lowest quintile 
had a relative risk (RR) of 1.73 for the development of diabetes. This observation was 
made after adjusting for multiple variables including age, sex, body mass index, waist 
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circumference, sports activity, education, occupational activity, alcohol, liver function test 
parameters, high sensitivity CRP (hsCRP), adiponectin, high density lipoprotein (HDL) and 
serum triglyceride concentration.[57]  
A recent review of 43 studies further supported these findings.[58] In this meta-analysis, 
the cohorts with the highest and lowest quartile of serum ferritin concentration were 
compared. The multivariable adjusted RR for the presence of diabetes was 1.91. This 
finding was consistent after including only studies that adjusted for inflammation (mostly 
hsCRP), RR 1.67. This related to a serum ferritin that was 43.54ng/ml higher in type II 
diabetics compared to controls. Studies assessing the relationship between type II 
diabetes and transferrin saturation have yielded conflicting results.[58-60] 
The persistence of association between serum ferritin concentration and type II diabetes 
after correction for hsCRP implies that inflammation alone does not entirely explain the 
association between hyperferritinemia and diabetes. However, it might be argued that 
even hsCRP may not reflect subtle degrees of inflammation as strongly as serum ferritin 
concentration.  
Serum ferritin concentration and NAFLD 
 
The association between hyperferritinemia and histologic markers of liver injury in NAFLD 
is reasonably strong. In 2004, Bugienesi et al. found that serum ferritin concentration is not 
associated with hepatic iron concentration in NAFLD, but is a marker of severe histologic 
damage.[61] Kowdley et al. demonstrated in the large NASH Clinical Research Network 
(CRN) cohort of 628 patients that a serum ferritin concentration greater than 1.5 times the 
upper limit of normal was independently associated with advanced fibrosis and increased 
NAFLD activity score.[62] Sumida et al., have demonstrated the utility of incorporating 
serum ferritin into a clinical scoring system to predict steatohepatitis in Japanese patients 
with NAFLD.[63] 
However, other studies have not found such a clear association.[64, 65] Notably, Valenti et 
al. showed in an Italian cohort of 587 patients with NAFLD that serum ferritin concentration 
did not predict fibrosis stage >1, although the proportion of patients with fibrosis stage >1 
in this cohort was relatively small.[64] As would be expected, serum ferritin concentration 
was higher in the patients who had hepatic iron staining than those who did not, but those 
with non-parenchymal iron had much higher ferritin values (606μg/L) than those with 
hepatocellular iron (serum ferritin 354μg/L) p<0.0001. This might suggest that macrophage 
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iron can cause hyperferritinemia either by direct release of ferritin or cytokine-mediated 
stimulation of ferritin release by other cells. An earlier study by Chitturi et al. of 93 patients 
with NASH, 33% of whom had advanced fibrosis, found that serum ferritin concentration 
was not an independent predictor of advanced fibrosis.[66]  
In a large prospective population-based study from South Korea, 2410 healthy men aged 
30 to 59 without sonographic evidence of steatosis were followed for 7545.9 person 
years.[67] Of these, 586 (24.3%) patients developed ultrasongraphically detectable fatty 
liver. Baseline serum ferritin concentration was found to be a strong predictor of steatosis. 
This evidence is notable as it demonstrates an association early in the disease suggesting 
that the process that elevates serum ferritin concentration is contributing to NAFLD 
pathogenesis very early in the disease and pre-dates the development of steatosis. This 
implies that the ferritin association with NAFLD is not simply a result of NAFLD itself 
causing hyperferritinemia. Moreover, the results might tend to suggest that the link 
between hyperferritinemia and NAFLD could be explained by insulin resistance. 
The strengths of these studies lie in the large numbers of individuals studied. However, 
serum ferritin concentration is an imprecise surrogate for body iron stores and its 
associations with both NAFLD and, type II diabetes are clearly not enough to attribute 
causality with respect to iron in either of these conditions. 
Hepatic iron and NAFLD 
 
The role of hepatic iron in NAFLD pathogenesis has largely focused on the generation of 
oxidative stress by iron. Given that oxidative stress is an established key component of 
NASH pathogenesis, [48] a role for iron mediating liver injury in NAFLD via this 
mechanism has been well studied. In NASH, oxidative stress leads to cell death via 
depletion of ATP, NAD and glutathione, and by direct damage to DNA, lipids and proteins 
within hepatocytes.[48] Furthermore, oxidative stress leads to an increase in the 
production of pro-inflammatory cytokines and a fibrogenic response.[48] Not only does 
oxidative stress potentiate steatohepatitis, characterized by inflammation and cell death, it 
can also increase steatosis by preventing the secretion of very low density lipoprotein 
(VLDL) by causing increased degradation of apolipoprotein B100 (ApoB100).[68] In 
cultured primary rodent hepatocytes, the iron chelator desferrioxamine was able to restore 
ApoB100 and enhance VLDL export.[68]  
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Reduced oxidative stress has been observed in the livers of rats fed an iron-deficient diet 
and after phlebotomy.[69] In a series of liver biopsies from patients with NAFLD, increased 
hepatic iron stores were found to be associated with increased lipid peroxidation.[70] In 
humans, iron overload has been shown to correlate with hepatic immunohistochemical 
staining for 7,8-dihydro-8-oxo-2’ deoxyguanosine (8-oxodG), a product of oxidative 
damage to DNA.[71] In this study, staining for 8-oxodG was significantly reduced with 
venesection.[71] Patients with NASH have been shown to have elevated levels of serum 
thioredoxin, a marker of oxidative stress, which declined following venesection.[72] In 
cultured AML-12 hepatocytes iron generated oxidative stress and led to impaired insulin 
signaling.[73] 
Iron also appears to have a direct role in the activation of hepatic macrophages and 
hepatic stellate cells. In humans with NAFLD, reticulo-endothelial iron has been shown to 
be associated with apoptosis, indicated by increased serum cytokeratin-18 (CK-18) 
fragments and increased hepatic TUNEL staining of liver sections.[74] In vitro, iron 
activates inflammatory signaling via hepatic macrophages.[75] Recently, dietary iron 
loading in leptin-receptor deficient mice was found to lead to inflammasome and immune 
cell activation with hepatocellular ballooning.[76] Furthermore, ferritin treatment of rat 
hepatic stellate cells has been shown to lead to a pro-inflammatory cascade by nuclear 
factor kappaB signaling.[77]  
Iron may also contribute to liver injury in NAFLD by generating endoplasmic reticulum 
stress.[50, 51] In a mouse model of dietary iron overload and NAFLD, iron induced an 
unfolded protein response and endoplasmic reticulum stress.[78] Additionally, hepatic iron 
loading in mice up-regulates cholesterol biosynthesis pathways and this has been 
proposed as an additional mechanism of iron-induced liver injury in NASH.[79] The 
proposed mechanisms relating to hepatic iron in NAFLD pathogenesis are summarized in 
Table 2.1. 
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Table 2.1 Proposed mechanisms for the involvement of iron in NAFLD pathogenesis 
 
Site Mechanism 
Hepatic iron Oxidative Stress[32, 53-57] 
 Reduced VLDL export[52] 
 Macrophage activation[58-60] 
 Stellate cell activation[61] 
 Endoplasmic reticulum stress[62] 
 Increased cholesterol synthesis[63] 
Adipose tissue iron Reduced adiponectin[19,75] 
 Reduced leptin[77] 
 Increased resistin[76] 
 Increased lipolysis[78,79] 
 
A number of studies have looked at the relationship between hepatic iron concentration 
(HIC) and liver injury in NAFLD. George et al. showed that HIC was associated with 
increased fibrosis in 51 patients with NASH.[80] Three subsequent and similar studies, 
however, have failed to reproduce these results.[61, 81, 82] Two much larger studies have 
looked at the association between hepatic iron (Perls’) staining and liver histology in 
NAFLD with conflicting results. In a study of 587 Italian patients with NAFLD, Valenti et al. 
found that hepatocellular rather than reticulo-endothelial iron was associated with 1.7 fold 
increased risk of significant fibrosis compared to those without iron staining.[64] Reticulo-
endothelial iron was found to have a trend towards an association with a lower risk of 
significant fibrosis. Nelson et al., however, found seemingly contradictory results, with 
reticulo-endothelial iron being associated with greater risk of advanced fibrosis, lobular 
inflammation and hepatocellular ballooning in the US cohort of 849 patients enrolled in the 
NASH Clinical Research Network (CRN) database.[83] In this study, the mean NAFLD 
Activity Score (NAS) [84] was 4.8 in the reticulo-endothelial iron staining group compared 
to 4.0 in the hepatocellular iron staining group. The exact reasons for this discrepancy 
between these two large well-designed studies is unclear, although it is noted that there 
were some differences between the Italian and US cohorts including the frequency of 
steatohepatitis and beta-globin mutations.[7]  
55 
 
One might argue, however, that the sum of the human data indicates that if hepatic iron 
does promote liver injury in NAFLD, then its effect is likely to be relatively small. 
Adipose tissue iron and insulin resistance 
 
In recent years, there has been increasing recognition of the role of adipose tissue 
dysfunction in the development of insulin resistance and NAFLD.[21] Adipose tissue is 
undoubtedly a significant endocrine organ.[85] It is comprised of adipocytes (fat cells), a 
mixture of cells categorized as the stromal-vascular fraction including reticuloendothelial 
cells, predominantly macrophages.[85] Central obesity and the metabolic syndrome are 
characterized by infiltration of bone marrow-derived macrophages into adipose tissue.[40, 
86] Macrophage accumulation in adipose tissue is associated with obesity and the 
development of NAFLD.[21, 40]  A loss of regulatory T-cells and an increase in CD8+ 
effector T-cells characterizes visceral adipose tissue in insulin resistance.[21, 87, 88] The 
net effect of this adipose tissue infiltration with immune cells is a state of systemic low 
grade inflammation that is mediated by a number of adipose tissue cytokines, termed 
adipokines.[85] Ectopic fat, such as omental (visceral) and epicardial or mediastinal fat, is 
dysfunctional tissue that is more likely to undergo inflammation.[89] In the case of visceral 
fat, this inflammation is particularly problematic with regards to liver physiology due to the 
direct transfer of adipokines to the liver via the portal vein.[16]  
Adipokines are polypeptides that are expressed significantly in adipose tissue in a 
regulated manner.[16] Of these, a number of important macrophage derived adipokines 
appear to play an important role in the development of NAFLD. Both tumor necrosis factor 
alpha (TNFα) and interleukin-6 (IL-6) have a pro-inflammatory role that may contribute 
directly to liver pathology in an endocrine fashion, and also via paracrine mechanisms that 
influence the production of other adipokines from adipocytes.[21] Adipokines produced by 
adipocytes which have been shown to influence NAFLD pathogenesis include adiponectin, 
leptin, resistin, suppressor of cytokine signalling-3 (SOCS-3) and secreted frizzled related 
protein 5 (SFRP5).[16, 21] 
Adipose tissue has been proposed as a site at which iron may have a major pathogenic 
role in NASH.[7] Unfortunately, to our knowledge, direct human data reporting iron 
concentrations in visceral adipose tissue and its significance in disease are lacking and 
this area represents both a target for future research and a technical challenge. 
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Evidence for the role of adipose tissue iron in NAFLD pathogenesis mainly comes 
indirectly from the association between adipocyte iron and insulin resistance. In 2012, 
Gabrielsen et al. demonstrated that adipocyte iron reduced adiponectin gene expression, 
serum adiponectin levels and glucose tolerance in an adipocyte-specific Ferroportin 
knockout mouse model.[17] Using the novel Ap2-Cre:Fpnfl/fl model they were able to 
selectively load iron into adipocytes. The model was developed following the observation 
that adipocytes are high expressers of ferroportin.[17] Using cultured pre-adipocytes (3T3-
L1 cells) and chromatin immunoprecipitation (ChIP) analysis, iron was shown to alter 
acetylation and binding of the forkhead transcription factor Foxo1 to adiponectin gene 
promoter binding sites. In a human arm of the same study, they were able to demonstrate 
an inverse correlation between serum ferritin concentration and adiponectin that was 
independent of inflammation. This observation has subsequently been replicated in 492 
Dutch individuals with risk factors for type II diabetes.[90] Moreover, in obese patients 
undergoing bariatric surgery, two gene expression markers of increased adipocyte iron 
loading: increased hepcidin gene (HAMP) mRNA expression and decreased transferrin 
receptor 1 (Tfr1) mRNA expression were associated with reduced quantities of Adipoq 
(adiponectin gene) mRNA.[91]  
Iron-mediated dysregulation of two other adipokines has been demonstrated in rodent 
models. Dongiovanni et al. have shown that dietary iron loading in mice leads to increased 
expression of resistin via SOCS-3 which are mediators of insulin resistance.[19] Recently, 
data from mouse and 3T3-L1 cell culture models found that iron down-regulates the 
expression of the appetite-suppressing adipokine, leptin – a hormone strongly implicated 
in NAFLD pathogenesis.[16, 18]  Intriguingly, this may help explain the symptom of 
anorexia in iron deficiency, although the significance of these findings in NAFLD is 
uncertain. 
Adipose tissue iron has been shown to directly enhance lipolysis in isolated rat adipocytes 
and cultured 3T3-L1 cells.[92, 93] As adipose tissue is the predominant source of free fatty 
acid flux to the liver [43], this is potentially a very important mechanism of adipose tissue 
iron action in NAFLD, although these findings are yet to be demonstrated in animal models 
or humans. Potential mechanisms relating to adipose tissue iron in NAFLD pathogenesis 
are summarized in Table 2.1. 
In summary, iron has been increasingly recognized as a regulator of adipose tissue 
function. Evidence supports a role for iron in the regulation of adipose tissue inflammation, 
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adipokine regulation and adipose tissue lipolysis. At present, most of the evidence 
supports a role for adipose tissue iron in the pathogenesis of insulin resistance and type II 
diabetes, although clearly these mechanisms may be highly relevant in NAFLD.  
Iron-related genetic polymorphisms in NAFLD pathogenesis 
 
The most common inherited disorder affecting the hepcidin-ferroportin axis is type I 
hereditary hemochromatosis.[5, 38] This usually results from homozygous p.C282Y 
mutation of HFE (HFE-hemochromatosis).[94] The additional insult of NAFLD acts as a co-
factor for the development of liver injury in C282Y homozygotes with hereditary 
hemochromatosis.[6] In non-hemochromatotics, the broader significance of HFE gene 
mutations as co-factors in the pathogenesis of NAFLD has received intense interest in 
recent years. The two most significant HFE mutations in Caucasian populations are the 
p.C282Y and p.H63D mutations.[38]  
Heterozygosity for the C282Y mutation is found in approximately 10-11% of individuals in 
Caucasian populations.[13, 95] C282Y heterozygosity is associated with a mild increase in 
serum iron markers, but not with overt hemochromatosis.[13]  
Many studies have looked at the association between HFE gene mutations and the 
incidence of NAFLD, but with conflicting results. These studies may have been limited by 
inadequate statistical power and heterogeneity of the cohorts. In 2011, Hernaez et al. 
published the results of a meta-analysis of 13 case-control studies specifically aimed at 
determining the association between HFE gene mutations and NAFLD.[96] In contrast to a 
previous meta-analysis by Ellervic et al., [14] they found no association between the 
C282Y/C282Y genotype and NAFLD. Similarly the presence of neither the C282Y 
mutation nor the H63D mutation resulted in an increased risk of NAFLD in Caucasians. In 
a sub-analysis of three studies of non-Caucasians, an association was found between the 
presence of the H63D mutation and the presence of NAFLD.[96]  
A limitation of the meta-analysis, as noted by its authors, is that it was not able to 
determine whether HFE gene mutations might have a disease modifying role in subjects 
after they have developed NAFLD.[96] This study appears to show that HFE gene 
mutations are generally no more common in subjects with NAFLD than in those without, 
however, the investigators were unable to determine whether those patients with NAFLD 
and HFE gene mutations are more likely to develop steatohepatitis and progressive liver 
injury than those without mutations.  
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The issue concerning the effect of heterozygous mutations in progression to NASH was 
highlighted by an analysis of HFE mutations within the NASH CRN cohort.[97] This is a 
well-defined cohort of patients with biopsy proven NAFLD. Subjects with the H63D 
mutation had higher steatosis grades and NAS than their wild-type controls. However, 
those NAFLD patients with C282Y mutations had lower rates of hepatocyte ballooning and 
steatohepatitis. 
Our group has previously shown that mice with homozygous knockout of the Hfe gene 
develop severe steatosis, steatohepatitis and early fibrosis when fed a high fat diet, 
whereas wild-type mice develop mild steatosis and no steatohepatitis or fibrosis when fed 
the same diet.[15] Hfe null mice had only modest increases in HIC, and it was proposed 
that the increased histologic injury seen in these animals may have been due to the lack of 
HFE protein rather than iron overload per se. Hfe null mice demonstrated dysregulated 
hepatic lipid metabolism with increased transcription of genes associated with de novo 
lipogenesis and reduced transcription of those associated with fatty acid oxidation.[15] 
A number of other non-HFE iron-loading polymorphisms have been proposed as 
modulators of NAFLD pathogenesis.[7, 98] Of these, the A736V polymorphism of the 
Trans-membrane protease serine-6 (TMPRSS6) gene has been studied in patients with 
NAFLD. The TMPRSS6 gene encodes for matriptase-2, an enzyme responsible for 
hemojuvelin cleavage that inhibits the bone morphogenetic protein-6 (BMP-6) pathway, 
thus reducing hepcidin expression and increasing duodenal iron absorption.[38, 98] Of 216 
Italian patients with NAFLD, 38% had the AA genotype, 47% AV and, 15% VV.[98] The VV 
genotype is associated with increased hepcidin expression and reduced iron loading and 
in this study was associated with a trend (p=0.05) towards a reduction in hepatocyte 
ballooning.[98]  
In summary, human and animal model data support a role for a co-toxic liver injury in the 
setting of hereditary hemochromatosis and NAFLD. Other more mild iron loading 
phenotypes such as heterozygous HFE gene mutations and polymorphisms of TMPRSS6 
may have disease modifying roles in NAFLD, although their effect is likely to be small. 
Clinical trials of iron reduction therapy 
 
Although associations of modest iron overload with NAFLD and diabetes appear 
reasonably well established, causality is difficult to determine using these studies alone. 
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The most useful information with which to more directly assess causality comes from 
human studies that have assessed the response to iron removal by venesection. 
Venesection has been shown to improve glucose tolerance in healthy individuals and 
improve insulin sensitivity in type II diabetics with a high serum ferritin concentration.[99, 
100] Moreover, in patients with the metabolic syndrome, venesection has been shown to 
improve metabolic syndrome parameters, including reduced blood pressure, blood 
glucose, glycosylated hemoglobin (HbA1C) and low-density lipoprotein/high density 
lipoprotein (LDL/HDL) ratio.[101] In patients with NAFLD and carbohydrate intolerance, 
venesection to near iron deficiency (decrease in serum ferritin from 299 ±41μg/L to 
15±1μg/L) not only improved insulin sensitivity, as measured by fasting glucose, insulin 
and homeostatic model assessment-insulin resistance (HOMA-IR) score, but also 
improved serum alanine aminotransferase levels from 61 ± 5U/L to 32 ± 2U/L.[102]  
Two randomized controlled trials investigating venesection efficacy in NAFLD have 
recently been published. In a study of 38 Italian patients with NAFLD and 
hyperferritinemia, participants were randomized to venesection versus no venesection with 
liver biopsy before and after treatment.[103] Of the 38 enrolled participants, 21 underwent 
liver biopsy at the end of treatment. Despite the small numbers, histological improvement, 
defined by an improvement in NAS, was seen in 8 of 12 participants in the venesection 
group compared to 2 of 9 participants in the control group (p=0.04).[103]  
The largest randomized study of venesection in NAFLD to date involved 74 Australian 
participants with NAFLD.[104] These included patients with sonographically detected 
NAFLD and a wide range of serum ferritin concentration, including many within the normal 
range. Non-invasive assessment was performed to assess response to randomized 
therapy of either venesection with lifestyle advice versus lifestyle advice alone. There was 
no observed effect of venesection on hepatic steatosis determined by magnetic resonance 
imaging, serum ALT or CK-18 fragments. Somewhat surprisingly, there was also no effect 
on static and dynamic measures of glucose homeostasis including the HOMA-IR score 
and insulin sensitivity index.[104] 
Overall, although there are promising results from small studies, venesection cannot 
currently be recommended as a suitable therapy for the majority of patients with 
NAFLD.[105] However, whether there are sub-groups of non-hemochromatotic NAFLD 
patients with increased iron that would benefit from venesection, remains to be determined 
by further studies. 
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Iron metabolism in NAFLD 
 
So far, we have discussed the effect of iron on the pathogenesis of NAFLD and insulin 
resistance. It is also necessary to consider to what extent NAFLD and associated 
conditions, such as insulin resistance and obesity, might themselves mediate iron 
metabolism. 
Serum hepcidin levels are typically elevated in individuals with NASH.[106] As this in itself 
fails to explain iron loading in NASH, one might consider that dysregulated iron 
metabolism occurs in NASH independently of hepcidin. In this regard, Transferrin receptor-
1 (Tfr1) has been shown to be upregulated as a consequence of a high fat diet in mice 
which may lead to hepatocellular uptake in NAFLD despite already increased 
hepatocellular iron.[107] Also, divalent metal transporter 1 (DMT-1), which is responsible 
for import of iron from the duodenal lumen into enterocytes is up-regulated in patients with 
NASH, despite increased serum hepcidin.[108] Another intriguing finding is that increased 
red cell fragility in response to a high fat diet in rabbits leads to increased 
erythrophagocytosis.[109] This may explain increases in hepatic reticuloendothelial iron 
that have been observed in some NASH cohorts.[83] 
It seems likely that elevated hepcidin in NASH is either a reflection of hepatocellular 
inflammation or simply that increased iron, which induces hepcidin, pre-dates the 
development of NASH. Indeed, hepcidin expression appears to be directly enhanced by 
insulin and down-regulated in the setting of insulin resistance, thus indicting a possible 
mechanism for iron loading as an early event in the pathogenesis of NAFLD and type II 
diabetes.[110] Furthermore, it has been observed that hepcidin is expressed in white 
adipose tissue and is increased in obesity.[23] Although the contribution of adipose tissue-
derived hepcidin to the serum hepcidin pool is uncertain, this is another potential factor 
that may explain increased serum hepcidin in NASH. Further complexity in these 
relationships arises when one considers that iron deficiency has been shown to be 
associated with obesity and in women with obesity and NAFLD.[111, 112] Together, these 
findings suggest that the interaction between iron and lipid metabolism is multi-faceted. It 
seems that ‘just enough’ but ‘not too much’ iron may be critical in preventing dysfunctional 
lipid metabolism. 
If one accepts a causal role for iron in NASH pathogenesis, then variations in dietary iron 
may explain much of the spectrum of iron loading in NASH. Although there is no specific 
evidence relating iron intake to NASH pathogenesis in humans, increased dietary iron, 
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particularly from red meat, seems to predispose individuals to the development of insulin 
resistance and type II diabetes.[113-115]  
Conclusions 
 
In summary, there is considerable evidence that links increased iron stores with insulin 
resistance and NAFLD. This includes a number of studies that have identified serum 
ferritin concentration as a predictor of liver injury. Hepatic iron itself is attractive culprit for 
liver injury, although the cellular location of iron within the liver may vary between 
genetically distinct populations. Increasingly, adipose tissue iron has been linked with 
adipose tissue dysfunction, including the dysregulation of adipokines, enhanced adipose 
tissue lipolysis and adipose tissue inflammation. These are plausible candidate 
mechanisms that may link adipose tissue iron to liver injury. However, assessment of 
adipose tissue iron concentrations in individuals with well characterized NAFLD remains a 
goal for future studies. 
Iron-related genetic polymorphisms, such as those of the HFE gene, may contribute to 
NAFLD pathogenesis, although it would appear that, other than for individuals with 
hereditary hemochromatosis, the effect of these polymorphisms, is likely to be small. The 
complexity of these relationships between iron and NAFLD is further increased when one 
considers the possibility that NAFLD itself is likely to have a number of effects on iron 
metabolism. 
Finally, venesection studies have offered a unique opportunity with which to assess 
causality of iron loading in the pathogenesis of NAFLD. The available data suggest that 
venesection is unsuitable as a general treatment for all patients with NAFLD. Therefore, 
the key for future human studies will be to determine whether a subset of patients with 
NAFLD can be identified that might still benefit from therapeutic manipulation of iron 
homeostasis. 
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Chapter 3 : Heterozygous Hfe gene deletion leads to impaired glucose 
homeostasis but not liver injury in mice fed a high calorie diet 
 
As described in Chapter 2, numerous human studies have evaluated the links between 
HFE gene mutations and NAFLD. It has previously been shown that homozygous deletion 
of Hfe in mice leads to a far greater severity of liver injury than wild-type mice when 
exposed to a high calorie diet.[15] The effects of heterozygous Hfe deletion, analogous to 
commonly observed heterozygous mutations have not been well studied in animal models 
of NAFLD. In this chapter, the effects of heterozygous Hfe gene deletion in a dietary 
mouse model of NAFLD are studied. 
This chapter is published in Physiological Reports. 
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Abstract 
 
Background & Aims: Heterozygous mutations of the HFE gene have been proposed as 
co-factors in the development and progression of non-alcoholic fatty liver disease 
(NAFLD). Homozygous Hfe deletion previously has been shown to lead to dysregulated 
hepatic lipid metabolism and accentuated liver injury in a dietary mouse model of NAFLD. 
We sought to establish whether heterozygous deletion of Hfe is sufficient to promote liver 
injury when mice are exposed to a high calorie diet (HCD). Methods: Eight-week-old wild 
type and Hfe+/- mice received eight weeks of a control diet or HCD. Liver histology and 
pathways of lipid and iron metabolism were analyzed. Results: Liver histology 
demonstrated that mice fed a HCD had increased NAFLD activity score (NAS), steatosis 
and hepatocyte ballooning. However, liver injury was unaffected by Hfe genotype.  Hepatic 
iron concentration (HIC) was increased in Hfe+/- mice of both dietary groups. HCD resulted 
in a hepcidin-independent reduction in HIC. Hfe+/- mice demonstrated raised fasting serum 
glucose concentrations and HOMA-IR score, despite unaltered serum adiponectin 
concentrations. Downstream regulators of hepatic de novo lipogenesis (pAKT, SREBP-1, 
Fas, Scd1) and fatty acid oxidation (AdipoR2, Pparα, Cpt1) were largely unaffected by 
genotype. Conclusions: Heterozygous Hfe gene deletion is associated with impaired iron 
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and glucose metabolism.  However, unlike homozygous Hfe deletion, heterozygous gene 
deletion did not affect lipid metabolism pathways or liver injury in this model. 
Background 
 
Non-alcoholic fatty liver disease (NAFLD) is increasingly common in the developed and 
developing world, affecting around 30% of many adult populations [116, 117]. The 
advanced form of the disease, non-alcoholic steatohepatitis (NASH) can lead to life-
threatening complications including liver failure and liver cancer [2]. At present, effective 
treatment strategies to halt or reverse the natural history of NASH are lacking. Co-factors 
such as type II diabetes mellitus and iron overload have been implicated in NASH 
pathogenesis and represent readily treatable therapeutic targets [3, 7]. A greater 
understanding of the mechanisms by which such co-factors promote NASH disease 
progression is essential in order to develop effective treatments. 
Iron overload due to homozygous p.C282Y mutation of HFE is responsible for the majority 
of cases of hereditary hemochromatosis seen worldwide [118]. Heterozygous p.C282Y 
mutations are found in approximately 11% of Caucasian populations and are associated 
with increased iron stores, but not with liver disease in the absence of an additional co-
factor [13]. In a large meta-analysis, HFE gene mutations have been shown to convey an 
increased risk of non-alcoholic steatohepatitis [14]. Amongst individuals with NAFLD, the 
presence of the heterozygous p.H63D mutation of HFE has been shown to be associated 
with more advanced histological injury as assessed by the NAFLD activity score [97].  
Liver injury in both hemochromatosis and NASH is characterized by the presence of 
oxidative stress [48, 118]. Insulin resistance, itself associated with oxidative stress, is 
commonly observed both in individuals with NASH and also in those with 
hemochromatosis [3, 34]. Given the prevalence of HFE gene mutations and shared 
pathogenic mechanisms with NASH, they have received intense interest in recent years as 
potential co-factors in NAFLD disease progression.  
Previous work from our group has demonstrated that mice with homozygous Hfe deletion 
which are fed a high calorie diet (HCD) develop steatohepatitis and early fibrosis [15]. This 
effect of diet is not seen in wild type controls which develop only simple steatosis. In this 
model, Hfe null mice demonstrated up-regulation of gene expression of de novo 
lipogenesis pathways and down-regulation of fatty acid oxidation pathways. This 
imbalance of fatty acid synthesis and oxidation, may explain the liver injury seen in these 
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Hfe null mice. However, the mechanisms by which Hfe deletion might dysregulate hepatic 
lipid metabolism remain to be defined.  
These findings led us to consider whether a partial deficiency of functional HFE, as seen in 
those with heterozygous C282Y and H63D mutations, might be sufficient to dysregulate 
hepatic lipid metabolism and promote liver injury in NAFLD. In this paper, we sought to 
explore the mechanisms of interaction between heterozygous HFE gene mutations and 
non-alcoholic fatty liver disease. We hypothesized that heterozygous Hfe deletion 
promotes dysregulated hepatic lipid metabolism as seen in the homozygous model. To 
test this hypothesis, we used a high calorie diet model of NAFLD in mice with and without 
heterozygous deletion of Hfe. 
Methods 
 
Experimental Animals: Eight-week-old male C57BL6/J Hfe+/- mice (bred at the QIMR 
Berghofer Medical Research Institute, Brisbane, Australia) and wild-type (WT) littermate 
controls were assigned to receive a control diet (CD) or a high calorie (40.5% sucrose, 
23.5% fat, 0.19% cholesterol by weight) diet (HCD), for eight weeks (n=10 per group). The 
constituents of these diets are summarized in Table 3.1. Both diets contained 1.3μmol/g 
iron. The high calorie diet is analogous to a ‘Western’ style diet, containing a high content 
of fat, simple carbohydrates and cholesterol [15]. Both diets were supplied by Specialty 
Feeds, Glen Forrest, Western Australia. All animals were cared for in accordance with the 
NHMRC code for the care and use of animals for scientific purposes and with approval of 
the Animal Ethics Committee of the QIMR Berghofer Medical Research Institute. Mice 
were housed in a temperature controlled environment (23°C) with a 12:12 hour light: dark 
cycle. Mice had ad libitum access to diet and water. 
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Table 3.1: Major components of experimental diets 
 
Dietary Component 
 
Control Diet (CD) High Calorie Diet (HCD) 
Protein (% weight) 19.4% 19.4% 
Total fat (% weight) 7.0% 23.0% 
Total carbohydrate (% weight) 61.7% 50% 
Digestible energy (MJ/kg) 16.1 20 
Cholesterol (% weight) 0% 0.19% 
Casein (acid) (g/kg) 200 200 
Sucrose (g/kg) 100 405 
Canola oil (g/kg) 70 50 
Cellulose (g/kg) 50 50 
Wheat starch (g/kg) 404 50 
Dextrinized starch (g/kg) 132 0 
Cocoa butter (g/kg) 0 50 
Hydrogenated vegetable oil (g/kg) 0 131 
 
Sixteen-week-old mice were sacrificed by general anesthesia with intraperitoneal injection 
of ketamine and xylazine, following a five hour fast. Blood was collected by cardiac 
puncture and serum was stored at -80°C. Livers were excised, and pieces of tissue were 
either dried at 100°C for 72 hours for hepatic iron concentration determination, fixed in 
formalin for histology or snap frozen in liquid nitrogen and stored at -80°C. Small bowel 
enterocytes were collected as previously described [119, 120]. In brief, 10 cm sections of 
proximal small bowel were cut longitudinally then washed in ice cold phosphate buffered 
saline (PBS). Samples were then gently rotated for 30 minutes at 4oC in 1.5mM 
ethylenediaminetetraacetic acid (EDTA) in PBS. The gut tissue was removed and the 
remaining sample containing enterocytes was centrifuged at 500 x g to pellet the 
enterocytes. 
Histological assessment: Formalin fixed samples were embedded in paraffin. Sections 
were stained with hematoxylin and eosin (H&E) for assessment of liver injury. Sirius Red 
staining was used to detect the presence of hepatic fibrosis. Histological scoring was 
performed by an expert histopathologist blinded to the study groups according to criteria 
described by Kleiner et al [84].  
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Hepatic iron concentration: Oven dried liver samples were weighing 4-9mg were added 
to 300μL of concentrated nitric acid. Duplicate samples for each liver were then digested in 
a heated sand bath. Chromagen reagent was prepared (0.1% banthophenanthroline 
sulphate, 1% mercaptoacetic acid). One part chromagen reagent was added to five parts 
saturated sodium acetate to make working chromagen reagent immediately prior to use. 
When fully digested, the volume of each sample was determined by pipette and 25μL was 
added to 125μL working chromagen reagent. Absorbance was measured at 540nm on a 
plate reader, Tecan infinite F200, Tecan, Switzerland. The iron concentration by dry weight 
was determined with reference to an iron standard (Iron standard for AAS, Sigma, St. 
Louis, USA).  
Serum analysis: Serum alanine aminotransferase (ALT) was measured on a Beckman 
(DxC800) General Chemistry Automated Analyzer (Beckman Coulter, Fullerton, USA). 
Serum glucose and insulin were measured on a Cobas Integra 400 Chemistry Automated 
Analyzer (Roche Diagnostics, Basel, Switzerland).  
RNA extraction and real-time quantitative PCR (RT-qPCR): RNA was extracted from 
tissue homogenates using QIAZOL reagent (Qiagen, Hilden, Germany). After treatment 
with deoxyribonuclease 1, cDNA was synthesized from 1µg RNA, using superscript III 
reverse transcriptase (Invitrogen, Mulgrave, Australia). RT-qPCR was performed in a ViiA 
7 real-time PCR machine (Invitrogen) with a Quantifast SYBR Green master mix (Qiagen) 
and thermal cycling as follows: 95⁰C for 5 minutes then 40 cycles at 95⁰C for 10 seconds 
followed by 60⁰C for 30 seconds prior to a melt curve analysis for validation. Relative 
mRNA expression was determined by calibration of Ct values to a standard curve of 
dilutions of a pooled mix of cDNA samples. Expression was then normalized to geometric 
mean of three reference genes Glyceraldehyde 3-phosphate dehydrogenase (Gapdh), 
Basic transcription factor-3 (Btf3) and Beta-2 microglobulin (B2-mg). Primer sequences 
that were used are shown in table 3.2. 
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Table 3.2:  RT-qPCR primer sequences (5’ to 3’)  
 
 Forward primer Reverse primer 
Hamp1 TTGCGATACCAATGCAGAAG GGATGTGGCTCTAGGCTATGTT 
Dmt1 CCAGCCAGTAAGTTCAAGGATC GCGTAGCAGCTGATCTGGG 
Hephaestin CCGACCTTACACCATTCACC GGACAGAATCATCCGCTTTC 
Fas TACCAAGCCAAGCACATTCG TGGCTTCGGCATGAGA 
AdipoR2 TACACACAGAGACGGGCAAC TGGCTCCCAAGAAGAACAAG 
Pparα CATGTGAAGGCTGTAAGGGCTT TCTTGCAGCTCCGATCACACT 
Cpt1 AGACCGTGAGGAACTCAAACCTA TGAAGAGTCGCTCCCACT 
Gapdh TCCTGCACCACCAACTGCTTAGC GCCTGCTTCACCACCTTCTTGAT 
Btf3 TGGCAGCAAACACCTTCACC AGCTTCAGCCAGTCTCCTTAAAC 
B2-mg CTGATACATACGCCTGCAGAGTTAA ATGAATCTTCAGAGCATCATGAT 
 
Western blotting: Serum adiponectin levels were determined by western blotting. 
Samples of 1:1000 serum (5μL) were electrophoresed in 2% Agarose (in Tris-Glycine) gels 
(Lonza, Basel, Switzerland) at 70V for 60 minutes. Protein levels of phosphoAKT (pAKT) 
and sterol regulatory element binding protein-1 (SREBP-1) were determined using western 
blotting of liver tissue extracts. Protein concentration was quantified using a Pierce BCA 
Protein Assay Kit (Thermo Scientific, Rockford, USA). 30µg of protein from whole liver 
protein extracts (pAKT) and 20μg of protein from liver nuclear extracts (SREBP-1) were 
electrophoresed in 10% sodium dodecyl sulfate-10% polyacrylamide gels for 10 minutes at 
75V then 50 minutes at 150V. Samples were then transferred onto polyvinylidene fluoride 
(PVDF) membranes (BioRad, Hercules, USA) at 100V for 60 mins. Membranes were 
blocked in 5% skim milk before immunostaining with primary antibodies. Secondary 
antibody binding was performed using horseradish peroxidase (HRP) antibodies (see 
supplementary information). Visualization was performed using a standard 
chemiluminescent kit (Supersignal West Femto, Thermo Scientific, Waltham, USA) on a 
4000MM pro Image Station (Carestream Health, Inc., New York, USA). pAKT and SREBP-
1 band net intensity were normalized to the reference proteins GAPDH and Histone-H3 
respectively. Primary and secondary antibodies used for Western blots were as follows: 
Adiponectin: (MAB3608, Millipore) 1:10,000, Goat anti-mouse HRP (Invitrogen) 1:200,000; 
pAKT: (sc-7985-R, Santa Cruz) 1:1000, Goat anti-rabbit HRP (Invitrogen) 1:200,000; 
SREBP-1: (sc-367, Santa Cruz) 1:500, Goat anti-rabbit HRP (Invitrogen). 1:100,000; 
GAPDH: (MAB374, Millipore) 1:150,000, Goat anti-mouse HRP (Invitrogen) 1:100,000; 
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Histone-H3: (FL-136, sc10809, Santa Cruz) 1:100, Goat anti-rabbit HRP (Invitrogen). 1: 
6000. All samples were processed concurrently using three gels with a minimum of three 
samples per group on each gel. 
Statistical analysis: Statistical analysis was performed using GraphPad Prism 6 software 
(GraphPad, San Diego, CA, USA). For normally distributed continuous data, groups were 
compared using two-way ANOVA based on diet and genotype. For instances in which a 
significant interaction existed between diet and genotype, two pre-defined post-hoc 
comparisons to evaluate the effect of genotype for each diet were performed using Sidak’s 
multiple comparisons test. These comparisons were: i) WT CD vs Hfe+/- CD and ii) WT 
HCD vs Hfe+/- HCD. In cases in which a significant interaction did not occur, p values 
relating to overall effect by two-way ANOVA of diet and genotype are reported. As initial 
body weight was measured prior to dietary intervention, an analysis between the two 
genotypes (n=20 per group) was performed using an unpaired Student’s t-test.  
For continuous data that were not normally distributed, a Kruskal-Wallis test was 
performed. When the results of this test were significant (p<0.05), post-hoc comparisons to 
evaluate the effect of genotype were performed using Dunn’s multiple comparisons test 
(group comparisons as for Sidak’s, above). Data for continuous variables are represented 
graphically with box and whisker plots, demonstrating the maximum, minimum, 25th and 
75th centile and median values. Categorical data were analyzed by Fisher’s exact test and 
represented in tabular form. 
Results 
 
Weight gain between 8 and 16 weeks of age was largely comparable between 
genotypes except for a small increase in weight gain in WT HCD fed mice compared 
to their Hfe+/- counterparts (13.1g vs 11.0g, p=0.04, Sidak’s multiple comparison test 
after two-way ANOVA). (figure 3.1A and 3.1B). This effect may be related to a higher initial 
weight at 8 weeks in WT mice. (28.4g vs 26.0g, p=0.016). The higher initial weight is 
unlikely to be a true genotype effect as a difference was not seen between the two CD 
groups. All four groups of mice (CD and HCD) had been fed only CD diet up until this 
stage. Mean initial weight for all WT mice (n=20) was 27.5g, compared to 26.9g for Hfe+/- 
mice (n=20) p=0.39 (Student’s t-test).  
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Figure 3.1: Body weight and serum ALT.  
(A) Initial body weight (8 weeks). An interaction between diet and genotype was present (p=0.0044, two-way ANOVA). 
Post hoc analysis found increased weight in WT mice fed a HCD compared to Hfe+/- mice (p=0.016, Sidak’s multiple 
comparisons test). No significant changes were seen in CD mice. (B) Weight gain (8 to 16 weeks). An interaction 
between diet and genotype was present (p=0.040, two-way ANOVA). Post hoc analysis found increased weight gain in 
WT mice fed a HCD compared to Hfe+/- mice (p=0.040, Sidak’s multiple comparisons test). No significant changes were 
seen in CD mice. (C) Serum alanine aminotransferase (ALT) is not influenced by diet or genotype. A significant 
interaction by two-way ANOVA was present (p=0.047). However, differences between genotype (Sidak’s multiple 
comparisons test) were not significant for either mice fed control diet or HCD. (n= 9-10 per group). 
 
Diet, but not Hfe genotype influences liver injury in this model. There was no 
observed genotype effect on serum ALT (figure 3.1C). Mice fed HCD of both genotypes 
developed steatosis without overt steatohepatitis (figure 3.2). Table 3.3 shows the 
histological scoring of liver sections. NAFLD activity score (NAS) (p=0.003), steatosis 
(p<0.001) and hepatocyte ballooning (p=0.038) were associated with experimental group 
by Fisher’s exact test. These associations evidently relate to diet rather than genotype. No 
more than minimal fibrosis was seen in any of the groups (data not shown). 
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Figure 3.2: High calorie diet leads to increased hepatic steatosis and ballooning 
degeneration in Hfe+/- mice.  
Light microscopy of representative liver sections stained with hematoxylin and eosin are shown (original magnification x 
100). (A) WT CD. (B) Hfe+/- CD. (C) WT HCD. (D) Hfe+/- HCD.  
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Table 3.3: High calorie diet, but not heterozygous Hfe gene deletion leads to 
increased hepatic steatosis, ballooning degeneration and NAS score.  
Number of mice (%) with NAS (≥2), any macrovesicular steatosis (≥ grade 1), lobular inflammation (≥ grade 1), or 
ballooning (≥ grade 1). P-value is the result of Fisher’s exact test. (n=10 per group)  
 
  Control diet High Calorie Diet   
  
WT Hfe+/- WT Hfe+/- 
p-
value 
NAS (≥2) 0 (0%) 0 (0%) 5 (50%) 5 (50%) 0.003 
Steatosis (Yes) 0 (0%) 0 (0%) 8 (80%) 8 (80%) <0.001 
Lobular Inflammation (Yes) 4 (40%) 3 (30%) 6 (60%) 6 (60%) 0.54 
Ballooning (Yes) 0 (0%) 0 (0%) 4 (40%) 2 (20%) 0.038 
 
Hepatic iron concentration (HIC) is increased in Hfe+/- mice in both dietary groups, 
consistent with the expected phenotype (figure 3.3A). Hamp1 is the gene encoding 
hepcidin, the master regulator of iron homeostasis. When Hamp1 is expressed as a ratio 
of HIC, expression was found to be approximately 50% lower in Hfe+/- mice across both 
dietary groups (figure 3.3C). This observation is consistent with haploinsufficiency of the 
HFE protein in Hfe+/- mice and supports HFE being the predominant regulator of Hamp1 
expression in this model. 
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Figure 3.3: High calorie diet induced reduction in hepatic iron concentration (HIC) 
occurs independently of hepcidin.  
(A) Hepatic Iron Concentration. HCD was associated with reduced HIC (p<0.0001, two-way ANOVA). Hfe+/- mice had 
increased HIC compared to WT mice (p<0.0001, two-way ANOVA). (B) Hepatic Hamp1 mRNA expression. Hamp1 was 
lower in animals fed HCD (p=0.0012, two-way ANOVA). Gene effect was not significant (NS). (C) Hepatic Hamp1 
mRNA/HIC. Hfe+/- mice had lower Hamp1/HIC ratios (p=0.0003, 2way ANOVA). Diet effect was NS. (D) Gut cell Dmt1 
mRNA expression. Diet effect and gene effect were both NS (two-way ANOVA). (E) Gut cell Hephaestin mRNA 
expression. Hfe+/- mice had lower Hephaestin expression than WT mice (p=0.015). Diet effect was NS (two-way 
ANOVA). (n= 6-10 per group). 
 
High calorie diet induced reduction of HIC occurs independently of hepcidin. HIC 
was significantly reduced by HCD in both genotypes (p<0.0001, two-way ANOVA) (figure 
3.3A). The explanation for this is unclear. Hamp1 mRNA expression was lower in HCD-fed 
mice (diet effect p=0.0012, two-way ANOVA, figure 3.3B). The Hamp1/HIC demonstrate 
that Hamp1 expression when normalized to HIC is unaffected by diet (figure 3.3C). As the 
hepcidin-ferroportin axis did not appear to be the cause of the reduced HIC, we sought to 
evaluate two further regulators of intestinal iron absorption, the divalent metal transporter-1 
(DMT1) and Hephaestin. There was no significant diet effect at the mRNA level for either 
of these by two-way ANOVA (figures 3.3D, 3.3E). 
Hfe+/- mice display impaired glucose homeostasis.  As glucose and insulin are 
established drivers of hepatic de novo lipogenesis [121], we measured their fasting serum 
concentrations. Serum glucose was significantly higher in Hfe+/- than WT animals 
(genotype effect p=0.0007, two-way ANOVA). 8.1 vs 7.3 mmol/L in CD fed mice and 8.0 vs 
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7.2 mmol/L in HCD fed mice (figure 3.4A). A trend towards a similar effect was seen for 
serum insulin although this did not reach statistical significance (figure 3.4B). HOMA-IR 
score, which is the product of serum glucose, serum insulin and a constant, has been 
shown to be a useful static measure of insulin resistance in the fasting state [122]. HOMA-
IR was significantly higher in Hfe+/- mice fed both CD (p=0.038) and also HCD (p=0.039) 
using Dunn’s multiple comparison test after a significant Kruskal-Wallis test (p=0.0024) 
(figure 3.4C). Serum adiponectin has previously been shown to be regulated by iron in 
mice and is a known key determinant of insulin resistance [17]. However, we did not find 
any significant effect of genotype on total serum adiponectin (figures 3.4D, 3.4E). 
Moreover, when we looked specifically at the active form, high molecular weight (HMW) 
adiponectin, we again found no genotype effect irrespective of whether we analyzed 
absolute HMW adiponectin serum concentration or HMW adiponectin as a fraction of total 
adiponectin. 
Figure 3.4: Hfe+/- mice have impaired glucose homeostasis irrespective of diet.  
(A) Serum glucose. Serum glucose was higher in Hfe+/- mice compared to WT mice (p=0.0007), Diet effect was NS (two-
way ANOVA). (B) Serum Insulin (mIU/L). Presented on logarithmic (base 10) scale. A difference between groups was 
present p=0.004 (Kruskal-Wallis test). Post hoc comparisons by genotype for CD and HCD mice were both NS (p=0.057, 
p=0.084 respectively by Dunn’s multiple comparison test). (C) HOMA-IR. Presented on logarithmic (base 10) scale. A 
difference between groups was present p=0.0024 (Kruskal-Wallis test). Hfe+/- was associated with increased HOMA-IR 
score for mice fed CD (p=0.038) and HCD (p=0.039) (Dunn’s multiple comparison test). (D, E) Immunoblotting for total 
serum adiponectin (D) densitometry, (E) representative blots. HMW = high molecular weight adiponectin. LMW= Low 
molecular weight adiponectin. Diet and gene effects were both NS (two-way ANOVA). (n= 9-10 per group).  
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Despite increased serum glucose and HOMA-IR score, downstream regulators of de 
novo lipogenesis and fatty acid oxidation are largely unaffected by heterozygous 
Hfe deletion (figure 3.5). The active form of serine/threonine kinase AKT, phospho AKT, 
which is a central regulator of insulin signaling to lipogenesis pathways, was entirely 
unaltered by diet or genotype (figures 3.5A, 3.5C). Similarly, nuclear extract quantities of 
sterol regulatory element binding protein-1 (SREBP-1), the main transcription factor 
responsible for regulation of de novo lipogenesis were also unaffected by genotype 
(figures 3.5B, 3.5C). HCD diet however was associated with an increase in nuclear 
SREBP-1 protein, which may be substrate driven. mRNA quantities of fatty acid synthase 
(Fas) and stearoyl coA desaturase- 1 (Scd1) which are enzymes involved in hepatic 
lipogenesis and are downstream targets of SREBP-1 were also unaffected by genotype 
(figures 3.5D, 3.5E). Similarly there was no effect of Hfe heterozygosity on mRNA 
quantities of three key regulators of fatty acid oxidation; adiponectin receptor-2 (Adipo R2), 
peroxisome proliferator activated receptor alpha (Pparα), and carnitine palmitoyl 
transferase-1 (Cpt1), except for a small increase in Cpt1 expression in Hfe+/- mice fed a 
HCD (p=0.040, Sidak’s multiple comparisons test) (Figure 3.6A, 3.6B, 3.6C). 
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Figure 3.5: Hepatic de novo lipogenesis pathways are not up-regulated despite 
hyperglycemia.  
(A) Immunoblotting densitometry of pAKT (whole liver protein extracts) normalized to GAPDH. Diet and genotype effect 
were both NS (two-way ANOVA). (B) Immunoblotting densitometry of SREBP-1 (nuclear protein extracts) normalized to 
Histone-H3. HCD was associated with increased nuclear SREBP-1 (p=0.022). Gene effect was NS (two-way ANOVA). 
(C) Representative immunoblots for pAKT, GAPDH, SREBP-1, Histone-H3. (n= 9-10 per group). (D) Hepatic fatty acid 
synthase (Fas) mRNA expression. Diet and genotype effect were both NS (two-way ANOVA). (E) Hepatic stearoyl coA 
desaturase- 1 (Scd1) mRNA expression. HCD was associated with increased Scd1 expression. Gene effect was NS 
(two-way ANOVA). 
 
 
Figure 3.6: Hepatic lipid metabolism mRNA  
(A) Hepatic adiponectin receptor-2 (Adipo R2) mRNA expression. HCD was associated with increased AdipoR2 
expression (p=0.0039). Gene effect was NS (two-way ANOVA). (B) Hepatic peroxisome proliferator activated receptor 
alpha (Pparα) mRNA expression. Pparα expression was increased by HCD. Gene effect was NS. (C) Hepatic carnitine 
palmitoyl transferase-1 (Cpt1) mRNA expression. There was a significant interaction between diet and genotype 
(p=0.045). Post hoc analysis found increased Cpt1 expression due to Hfe+/- in HCD fed mice (p=0.040). In CD fed mice 
the results are NS (Sidak’s multiple comparisons test). (n=10 per group). 
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Discussion 
 
In this study, we have demonstrated that heterozygous Hfe gene deletion in our mouse 
model of NAFLD leads to impaired glucose homeostasis in the fasted state, characterized 
by raised serum glucose concentrations and HOMA-IR scores. Despite this, the 
dysregulation of hepatic lipid metabolism and histological evidence of increased liver injury 
seen previously in Hfe-/- mice were not seen in Hfe+/- mice.  
Increased serum glucose in Hfe+/- mice is a notable finding and is significant in relation to 
HFE’s role in insulin sensitivity, type II diabetes mellitus and NAFLD [97, 123]. This study 
however was not primarily designed to investigate glucose homeostasis. Undoubtedly, 
dynamic measures of glucose homeostasis such as glucose and pyruvate tolerance 
testing with hyperinsulinemic-euglycemic clamp studies would help future studies to 
characterize the extent and specific location of insulin resistance in this model.  
The links between iron, insulin resistance and type II diabetes have been extensively 
studied [34]. Two large longitudinal cohort studies have demonstrated increased risk of 
diabetes associated with hyperferritinemia [55, 57]. These associations remained valid 
even after accounting for known confounders such as inflammation. Furthermore, 
therapeutic phlebotomy as a method of iron depletion has been shown in small studies to 
improve glycemic control in non-diabetic, pre-diabetic and diabetic subjects [99-101].  
Somewhat counterintuitively, previous studies have suggested enhanced insulin sensitivity 
in homozygous Hfe null mice [54, 124]. This has been proposed to be due to 
internalization of adipocyte ferroportin resulting in adipocyte iron loading and down-
regulation of the expression of the insulin sensitizing adipokine, adiponectin [17]. This 
effect however was not seen in our model, as heterozygous Hfe+/- deletion did not appear 
to be sufficient to interfere with serum adiponectin levels. 
The findings of our study are relevant if one considers the human data regarding HFE 
mutations and type II diabetes mellitus risk. A large meta-analysis that reviewed studies 
describing HFE gene polymorphisms and the risk of type II diabetes concluded that the 
heterozygous H63D mutation was associated with increased risk of diabetes [123]. In the 
context of this human data, our study provides a clear framework and suitable model for 
future animal studies exploring the mechanistic links between HFE and type II diabetes. 
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Amongst individuals with NAFLD, the presence of heterozygous H63D mutation has been 
associated with higher steatosis grades and NAS score [97]. Given that H63D has less 
iron loading potential than the C282Y mutation, this raises the intriguing possibility of an 
iron-independent role for the HFE protein in macronutrient metabolism that might protect 
against diabetes and NASH. 
Heterozygous Hfe deletion did not appear to influence liver injury in this model, but it may 
be possible that histological differences between Hfe+/- and WT mice would only become 
evident in older mice with a more prolonged exposure to HCD and greater hepatic iron 
loading. Alternatively, it may be that these alterations in lipid and glucose metabolism are 
simply insufficient to impact on liver injury over even a prolonged period of time. It was 
suggested in previous studies of Hfe-/- mice that liver injury may have been attributed 
directly to a deficiency of Hfe protein rather than iron overload per se. Given the lack of 
genotype effect on liver injury seen in the Hfe+/- model, it is not possible to confirm this 
hypothesis. Further studies are planned to investigate the effect of an iron deficient diet in 
Hfe-/- animals in order to address this issue. 
An interesting finding in this study was the effect of both diet and genotype on hepatic iron 
concentration (HIC). Increased hepatic iron in Hfe+/- mice is consistent with reduced 
stimulation of hepcidin-ferroportin axis in the setting of HFE deficiency. Humans with 
heterozygous C282Y mutations have been shown to have increased levels of serum 
ferritin, a marker of tissue iron stores, when compared to wild type controls [13]. The lower 
HIC observed with HCD is consistent with other previous studies [15, 125]. Whether lower 
HIC in association with HCD might be a protective or injurious response is difficult to 
determine. However, the lack of dietary effect on Hamp1 mRNA when normalized to HIC 
suggests that hepcidin response remains appropriate in this model. Similarly, we found no 
dietary effect on the mRNA levels of two other regulators of iron absorption, the enterocyte 
iron transporter DMT1 and the ferroxidase, Hephaestin, despite a previous report of 
dysregulation of the mRNA transcripts of these genes in response to a high fat diet [125]. 
Recently Orr et al have demonstrated a repartitioning of iron from the liver to adipose 
tissue in the setting of a high fat diet [24]. This may explain the reduced HICs with HCD 
noted in our study. This will be further evaluated in future studies (Chapter 5).  
In conclusion, we have demonstrated impaired glucose and iron homeostasis with 
heterozygous Hfe gene deletion in a mouse model of NAFLD. The genetic defect however 
was not associated with increased liver injury or impaired hepatic lipid metabolism. 
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Chapter 4 : Hepatic iron concentration correlates with insulin sensitivity 
in non-alcoholic fatty liver disease 
 
The previous chapter demonstrated that heterozygous Hfe gene deletion in mice leads to 
impaired iron and glucose homeostasis. In order to further explore the relationships 
between iron and insulin resistance, data and human serum samples from a randomized, 
controlled trial of venesection in NAFLD were utilised.[104] Firstly associations between 
measures of iron status, serum ferritin, hepatic iron concentration (HIC) and multiple 
measures of insulin resistance were studied. Secondly, the effect of iron depletion through 
venesection on six adipokines with potential relevance to iron’s role in NAFLD 
pathogenesis was determined. 
This chapter is published in Hepatology Communications. 
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Abstract 
Rodent and cell-culture models support a role for iron-related adipokine dysregulation and 
insulin resistance in the pathogenesis of non-alcoholic fatty liver disease (NAFLD), 
however substantial human data is lacking. We examined the relationship between 
measures of iron status, adipokines and insulin resistance in NAFLD patients in the 
presence and absence of venesection. This study forms part of the IIRON2 study, a 
prospective randomized controlled trial of venesection for adults with NAFLD. Paired 
serum samples at baseline and six months (end of treatment) in controls (n=28) and 
venesection patients (n=23) were assayed for adiponectin, leptin, resistin, retinol binding 
protein-4, TNFα and IL-6 using a Quantibody customized multiplexed ELISA array. Hepatic 
iron concentration (HIC) was determined using MR FerriScan. Unexpectedly, analysis 
revealed a significant positive correlation between baseline serum adiponectin 
concentration and HIC, which strengthened after correction for age, gender and body 
mass index (rho 0.36, p=0.007). In addition there were significant inverse correlations 
between HIC and measures of insulin resistance; Adipo-IR, serum insulin, serum glucose, 
HOMA-IR, HbA1C and hepatic steatosis whereas a positive correlation was noted with 
insulin sensitivity index. Changes in serum adipokines over six months did not differ 
between the control and venesection groups. Conclusion: HIC positively correlates with 
serum adiponectin and insulin sensitivity in patients with NAFLD. Further study is required 
to establish causality and mechanistic explanations for these associations and their 
relevance in the pathogenesis of insulin resistance and NAFLD.  
Background 
 
The epidemic of obesity in both the developed and developing world has led to a major 
rise in the prevalence of non-alcoholic fatty liver disease (NAFLD). NAFLD is estimated to 
be present in 20-30 percent of the adult population.[28] Non-alcoholic steatohepatitis, the 
aggressive form of NAFLD, predisposes individuals towards liver failure and hepatocellular 
carcinoma.[30] Furthermore, NAFLD has been shown to be an independent risk factor for 
cardiovascular disease and type II diabetes.[2]  
 
Unfortunately, currently available treatment options for NAFLD are largely ineffective and 
novel therapeutic targets are urgently needed for this disease. Iron has long been 
considered to have role in the pathogenesis of NAFLD and insulin resistance, a hallmark 
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feature of NAFLD.[7, 8, 34] Therefore, iron has been considered as a potential therapeutic 
target in NAFLD and type 2 diabetes mellitus.[7, 34] 
In recent years, there has been considerable interest in the role of iron in adipose tissue 
biology and the regulation of adipokines.[7, 21] Adipokines are defined as "polypeptides 
that are secreted in the adipose tissue in a regulated manner”.[16] Many of these 
adipokines have endocrine effects on the liver as well as local effects on adipose 
tissue.[16] Altered adipose tissue biology and dysregulation of adipokine synthesis may 
promote liver injury via increased insulin resistance and also by other direct and indirect 
effects on hepatic and adipose tissue lipid metabolism.[16] Studies in animals and tissue 
culture models have demonstrated an iron-induced dysregulation of the synthesis of three 
adipokines with such roles, namely adiponectin, leptin and resistin.[17-19]  
 
Adiponectin is the most abundant adipokine in serum and has a number of hepato-
protective effects in NAFLD.[16, 21] Iron has been shown to down-regulate adiponectin in 
a rodent model of selective adipocyte iron loading and also in cultured 3T3-L1 pre-
adipocytes via decreased acetylation of the transcription factor FOX01.[17] More recently, 
it has been demonstrated that iron down-regulates the appetite-suppressing hormone, 
leptin in mice fed a high iron diet via iron-dependent activation of cAMP-responsive 
element binding protein (CREB).[18] Two other adipokines, resistin and retinol binding 
protein-4 (RBP-4), have been associated with insulin resistance [16] and iron has been 
proposed as a regulator of serum concentrations of both of these hormones.[19, 20] 
Tumor necrosis factor-alpha (TNFα) and interleukin-6 (IL-6) are cytokines secreted from 
adipose tissue as adipokines as well as from other tissues.[16] Both have important roles 
in the induction of insulin resistance in NAFLD and type II diabetes[16, 126, 127] and iron 
has been shown in cell culture studies to promote a pro-inflammatory phenotype in 
macrophages.[75]   
 
To date, studies regarding iron and the regulation of adipokines in humans are relatively 
sparse. Recently, a randomized controlled trial of 274 adults with dysmetabolic iron 
overload syndrome showed that venesection did not affect serum adiponectin levels, 
however other adipokines were not assessed.[128] Venesection in a cohort of six patients 
with type 2 diabetes led to a reduction in serum levels of RBP-4.[20] 
 
At present therefore, there is a clear need for more comprehensive human data to 
determine whether iron-adipokine interactions observed in animal studies might translate 
83 
 
to humans.  We hypothesized that iron is a key determinant in the regulation of insulin 
sensitivity and a number of adipokines relevant to NAFLD pathogenesis. To investigate 
these relationships further, we analyzed the relationships between hepatic iron 
concentration and serum ferritin with markers of insulin resistance and serum 
concentrations of six target adipokines. We also assessed the effect of iron removal by 
venesection on serum levels of these adipokines.  
 
The IIRON2 study is a multi-center, prospective, randomized, controlled trial evaluating the 
effect of venesection on liver injury in adults with NAFLD.[104]  As a component of this 
larger study, this report describes the relationships between baseline iron loading and 
measures of insulin resistance as well as the effect of venesection and lifestyle advice 
versus lifestyle advice alone on serum concentrations of adiponectin, leptin, resistin, RBP-
4, TNFα and IL-6.  
Methods 
 
Participants 
 
Subjects were recruited from hepatology clinics at the Sir Charles Gairdner and Fremantle 
Hospitals in Western Australia and Greenslopes Private Hospital, Queensland, Australia 
between November 2010 and December 2012, by the physicians involved in the study 
(LA, JO, DC and KS).[104] Subjects were adults with hepatic steatosis evident on 
ultrasonography or computed tomography scan and serum ferritin >50 ng/ml. Exclusion 
criteria included the presence of an HFE hemochromatosis genotype (C282Y/C282Y or 
C282Y/H63D), liver disease other than NAFLD, ischemic heart disease, uncontrolled 
diabetes (HbA1C>8.0%) or evidence of decompensated liver disease. Detailed inclusion 
and exclusion criteria have been previously described.[104] The current study also 
excluded those screened with hemochromatosis range HIC (greater than two times the 
upper limit of normal) in order to avoid bias in parametric correlation analyses. The IIRON2 
study was registered with the Australia New Zealand Clinical Trials Registry (Registration 
no. ACTRN12610000868088). This registration included an ‘a priori’ assessment of serum 
adipokine levels as a secondary endpoint (secondary endpoint 4). Written informed 
consent was obtained from all participants. The study protocol conforms to the ethical 
guidelines of the 1975 declaration of Helsinki and was approved by the human research 
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ethics committees of the Sir Charles Gairdner, Fremantle and Greenslopes Private 
Hospitals.  
 
Randomization 
 
Participants were randomized, using a randomization sequence generated by the study 
research coordinator from a computerized random number generator, to venesection with 
lifestyle advice (venesection group) or lifestyle advice alone (control group) at a ratio of 1:1 
as previously described.[104] Allocation concealment prior to randomization was achieved 
using numbered sealed opaque envelopes. Assignment was performed by the research 
coordinators. All subjects received dietary advice regarding the institution of a hypocaloric 
diet from an accredited dietician and all received standardized advice regarding exercise. 
Participants in the venesection group underwent two to three weekly venesections 
targeting a serum ferritin of <45ng/ml. 
 
Clinical and laboratory assessment 
 
A thorough clinical assessment including history and physical examination was performed 
at baseline, three months and at six months (end of study). Standard laboratory 
parameters were measured including liver function tests, serum triglycerides, high density 
lipoprotein (HDL-cholesterol), free (non-esterified) fatty acids (FFA), glucose, insulin, 
glycosylated hemoglobin (HbA1C), 75g oral glucose tolerance test, transferrin saturation, 
serum ferritin and full blood count. Hepascore, a validated serum measure of hepatic 
fibrosis in NAFLD [129]  was performed at the Western Australia state referral laboratory 
(Pathwest, Queen Elizabeth II Medical Centre, Nedlands, Australia). Serum cytokeratin-18 
(CK-18) fragments were measured using an m30 Aptosense ELISA kit (Peviva, Nacka, 
Sweden). 
 
Serum concentrations of adiponectin, leptin, resistin, RBP-4, TNFα and IL-6 were 
measured using a customized multiplexed Quantibody enzyme-linked immunosorbent 
assay (ELISA) array (Human Obesity Array Q3, Raybiotech, Norcross, USA). Assays of 
participant serum samples at 1:2 dilution and adipokine control dilutions for a standard 
curve were performed in quadruplicate by Jomar Life Research, Scoresby, Australia 
according to the manufacturer’s instructions. Hepcidin-25 was isolated from patient serum 
by solid phase extraction, and measured by liquid chromatography quadrupole time-of-
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flight mass spectrometry (LC-qTOF-MS) as previously described.[130-132] Quantitation 
was by reference to a synthetic hepcidin-25 (13C18,15N3) peptide internal standard 
(Peptides International, Inc., Kentucky, USA). 
 
Imaging studies 
 
Hepatic steatosis and hepatic iron concentration (HIC) were measured using non-invasive 
magnetic resonance imaging (MRI) methods on a 1.5T Avanto scanner (Siemens Medical 
Systems, Erlagen, Germany). Hepatic steatosis was quantified, as a volumetric 
percentage, using a validated opposed phase, in-phase gradient echo protocol.[133] A 
validated MRI method (FerriScan) was used to determine HIC.[134]  
 
Statistical analysis 
 
Comparison of baseline variables between groups was performed using two-tailed 
Student’s t-test for continuous variables and Pearson’s Chi-squared or Fisher’s exact test, 
as appropriate, for categorical variables. Baseline correlation analyses were performed 
using Pearson’s correlation.  As the dependency between adipokines and measures of 
iron is unknown, bivariate correlation analysis was used to detect associations. The 
relationships between serum adipokine concentrations, measures of insulin resistance, 
serum ferritin and HIC after correction for body mass index (BMI), age and gender were 
assessed using a partial correlation analysis. The relationships between serum hepcidin 
and surrogates of insulin resistance were assessed using a partial correlation analysis 
correcting for HIC.  
 
For each of the six adipokines, comparisons between the venesection and control groups 
of the change of serum concentration were made using a two-sided independent-sample t-
test. A further analysis of this data was performed using analysis of covariance (ANCOVA) 
with correction for BMI, age and gender. 
Results  
 
Participant characteristics. 
Seventy-four participants were randomized in the study.[104] This cohort was used to 
analyze baseline relationships of measures of insulin resistance and serum adipokines 
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with measures of iron status. The characteristics of this cohort are summarized in Table 
4.1. Of these, 60 patients had serum stored at baseline available for measurement of 
serum adipokine concentrations. Fifty-one also had serum available from the end of the 
study and this cohort was used in the analysis comparing the effect of venesection (n=23) 
versus control (n=28) as shown in Figure 4.1. The baseline characteristics of the 
participants from each randomized group with available paired sera are outlined in Table 
4.2. Baseline characteristics including serum adipokine concentrations were not 
significantly different between groups.  
 
Table 4.1: Baseline characteristics of randomized participants.  
Data is presented as mean and standard deviation except for diabetes and male gender, for which the total number of 
participants and percentage of participants is presented. 
 
Characteristic (n=73) Mean (standard deviation) 
  
Age, years 51.3 (10.8) 
Male gender (%) 43 (59%) 
BMI, kg/m2 31.4 (5.0) 
Waist circumference, cm 105 (13) 
Diabetes (%) 13 (18%) 
ALT, IU/L 72 (56) 
Hepascore 0.33 (0.26) 
Glucose, mmol/L 6.1 (2.1) 
Serum ferritin, ng/mL 507 (442) 
Transferrin saturation, % 31.6 (13.5) 
Hepatic iron concentration, mmol/kg 23.0 (11.3) 
Hepatic steatosis, % by volume 18.1 (10.9) 
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Figure 4.1: Patient flow diagram for the analysis of venesection effect on serum 
adipokine concentrations 
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Table 4.2: Baseline characteristics of participants with available paired sera  
Data is presented as mean and standard deviation except for diabetes, male gender and metabolic syndrome, for which 
the total number of participants and percentage of participants is presented. Values presented are mean values with 
standard deviation in parentheses except where indicated otherwise. p values are the result of unpaired t-tests unless 
indicated otherwise. * p <0.05, # Exact p value from Fisher’s exact test, ‡ Pearson’s Chi-squared test. 
Characteristic 
Control group 
(n=28) 
Venesection 
group (n=23) 
p 
value 
Age, years 51.8 (11.3) 54.0 (9.7) 0.45 
Male gender 18 (64%) 14 (61%) 0.80‡ 
BMI, kg/m2 30.9 (5.3) 31.8 (4.4) 0.52 
Waist circumference, cm 103.4 (13.9) 108.5 (11.3) 0.17 
Diabetes 5 (18%) 4 (17%) 1.0 # 
ALT, IU/L 65.0 (37.7) 81.6 (74.0) 0.31 
AST, IU/L 41.8 (20.5) 47.4 (36.6) 0.49 
Bilirubin, μmol/L 13.8 (5.5) 14.0 (6.5) 0.92 
Alkaline Phosphatase, IU/L 84.5 (19.9) 89.2 (24.8) 0.45 
Albumin, mg/dl 45.0 (3) 43.5 (2.6) 0.054 
CK-18, U/L 287.2 (286.9) 367.8 (322.5) 0.36 
Hepascore 0.29 (0.2) 0.42 (0.3) 0.059 
Triglycerides, mmol/L 1.74 (0.9) 1.63 (0.8) 0.65 
HDL-cholesterol, mmol/L 1.16 (0.3) 1.07 (0.3) 0.26 
Free fatty acids, mmol/L 0.32 (0.2) 0.38 (0.2) 0.28 
Glucose, mmol/L 5.64 (0.8) 6.16 (2.3) 0.27 
Insulin, mU/L 15.6 (12) 14.1 (6.8) 0.60 
HbA1C, % 5.89 (0.7) 6.10 (1.2) 0.46 
HOMA-IR 4.24 (4.1) 4.07 (2.9) 0.86 
ISI 3.44 (3.4) 3.55 (2.9) 0.91 
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Hemoglobin, g/L 152.7 (13.7) 149.2 (12.1) 0.34 
Platelet, x109/dL 216.7 (33.8) 231.6 (99.2) 0.46 
Ferritin, ng/mL 448.1 (388.2) 587.2.1 (353.1) 0.19 
Transferrin saturation, % 31.6 (11.1) 33.4 (14.0) 0.63 
Hepatic iron concentration, mmol/kg 22.1 (10.2)  24.6 (12.7) 0.44 
Hepatic steatosis, % 17.0 (12.7) 18.0 (8.6) 0.76 
Metabolic syndrome 17 (61%) 16 (70%) 0.57# 
Adiponectin, ng/ml 538.4 (249.8) 471.2 (216.7) 0.32 
Leptin, ng/ml 19.5 (18.8) 22.7 (14.2) 0.50 
Resistin, ng/ml 7.55 (2.6) 8.01 (2.0) 0.49 
RBP-4, ng/ml 42.8 (20.1) 38.4 (12.7) 0.37 
TNFα, pg/ml 292.2 (395.4) 249.2 (336.6) 0.68 
IL-6, pg/ml 114.9 (171.4) 114.2 (136.3) 0.99 
 
Correlation of measures of iron loading with baseline serum adipokine 
concentrations 
The 61 participants with available baseline serum were assessed to evaluate the 
relationships between serum adipokine concentrations with two baseline measures of iron 
status, serum ferritin and HIC (Table 4.3). All participants had serum ferritin measured and 
HIC was available for 57 of the 61 participants. A single participant with hemochromatosis-
range HIC (99mmol/kg) was excluded from the analysis. HIC was corrected for steatosis 
percentage volume as determined by MRI in order to provide a true, comparable iron 
concentration in the aqueous (non-lipid) fraction of the liver. Baseline serum hepcidin data 
was available for 37 of the randomized participants. 
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Table 4.3: Correlation between baseline serum ferritin, HIC and serum adipokine 
concentrations 
*p<0.05, df = degrees of freedom 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline serum ferritin was not associated with serum concentrations of any of the six 
adipokines. HIC however, showed a significant positive correlation with serum adiponectin 
(p=0.048, rho= +0.26, Table 4.3, Figure 4.2(a)), but not with the other five adipokines. In 
the cohort, six subjects were taking the insulin sensitizing drug, metformin. No other insulin 
sensitizing drugs were in use amongst the cohort. In particular, no subjects were using 
thiazolidinediones. As metformin might increase serum adiponectin concentrations [135], 
an analysis of the correlation between HIC and adiponectin was performed after excluding 
those subjects taking metformin.  In this analysis, the association between HIC and serum 
adiponectin lost statistical significance, (n= 51, rho= +0.25, p= 0.08), however significance 
was maintained after correction for age, BMI and gender with partial correlation analysis 
(df= 46, rho= +0.34, p= 0.02). BMI correlated with serum leptin concentration (p<0.0001, 
rho=0.585), but not with other adipokines (data not shown). Baseline serum ferritin and 
HIC were correlated (n=65, rho=+0.41, p=0.001). 
  
Pearson’s correlation 
Partial correlation, 
corrected for age, gender 
and BMI 
  
Ferritin 
n=60 
HIC 
n=57 
Ferritin 
df=55 
HIC 
df=52 
Adiponectin 
rho 
p 
-0.06 
0.67 
+0.26 
0.048* 
+0.02 
0.90 
+0.36 
0.007* 
Leptin 
rho 
p 
-0.20 
0.13 
-0.20 
0.13 
-0.01 
0.92 
-0.12 
0.38 
Resistin 
rho 
p 
-0.01 
0.93 
-0.04 
0.77 
+0.10 
0.46 
+0.05 
0.73 
RBP-4 
rho 
p 
+0.05 
0.68 
+0.11 
0.44 
+0.07 
0.60 
+0.14 
0.31 
TNFα 
rho 
p 
+0.07 
0.58 
-0.04 
0.79 
+0.10 
0.45 
-0.02 
0.90 
IL-6 
rho 
p 
+0.07 
0.59 
-0.09 
0.50 
+0.06 
0.65 
-0.10 
0.46 
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Figure 4.2: Relationships between HIC and insulin sensitivity 
HIC and a) adiponectin, b) adipo-IR, c) percentage hepatic steatosis, d) HOMA-IR, e) HbA1C, f) insulin sensitivity index 
(ISI) 
 
Correlation analysis of the baseline data was repeated for all adipokines using partial 
correlation adjusting for three potential confounders: baseline age, gender and BMI (Table 
4.3). This correction strengthened the positive relationship between serum adiponectin and 
HIC (p=0.007, rho= +0.36). There remained no association between HIC and the other five 
adipokines. When also corrected for the same factors, there was no significant correlation 
between serum ferritin and the six adipokines. An analysis of the correlation between 
adiponectin and HIC in non-diabetics and particularly in diabetics is limited by sample size. 
In non-diabetics, there was no significant correlation between adiponectin and HIC (n=49, 
rho=+0.21, p=0.15), however after correction for age, gender and BMI, partial correlation 
remained just significant (df=43, rho=+0.33, p=0.0496). 
 
Correlation of HIC with measures of insulin resistance 
Next, we sought to determine whether the association between HIC and adiponectin was 
an isolated finding or whether HIC is associated with measures of insulin resistance. We 
found that HIC negatively correlated with six surrogates of insulin resistance relating to 
different sites of insulin action. These were: Adipo-IR [136] percentage hepatic steatosis, 
serum insulin, serum glucose, homeostatic model assessment of insulin resistance 
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(HOMA-IR)[122] and HbA1C (Table 4.4 and Figure 4.2(b-e)). Furthermore, the insulin 
sensitivity index (ISI)[137] was significantly positively correlated with HIC (Table 4.4 and 
Figure 4.2(f)). After correction for age, gender and BMI by partial correlation, all 
associations remained significant except for Adipo-IR (Table 4.4).  
In order to determine whether insulin might mediate hepcidin response, we analyzed the 
relationships between hepcidin and the seven surrogates for insulin resistance, using a 
partial correlation analysis, correcting for HIC (Table 4.4). We found that serum insulin and 
serum hepcidin levels positively correlated (df=29, rho=+0.37, p=0.04). However, there 
were no significant relationships between serum hepcidin and the other seven surrogates 
for insulin resistance. 
Table 4.4: Correlation between HIC and hepcidin with measures of insulin resistance 
* p<0.05, df = degrees of freedom 
 
 HIC  
(Pearson’s 
correlation) 
HIC (partial 
correlation, 
correction for age, 
gender and BMI) 
Serum hepcidin  
(partial correlation 
corrected for HIC) 
n rho p df rho p df rho p 
Adipo-IR 62 -0.26 0.045* 57 -0.23 0.08 29 +0.14 0.46 
Steatosis(%) 65 -0.28 0.03* 60 -0.28 0.03* 29 +0.09 0.63 
Insulin 65 -0.26 0.04* 60 -0.28 0.03* 29 +0.37 0.04* 
FFAs 62 -0.21 0.10 57 -0.14 0.29 29 -0.34 0.06 
Glucose 65 -0.31 0.01* 60 -0.26 0.04* 29 -0.12 0.53 
HOMA-IR 65 -0.31 0.01* 60 -0.30 0.02* 29 +0.30 0.10 
HbA1C 64 -0.36 0.003* 59 -0.31 0.01* 29 +0.09 0.63 
ISI 59 +0.30 0.02* 54 +0.28 0.04* 24 +0.05 0.80 
* p<0.05, df = degrees of freedom 
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Serum adipokine concentrations in response to venesection 
Subjects in the venesection group underwent a median of 7 venesections (range 2-19). 
This is roughly equivalent to 1.58g of iron (range 450mg to 4.28g). [118] Change in body 
mass index (BMI) during the study did not differ between groups (-0.67kg/m2 (control 
group) vs +0.24kg/m2 (venesection group), p=0.08, Student’s t-test). BMI, serum 
triglycerides, HDL, LDL cholesterol, HOMA-IR and ISI were not significantly different 
between groups at the end of the study.  
Serum adipokine concentrations did not significantly change between baseline and six 
months for each of the six adipokines in each group except for a 63pg/ml (26%) rise in 
serum TNFα in the venesection group (p=0.048). When comparing the difference in 
absolute change of serum concentration for each adipokine between the control and 
venesection groups, there were no significant differences (Figure 4.3). An ANCOVA 
analysis was performed correcting for baseline body mass index, age and gender and no 
significant differences between groups were observed for each of the six adipokines (data 
not shown).  
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Figure 4.3: Change in serum adipokine concentrations over six months 
Mean change is represented as a percentage of the baseline mean for each adipokine. No significant differences were 
observed for each adipokine between the control (n=28) and venesection groups (n=23). Values represented are mean 
absolute change in serum adipokine concentration with error bars to represent standard error of the mean. Measured 
serum concentration of TNFα and IL-6 was below the lower limit of detection of the assays in 11 (of 102) and 23 (of 102) 
samples respectively. In these instances, the lower limit of detection value was used for statistical analysis. A analysis in 
which zero values were used instead of the lower limit of detection values, did not substantially alter the results (data not 
shown) 
 
Discussion 
 
In this prospective, randomized, controlled clinical trial, we have shown that venesection 
does not alter the serum concentrations of six key adipokines in participants with NAFLD. 
To our surprise however, we demonstrated a significant positive relationship between HIC 
and serum adiponectin concentration in this cohort. This observation was strengthened 
further after correction for age, gender and BMI.  Furthermore, we have shown that HIC 
negatively correlated with multiple measures of insulin resistance. We looked at eight 
surrogate measures of insulin resistance and their relationship to iron. In all cases, except 
for FFAs, a significant relationship was found associating enhanced insulin sensitivity with 
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increasing HIC. These data suggest that HIC inversely predicts insulin resistance in the 
periphery (adipose tissue and skeletal muscle) as well as within the liver. 
 
Notably, in keeping with our findings, a cross-sectional study of 80 Italian patients with 
biopsy-proven NAFLD, found that the Oral Glucose Sensitivity Index increased with 
increasing HIC.[61] Furthermore, a recently published randomized controlled study by 
Lainé et al of 274 participants with dysmetabolic iron overload and significantly elevated 
HIC (>50mmol/kg) found that venesection was associated with significantly increased 
serum insulin and HOMA-IR scores over time[128]. We found no difference between 
groups in HOMA-IR scores, ISI or change in HOMA-IR or ISI over time.[104] This 
remained the case in sub-group analyses of diabetics and non-diabetics (data not shown). 
Although we did not find that venesection altered insulin resistance, the longer duration of 
venesection (12 months versus 6 months) and higher baseline HIC in the Lainé study may 
account for the change in insulin resistance in that study. It is therefore worth considering 
however that there may be subgroups of patients with NAFLD that may develop altered 
adipokine concentrations in response to venesection, possibly over a longer duration of 
treatment.  
 
Our findings add weight to the possibility of a causal relationship between iron and insulin 
sensitivity in individuals with NAFLD. These results suggest that hepatic iron loading below 
the hemochromatosis range (less than two times the upper limit of normal, normal range 3-
33mmol/kg[138]) may actually be beneficial in terms of insulin sensitivity. In contrast, the 
association between excess hepatic iron seen in hemochromatosis and insulin resistance 
and diabetes is well established.[34] Pathologic iron overload from hereditary 
hemochromatosis can cause diabetes through both insulin deficiency from beta-cell loss in 
the pancreas as well as insulin resistance.[34]  Our data, coupled with these observed 
relationships between hemochromatosis and insulin resistance suggest that a ‘sweet-spot’ 
of HIC for maximal insulin sensitivity exits, above and below which, increased insulin 
resistance is observed. 
 
An alternative explanation for the relationship between HIC and insulin sensitivity might be 
that insulin or some aspect of insulin resistance might regulate iron homeostasis. In order 
to explore this possibility further we looked at serum hepcidin concentrations and their 
relationship to our eight measures of insulin sensitivity. Hepcidin is the key regulator of 
systemic iron absorption through its effect on small bowel enterocyte iron export.[36, 38] 
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Hepcidin is predominantly produced by hepatocytes and is transcriptionally regulated by a 
number of factors, including hepatic iron.[36, 38] As such, we examined the markers of 
insulin resistance in relation to hepcidin after correction for HIC. We found that serum 
hepcidin levels positively correlated with serum insulin. This could indicate that insulin 
signaling may play a role in hepcidin regulation, whereby insulin resistance leads to 
reduced intestinal iron absorption. However, as the other measures of insulin resistance 
were not associated with serum hepcidin levels, a direct link would seem unlikely.  
 
We found that serum concentrations of the insulin sensitizing adipokine, adiponectin, 
positively correlate with HIC. This may in part explain the relationship between iron and 
insulin sensitivity in this cohort. However, adipokines by definition, are cytokines that are 
synthesized in adipose tissue and therefore adipocyte, or adipose tissue, iron 
concentrations are likely to be most important with respect to iron-adipokine interactions.   
Indeed, HIC may not be an accurate surrogate measure of adipose tissue iron. Rodent 
data have shown that a high fat diet leads to a redistribution of iron from the liver to 
adipose tissue with a four-fold increase in adipocyte iron concentration and a two-fold 
reduction in HIC.[24] Human studies demonstrate that obesity is associated not only with 
iron deficiency, but paradoxically also with increased sub-cutaneous and visceral adipose 
tissue iron.[22, 111, 112] Furthermore, increased adipocyte iron leading to a reduction in 
adiponectin expression has been demonstrated in a variety of mouse and adipocyte 
culture models.[17] Taken together, it may be possible in NAFLD that iron redistributes 
from the liver to adipose tissue, thus contributing to insulin resistance and a reduction in 
serum adiponectin.  
 
In this study, we have measured HIC, as a well validated surrogate for total body iron 
stores.[139] We corrected HIC for percentage steatosis volume, in order to give a truer, 
more physiologically relevant HIC that is reflective of iron concentration in the aqueous 
(non-lipid) fraction of the liver. By doing this, we have demonstrated that it is not simply 
HIC dilution by lipid that erroneously explains the relationships between iron, steatosis and 
other measures of insulin resistance. It should be noted that this HIC correction is a 
conservative approach to the data that weakens the associations observed compared to 
when un-corrected HIC is used (data not shown). 
 
Contrary to our findings, a number of other studies have indicated a positive association 
between serum adiponectin and measures of human iron stores.[17, 90, 140] These 
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studies may be limited by the choice of surrogate for HIC. In all three studies, inverse 
correlations were noted between serum ferritin and serum adiponectin, however this only 
reached statistical significance in two of the studies. [17, 90]. These are interesting 
observations that were not seen in our cohort. However, although serum ferritin 
undoubtedly correlates with HIC, it is clearly an imprecise measure of HIC. Our data show 
that despite strong statistical significance (p<0.001), the association itself is not strong (r2= 
0.17), indicating that only 17% of the variance in serum ferritin is attributable to HIC. Ryan 
et al, have recently reported an inverse association between liver iron and serum 
adiponectin. [140] However, the MRI T2* values, used as an inverse surrogate for HIC, 
were not corrected for volume of hepatic steatosis. In addition there may have been a 
greater degree of liver injury in the Ryan et al cohort with 35.3% of individuals reported as 
having tissue elastography measurements indicative of bridging fibrosis or cirrhosis. These 
factors may, in part, explain the disparity between the two cohorts. 
 
A weakness of our study is that it presupposes that venesection mobilizes adipose tissue 
iron as it does for other tissues. Although it is increasingly clear that adipocytes utilize 
much of the iron metabolism apparatus that is used in other tissues, such as transferrin 
receptor 1, hepcidin and ferroportin, we are not aware of any human data that has 
addressed the degree to which adipose tissue iron is mobilized by venesection.[17, 23]  
 
Another limitation of our study is the lack of liver histology. It is likely that there was degree 
of heterogeneity of liver injury among participants studied. In addition, the lack of liver 
histology does not allow for determination of the relative distribution of iron between 
hepatocytes and reticuloendothelial cells. This may be critical to iron’s impact within the 
liver as reticuloendothelial iron has been shown to be associated with apoptosis and a 
greater risk of hepatocellular ballooning, steatohepatitis and advanced fibrosis in humans 
with NAFLD. [74, 83] 
 
A strength of this study is that it represents an ‘a priori’ assessment as part of a 
randomized, controlled trial. Our study failed to demonstrate any effect of venesection on 
serum concentrations of the six adipokines studied. It is possible that our study may be 
underpowered for some of the adipokines as these were secondary endpoints for which 
the study was not prospectively powered.  
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A number of avenues for future work in this field present themselves. Firstly, obtaining 
human adipose tissue samples for the determination of adipose tissue and adipocyte iron 
concentrations would be technically challenging but likely highly informative. A pragmatic 
approach to this would be obtaining visceral adipose tissue samples in patients 
undergoing laparoscopic cholecystectomy. Coupled with an in depth assessment of insulin 
resistance and serum adipokine concentrations, ideally using hyperinsulinemic-euglycemic 
clamps,  relationships between insulin resistance and adipose tissue iron concentrations 
could be readily evaluated in a cross-sectional cohort such as this. Another approach, 
would be to perform a study in which insulin resistance, using hyperinsulinemic-
euglycemic clamp studies and serum adipokine concentrations were assessed before and 
after and the infusion of intravenous iron. 
 
In conclusion, we have found a lack of effect of venesection on serum concentrations of 
six important adipokines in patients with NAFLD. We have however demonstrated 
significant correlations between hepatic iron, serum adiponectin and multiple surrogate 
measures of insulin sensitivity. The causality of these relationships remains uncertain. 
Mechanistic explanations for the relationships between iron metabolism and insulin 
resistance are targets for future studies. 
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Chapter 5 : Ferroportin expression in adipocytes does not contribute to 
iron homeostasis or metabolic responses to a high calorie diet 
 
The previous two chapters have demonstrated seemingly conflicting observations between 
a human and an animal study regarding the associations between hepatic iron and insulin 
resistance in NAFLD. Chapter 3 showed that mild increases in iron in the context of 
heterozygous Hfe gene deletion in mice are associated with impaired glucose 
homeostasis. In humans with NAFLD however, increased hepatic iron concentration 
appears to be associated with increased insulin sensitivity. In this chapter, the theme of 
mild increases in iron in insulin resistance and NAFLD pathogenesis is explored further. It 
is increasingly evident that the key site of iron’s impact on insulin resistance and NAFLD 
may centre upon its effects on adipocyte biology.[7, 17, 18, 34] In this chapter, a model of 
selective knockout of the iron exporter ferroportin in adipocytes is developed, focusing on 
the effects on adipocyte iron metabolism, glucose homeostasis and liver injury. 
This chapter is published in Cellular and Molecular Gastroenterology and Hepatology   
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Abstract 
 
Background & Aims: Iron has an increasingly recognized role in the regulation of adipose 
tissue function, including the expression of adipokines involved in the pathogenesis of non-
alcoholic fatty liver disease (NAFLD). The cellular iron exporter, ferroportin, has been 
proposed as being a key determinant of adipocyte iron homeostasis. Methods: We studied 
an adipocyte-specific ferroportin (Fpn1) knockout (FKO) mouse model, using an Adipoq-
Cre recombinase driven Fpn1 deletion and fed mice according to the fast food diet model 
of non-alcoholic steatohepatitis. Results: We demonstrated successful selective deletion of 
Fpn1 in adipocytes, but found that this did not lead to increased adipocyte iron stores as 
measured by atomic absorption spectroscopy or histologically quantified iron granules 
after staining with DAB enhanced Perls’ stain.  Mice with adipocyte-specific Fpn1 deletion 
did not demonstrate dysregulation of adiponectin, leptin, resistin or retinol-binding protein-
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4 (RBP-4) expression. Similarly, adipocyte-specific Fpn1 deletion did not affect insulin 
sensitivity during hyperinsulinemic-euglycemic clamp studies or lead to histological 
evidence of increased liver injury. We have however shown that the fast food diet model of 
non-alcoholic steatohepatitis generates an increase in adipose tissue macrophage 
infiltration with crown-like structures, as seen in humans, further validating the utility of this 
model. Conclusions: Ferroportin may not be a key determinant of adipocyte iron 
homeostasis in this knockout model. Further studies are needed to determine the 
mechanisms of iron metabolism in adipocytes and adipose tissue. 
Background 
 
Non-alcoholic fatty liver disease (NAFLD) affects around one billion people worldwide [1]. 
Many of these individuals develop non-alcoholic steatohepatitis (NASH) and hepatic 
fibrosis, which can lead to liver failure and hepatocellular carcinoma [2, 30, 31]. 
Treatments that effectively alter the natural history of this disease are lacking and a 
greater understanding of its pathogenesis is essential in order to develop such therapies. 
Dysfunctional adipose tissue has been shown to be central to the pathogenesis of insulin 
resistance and NAFLD [21]. Adipose tissue serves as the predominant source of liver fat in 
NAFLD and is the source of adipokines that have significant roles in the regulation of liver 
injury [16, 43].  
Iron is an essential element in cellular metabolism, but has also been implicated in a wide 
range of human disease [36]. It has been reported that adipocytes within adipose tissue 
utilize the same apparatus for iron metabolism as other cell types, such as transferrin 
receptor 1 (Tfr1), hepcidin and ferroportin, [17, 22, 141]. Recent data support a role for iron 
in the regulation of adipose tissue function. Adipose tissue iron has been proposed as 
having roles in the pathogenesis of NAFLD as well as type 2 diabetes mellitus [7, 34]. 
Studies have implicated adipose tissue iron in the dysregulation of four key adipokines in 
NAFLD: adiponectin, leptin, resistin and retinol binding protein-4 (RBP-4) [17-20, 22]. 
Furthermore, iron has been shown to increase lipolysis in isolated rat adipocytes [142]. 
It has been proposed that the cellular iron-exporter ferroportin is a key determinant of 
adipocyte iron metabolism [17]. Gabrielsen et al demonstrated the down-regulation of 
adiponectin in response to iron across a range of in vivo and in vitro models [17]. The 
authors employed an AP2-Cre:Fpn1fl/fl model of selective adipocyte ferroportin deletion as 
a model of adipocyte iron loading. However, results of direct measurement of adipocyte 
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iron were not presented and an iron-loading phenotype was inferred solely on the basis of 
reduced Tfr1 mRNA quantities [143]. Tfr1 mRNA quantification remains, at best, an 
indirect surrogate for iron loading that has not been well validated in adipocytes. 
Furthermore, the AP2 gene has been shown to be significantly expressed in other cell 
types, notably macrophages [26, 27, 144]. As such, the importance of ferroportin in 
adipocyte iron handling requires further validation. The Adipoq-Cre model which utilizes a 
BAC transgene Cre recombinase in the promoter region of the adiponectin gene has been 
shown to have greater adipocyte specificity than the AP2-Cre and is considered to be a 
superior model of selective adipocyte-specific gene deletion [26, 27]. 
In this study, we sought to determine whether ferroportin regulates adipocyte iron 
metabolism by selectively knocking out Fpn1 in adipocytes using an Adipoq-Cre 
recombinase mouse model. We utilized the fast food diet model, as described by Charlton 
et al, as a model for non-alcoholic steatohepatitis in these mice [25]. This paper 
investigates the role of ferroportin in the handling of iron by adipose tissue. In addition, we 
examine the effect of adipocyte-specific ferroportin deletion on glucose metabolism and 
liver injury using the fast food diet model of NASH. We also evaluate the utility of the fast 
food diet model as a model for adipose tissue dysfunction in NASH.  
Methods 
 
Experimental Animals 
Mice with loxP fragments inserted in exons 6 and 7 of the mouse Ferroportin gene (Fpn1fl/fl 
mice) on a 129/SvEvTac background were a kind gift of Prof Nancy Andrews, Duke 
University, Durham, USA [145]. Fpn1fl/fl mice were backcrossed for at least eight 
generations onto a C57BL/6 background. Male Fpn1fl/fl mice were then crossed with 
female heterozygous C57BL/6 Adipoq-Cre+/- mice expressing Cre recombinase under the 
control of Adipoq (adiponectin gene) promotor regions on a BAC transgene (Jackson 
Laboratory, Bar Harbor, USA) [27]. This generated both Adipoq-Cre:Fpn1fl/fl, adipocyte-
specific ferroportin knockout (FKO) and Fpn1fl/fl (Flox) littermate control mice.  
After weaning, mice were housed singly. Sixteen week-old male mice were randomly 
assigned, using a computerized random allocation sequence generator, to receive either 
control diet or fast food diet for 25 weeks until the end of the experiment [25]. Control diet 
mice were provided with drinking water and fast food diet mice were supplied with 42g/L 
high fructose corn syrup (23.1g/L fructose, 18.9g/L glucose, Chem-supply, Gillman, 
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Australia) in the drinking water [146]. Diets were supplied by Specialty Feeds (Glen 
Forrest, WA, Australia). Mice had ad libitum access to diet and water (control diet) or high 
fructose corn syrup in water (fast food diet). The key constituents of the diets are outlined 
in Table 5.1.  
Table 5.1: Major components of experimental diets 
 
Dietary component Control diet Fast food diet 
Protein (% weight) 13.6 17.4 
Total fat (% weight) 4.0 20 
Total digestible carbohydrate (% weight) 64.8 48.2 
Digestible energy (MJ/kg) 15.1 18.6 
Cholesterol (% weight) 0 0.15 
Casein (acid) (g/kg) 140 180 
Sucrose (g/kg) 100 341 
Clarified butter (ghee) g/kg 0 200 
Wheat starch (g/kg) 472 82 
Dextrinized starch (g/kg) 155 0 
Iron (mg/kg) 75 75 
High fructose corn syrup in drinking water (g/L) 0 42 
 
At 41 weeks of age, mice were weighed. After a five hour fast, mice received an 
intraperitoneal injection of either 0.75 mU/g humulin R insulin (Eli-Lilly, Indianapolis, USA) 
in sterile 0.9% sodium chloride (0.15 mU/µL), (Pfizer, New York, USA) or 5 µL/g 0.9% 
sodium chloride alone. After ten minutes, mice were sacrificed as previously described 
[147]. 
Whole liver and epididymal fat pad weights were recorded. Liver and epididymal fat pad 
samples were fixed in formalin for histology. Liver samples were snap frozen in liquid 
nitrogen and stored at -80 oC. Liver and spleen samples were dried at 110 oC for 72 hours 
for measurement of tissue iron concentration. Blood was collected by cardiac puncture and 
serum was stored at -80 oC. Adipocytes were isolated from epididymal fat pads following 
collagenase-dispase digestion as previously described and stored at -80 oC [144].  
All experiments were performed with approval from the Animal Ethics Committee of the 
QIMR Berghofer Medical Research Institute and were conducted in accordance with the 
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NHMRC code for the care and use of animals for scientific purposes. Mice were housed in 
a temperature controlled environment (23 oC) in a 12:12 hour light: dark cycle. All authors 
had access to the study data and reviewed and approved the final manuscript. 
Glucose tolerance tests 
Glucose tolerance tests were performed one week prior to sacrifice, at 40 weeks of age. 
After a five hour fast, mice were given 1 g/kg glucose via the intraperitoneal route. Tail vein 
sampling was performed at 0, 15, 30, 60 and 120 minutes and blood glucose was 
measured using an Accu-Chek Performa II hand-held glucometer (Roche, Basel, 
Switzerland). 
Hyperinsulinemic-euglycemic clamp studies 
Hyperinsulinemic–euglycemic clamps were performed as previously described in 6 hour-
fasted mice [148]. An initial two minute-priming dose of insulin (150 mU/kg/min) was 
followed by a constant infusion at a rate of 15 mU/kg/min. Maintenance of euglycemia was 
achieved by a variable infusion of 25% glucose solution. Steele’s steady-state equation 
was used to calculate glucose turnover. 
Tissue iron concentration 
Hepatic and splenic iron concentrations were measured as previously described [147]. 
Adipocyte iron concentration was performed on isolated adipocytes by atomic absorption 
spectroscopy (AAS). Approximately 100 mg of adipocytes for each animal were weighed 
and then dried down at 60 oC for 60 hours and 100 µL concentrated nitric acid was added. 
Samples were then incubated at 60 oC for 30 minutes, before dilution 1:5 with zero 
standard (0.2% nitric acid). Standards over a range of 0-25 µmol/L were prepared using 
iron pure single element standard 1000 mg/L iron in 2% nitric acid (Perkin Elmer, 
Waltham, USA). All samples (including standards, quality control and analytical samples) 
were further diluted 1:3 with 10g/L palladium matrix modifier for graphite furnace AAS 
(Merck Millipore, Darmstadt, Germany). AAS was performed at a wavelength of 372nm 
using an AA280Z, Zeeman Atomic Absorption Spectrometer (Varian, Palo Alto, USA) with 
a GTA 120 Graphite Tube Atomizer (Agilent Technologies, Santa Clara, USA). Zeeman 
background correction was used. The final results were expressed per gram wet weight. 
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RNA extraction, real time quantitative (RT-qPCR) and DNA electrophoresis 
RNA was extracted from liver and adipocyte homogenates using Trisure reagent (Bioline, 
London, UK). Samples were treated with DNAse 1 (Invitrogen, Carlsbad, USA) and cDNA 
was synthesized from 1 µg RNA (liver) and 500 ng RNA (adipocytes) using a Sensifast 
cDNA synthesis kit (Bioline).  For RT-qPCR, a ViiA7 real-time PCR machine (Invitrogen) 
with a SensiFAST SYBR Lo-ROX Kit was used (Bioline). Samples underwent thermal 
cycling as follows: 95 oC for 2 minutes then 40 cycles at 95 oC for 5 seconds followed by 
63 oC for 20 seconds prior to a melt curve analysis. Relative mRNA expression was 
determined by calibration of Ct values to standard curve of pooled cDNA samples and 
normalized to the geometric mean of three reference genes (basic transcription factor-3 
(Btf3), glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and beta-2-microglobulin (β2-
mg) for liver samples and RNA Polymerase II Subunit A (Polr2a), Beta-actin and 
hypoxanthine guanine phosphoribosyl transferase (Hprt) for adipocyte samples. Primer 
sequences are provided in Table 5.2. 
Table 5.2: RT-qPCR primer sequences (5’ to 3’) 
 
 Forward primer Reverse primer 
Tfr1 GAGGCAGACCTTGCACTCTT TGACTGAGATGGCGGAAAC 
Fpn1 GCCACTGCGATCACAATCC TGGAGTTCTGCACACCATTGAT 
Hamp1 TTGCGATACCAATGCAGAAG GGATGTGGCTCTAGGCTATGTT 
Adiponectin GGAGATGCAGGTCTTCTTGG TCCAGGCTCTCCTTTCCTG 
Leptin GCAGTGCCTATCCAGAAAGTCC GGAATGAAGTCCAAGCCAGTGAC 
Resistin CATGCCACTGTGTCCCATCGAT ACTTCCCTCTGGAGGAGACTGT 
Rbp-4 TGTAGCCTCCTTTCTCCAGCGA ACAGGTGCCATCCAGATTCTGC 
Β2-mg CTGATACATACGCCTGCAGAGTTAA ATGAATCTTCAGAGCATCATGAT 
Btf-3 TGGCAGCAAACACCTTCACC AGCTTCAGCCAGTCTCCTTAAAC 
Gapdh TCCTGCACCACCAACTGCTTAGC GCCTGCTTCACCACCTTCTTGAT 
Polr2a AGCTGGTCCTTCGAATCCGC CTGATCTGCTCGATACCCTGC 
Beta-actin CATTGCTGACAGGATGCAGAAGG TGCTGGAAGGTGGACAGTGAGG 
Hprt GGACTGATTATGGACAGGA GAGGGCCACAATGTGATG 
Hmox1 CACTCTGGAGATGACACCTGAG GTGTTCCTCTGTCAGCATCACC 
 
For confirmation of adipocyte-specific ferroportin knockout, 10µl of adipocyte Fpn1 DNA 
amplification product, created using primers flanking exons 6 and 7 (Table 5.2) (thermal 
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cycling: 95 oC for 2 minutes then 40 cycles at 95 oC for 5 seconds followed by 63 oC for 45 
seconds) was mixed with 2 µl of 6X DNA loading buffer (New England Biolabs, Ipswich, 
USA). Samples were electrophoresed at 110 V for 40 minutes in a 1.5% agarose gel 
(Bioline) mixed with Sybr safe buffer (Invitrogen). The products were visualized on an 
ImageQuant LAS 500 machine (GE Healthcare Life Sciences, Little Chalfont, UK).  
Immunoblotting 
Eight µL of 1:1000 mouse serum was electrophoresed on 2% Metaphor Agarose gels 
(Lonza, Basel, Switzerland) for 75 minutes at 75 V. Protein was transferred onto 
polyvinylidene fluoride (PVDF) membranes (Biorad, Hercules, USA) over 60 minutes at 
100 V. Blocking was performed using 5% skim milk powder. A 1:10,000 dilution of primary 
antibody against adiponectin (MAB3608, Merck Millipore) was applied to the membranes. 
A 1:50,000 dilution of goat anti-mouse horseradish peroxidase antibody (Invitrogen) was 
applied as secondary antibody. Visualization was performed using a Supersignal West 
Femto chemiluminescent kit (Thermo Fisher Scientific, Waltham, USA) on an ImageQuant 
LAS 500 machine (GE Healthcare Life Sciences). 
Histological assessment and hepatic hydroxyproline assays 
Formalin fixed samples of liver and epididymal fat pad (EFP) were embedded in paraffin. 
Liver sections were stained with Hematoxylin and Eosin (H&E) for assessment of 
steatohepatitis and Sirius Red for assessment of fibrosis. Scoring was performed 
according to criteria established by Kleiner et al [84]. Further liver sections were stained 
with Oil Red O and percentage area stained was measured using ImageJ software, 
version 2. EFP sections were stained with H&E and the absolute count of macrophage 
clusters over ten high power fields (x400) was determined. Additional EFP sections were 
stained with 3,3'-diaminobenzidine (DAB) enhanced Perls’ stain and Eosin counterstain. 
The average count of iron granules within adipocytes in five adjacent high power fields 
(x400 magnification) was determined. Small iron granules were counted individually 
(score=1), granules filling the whole cell scored 10. All histological assessments were 
performed by an expert histopathologist blinded to study group. Photomicrographs were 
created using a MicroPublisher 3.3 RTV camera (Q Imaging, Surrey, Canada) and a 
Biological System Microscope CX41 (Olympus, Tokyo, Japan). Hepatic hydroxyproline 
assay was performed as previously described.[149] 
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Statistical analysis 
Statistical analysis was performed using GraphPad Prism software, version 7.03 
(GraphPad, San Diego, USA). Hyperinsulinemic-euglycemic clamp data and glucose 
concentrations during glucose tolerance tests were analyzed using two-tailed Student’s t-
tests. For liver histology scoring, Mann-Whitney tests were used to compare genotypes for 
each diet. For all remaining data, two-way ANOVA was used to assess the effect of diet 
and genotype. If a significant interaction (p<0.05) was found, Sidak’s multiple 
comparison’s test was used to compare between genotypes for each diet and between 
diets for each genotype. In cases in which no interaction was found, p values for the diet 
and genotype effect are indicated. Data presented on box and whisker plots show bars 
representing the median and interquartile range with whiskers representing the maximum 
and minimum values. 
Results 
 
Fast food diet was associated with increased body, liver and epididymal fat pad 
weights.  Initial body weight was comparable across all four groups (all non-significant 
(NS), Sidak’s multiple comparisons test, data not shown). Consistent with the description 
of the fast food diet model [25], mice fed with the fast food diet had greater final body 
weight (p<0.0001) and liver weight (p<0.0001, two-way ANOVA) (Fig. 5.1). EFP weight 
was higher in both genotypes with fast food diet (p=0.0001 Flox mice, p<0.0001 FKO 
mice, Sidak’s multiple comparisons test) (Fig. 4.1).  
Figure 5.1: Tissue and body weights.  
(A) Total body weight. Total body weight was increased in in animals fed the fast food diet (FFD), P<0.0001, genotype 
effect was not significant (NS, two-way ANOVA) (B) Liver weight. Liver weight was increased in animals fed FFD, 
P<0.0001, gene effect was NS, (two-way ANOVA) (C) Epididymal fat pad (EFP) weight. There was a significant 
interaction between diet and genotype effects (P=0.03, two-way ANOVA). Post-hoc analysis demonstrated lower EFP 
weight in FKO mice compared to Flox mice fed FFD (P=0.02) and increased weight with FFD diet for both Flox and FKO 
mice (P=0.0001 and P<0.0001 respectively, Sidak’s multiple comparisons test) n = 8-12 per group. 
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FKO mice demonstrate successful selective adipocyte knockout of ferroportin in 
adipocytes, but not in other tissues. Fpn1 primers targeting sequences in exons 5 and 
8 which flank the Fpn1 loxP sites predicted amplification products of 1048 base pairs (bp) 
for the intact gene and 163bp for Cre-recombinase-deleted Fpn1 gene. DNA 
electrophoresis of Fpn1 qRT-PCR products from isolated adipocytes demonstrated a clear 
163 bp band in all 20 samples of FKO mice and no 163bp band in all 24 samples in Flox 
mice, indicating adipocyte Fpn1 deletion in FKO, but not in Flox mice. A representative gel 
is shown in Fig. 5.2A. In all liver samples, Flox (n=9), FKO (n=8) and all spleen samples 
Flox (n=7), FKO (n=14), the 163 bp band was absent whereas a 1048 bp band was 
present indicating a lack of Cre recombinase effect in liver and spleen, irrespective of 
genotype. 
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Figure 5.2: Adipocyte-specific ferroportin knockout does not alter adipocyte iron 
phenotype.  
(A) Representative DNA electrophoresis blot of adipocyte Fpn1 RT-PCR products showing the predicted 163bp band in 
adipocytes from FKO but not Flox mice. (B) TfR1 mRNA expression. Diet and genotype effects were both NS (two-way 
ANOVA) (n = 8-12 per group). (C) Adipocyte iron concentration. Diet and genotype effects were both NS (two-way 
ANOVA) (n = 8-12 per group).  (D) Quantified adipocyte iron granules. Mean count of granules of iron in five adjacent 
high power fields (x400 magnification). Diet and genotype effects were both NS (two-way ANOVA) (n = 8-12 per group).  
(E-H) Perls’ staining of epididymal fat pads. Representative light microscopy sections are shown of Eosin and DAB 
enhanced Perls’ stained sections of epididymal fat pads with arrows indicating small iron granules (x 400 magnification) 
(E) Flox control diet. (F) Flox fast food diet. (G) FKO control diet. (H) FKO fast food diet (n = 7-12 per group). 
 
Adipocyte-specific ferroportin deletion does not alter adipocyte iron phenotype. All 
three measures of adipocyte iron loading in adipocytes consistently showed no effect of 
Fpn1 deletion on iron phenotype (Fig. 5.2B-H). Quantification of Tfr1 mRNA as an 
inversely related surrogate for cellular iron concentration found no genotype effect (NS, 
two-way ANOVA) (Fig. 5.2B). Similarly, adipocyte iron concentration by atomic absorption 
spectroscopy was not altered by Fpn1 deletion (NS, two-way ANOVA) (Fig. 5.2C). 
Histologic assessment of adipocyte iron granules using DAB-enhanced Perls’ stain found 
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that iron granule numbers were not increased in FKO mice (NS, two-way ANOVA) (Fig. 
5.2D-H). 
Fast food diet leads to reduced tissue iron concentrations via a hepcidin-
independent mechanism. Hepatic iron concentration (HIC) was reduced by fast food diet 
in FKO mice (p<0.0001, Sidak’s multiple comparison test) (Fig. 5.3A). Reduced HIC with 
fast food diet does not appear to be explained by an increase in Hamp1 (encoding 
hepcidin) mRNA, as Hamp1 mRNA levels were substantially reduced in fast food diet mice 
in both genotypes (p<0.0001, two-way ANOVA) (Fig. 5.3B). As HIC is an established 
regulator of hepcidin transcription [36, 38], we normalized Hamp1 mRNA to HIC and found 
markedly reduced Hamp1/HIC levels with fast food diet, likely indicating an appropriate 
compensatory Hamp1 response to reduced HIC (p<0.0001, two-way ANOVA) (Fig. 5.3C). 
Splenic iron concentration was also reduced by fast food diet (p<0.0001, two-way ANOVA) 
(Fig. 5.3D). 
Figure 5.3: Fast food diet leads to reduced tissue iron concentrations via a hepcidin-
independent mechanism  
(A) Hepatic iron concentration (HIC). There was a significant interaction between diet and genotype (P=0.03, two-way 
ANOVA). Post hoc analysis demonstrated significantly lower HIC in FKO animals fed fast food diet compared to control 
diet (P<0.0001, Sidak’s multiple comparisons test). (B) Hepatic Hamp1 mRNA expression. Hepatic Hamp1 mRNA was 
reduced by fast food diet (P<0.0001). Genotype effect was NS. (two-way ANOVA). (C) Hepatic Hamp1 mRNA/HIC. 
Hepatic Hamp1 mRNA/HIC ratio was reduced by fast food diet (P<0.0001). Genotype effect was NS. (two-way ANOVA). 
(D) Splenic iron concentration. Splenic iron concentration was reduced by fast food diet (P<0.0001). Genotype effect was 
NS (two-way ANOVA) (n= 8-12 per group). 
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The fast food diet model is associated with adipose tissue macrophage 
accumulation. Clusters of macrophages, resembling crown-like structures [150] (as 
indicated by arrows in Fig. 5.4C, 5.4E) were frequently observed in adipose tissue sections 
from fast food diet-fed mice but not in their control diet counterparts (p<0.0001, two-way 
ANOVA). Fpn1 deletion had no effect on the numbers of macrophage clusters (NS, two 
way ANOVA) (Fig. 5.4). 
Figure 5.4: Fast food diet is associated with adipose tissue macrophage 
accumulation  
(A) Number of macrophage clusters. Absolute count over ten high power fields. Macrophage clusters were increased by 
fast food diet (P<0.0001, two-way ANOVA). (B-E) Light microscopy of representative sections of Hematoxylin and Eosin 
stained epididymal fat pads (x 400 magnification). (B) Flox control diet. (C) Flox fast food diet. (D) FKO control diet. (E) 
FKO fast food diet. Arrows indicate examples of macrophage clusters. (n = 8-12 per group) 
 
 
Adipokine expression is unchanged in FKO mice. There was no effect of Fpn1 deletion 
on mRNA quantities of the four studied adipokines (adiponectin, leptin, resistin and RBP-4) 
in both non-insulin stimulated (basal, fasted state) animals (Fig. 5.5A-D) and in insulin 
stimulated animals (Fig. 5.6A-D) (all NS, two way ANOVA). Fast food diet led to increased 
leptin mRNA quantities in both basal-state and insulin stimulated animals (p=0.03 and 
p=0.01 respectively, two-way ANOVA). Fast food diet was associated with reduced 
adiponectin and resistin mRNA in insulin stimulated animals (p=0.0003 and p=0.01 
respectively, two-way ANOVA). A reduction in RBP-4 mRNA was seen in basal-state 
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animals (p=0.01, two way ANOVA) and insulin stimulated FKO animals (p=0.0008, Sidak’s 
multiple comparisons test). Total serum adiponectin was unaffected by diet or genotype in 
basal-state and insulin-stimulated animals (NS in all cases, two way ANOVA) (Fig. 5.5E, 
F). There were also no significant differences with diet or genotype in basal state or 
insulin-stimulated animals for high molecular weight (HMW) adiponectin or HMW/total 
adiponectin ratios (all NS, two-way ANOVA, data not shown).  
Figure 5.5: Adipokine expression is unchanged in FKO mice.  
(A-D) Relative mRNA expression of the adipocyte fraction of epididymal fad pads for non-insulin stimulated animals. (A) 
Adiponectin mRNA. Diet and genotype effects were both NS (two-way ANOVA). (B) Leptin mRNA. Fast food diet was 
associated with increased Leptin mRNA (p=0.03, two-way ANOVA). (C) Resistin mRNA. Diet and genotype effects were 
both NS (two-way ANOVA).  (D) RBP-4 mRNA. Fast food diet was associated with decreased RBP-4 mRNA (p=0.01, 
two-way ANOVA). (E) Immunoblotting densitometry of total serum adiponectin (non-insulin stimulated only is represented 
here). Diet and genotype effects were both NS (two-way ANOVA). (n = 4-6 per group)  (F) Representative immunoblots 
of serum adiponectin (presented blot includes both non-insulin and insulin stimulated animals as indicated: S=Saline 
(vehicle), I= Insulin). 
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Figure 5.6: Adipokine expression is unchanged in insulin stimulated FKO mice  
(A-D) Relative mRNA expression of the adipocyte fraction of epididymal fad pads (insulin stimulated state). (A) 
Adiponectin. Adiponectin mRNA was reduced by fast food diet (p=0.0003, two-way ANOVA). Genotype effect NS. (B) 
Leptin. Leptin mRNA was increased by fast food diet (p=0.01, two-way ANOVA). Genotype effect NS. (C) Resistin. 
Resistin mRNA was reduced by fast food diet (p=0.01, two way ANOVA). Genotype effect NS. (D) RBP-4. There was a 
significant interaction between diet and genotype (p=0.049). Post-hoc analysis found RBP-4 mRNA was reduced by fast 
food diet among FKO animals (p=0.0008, Sidak’s multiple comparisons test). In Flox mice the results were NS. (n= 4-6 
per group). 
 
Adipocyte-specific ferroportin deletion does not influence glucose homeostasis. 
Intraperitoneal glucose tolerance tests found no significant differences in blood glucose 
concentrations for both diets at every time-point except 120 minutes (Fig. 5.7A, B). For 
control diet-fed Flox mice, mean glucose at 120 minutes was 16.1 mmol/L vs 12.8 mmol/L 
in FKO mice (p=0.02, Student’s t-test). In fast food diet-fed Flox mice, mean glucose at 
120 minutes was 13.8mmol/L vs 11.3mmmol/L in FKO mice (p=0.046, Student’s t-test) 
(Fig. 5.7A, B). Area under the curve (AUC) was measured above the minimum glucose 
value of 7.7 mmol/L as a baseline. Both diet and genotype effects for AUC were non-
significant (two-way ANOVA, data not shown). For hyperinsulinemic-euglycemic clamp 
studies performed on fast food diet-fed mice, mean body weight between the two groups 
was comparable 42.8 g (Flox) vs 43.4 g (FKO) (NS, Student’s t-test, Fig. 5.7C). Flox mice 
had similar basal plasma glucose levels to FKO mice (9.3 vs 9.9 mmol/L) and clamp 
glucose levels (8.3 vs 8.4 mmol/L), both NS, Student’s t-test (data not shown). Both 
groups of mice had substantial rises in mean plasma insulin levels during the clamp 
studies compared with basal levels (8.3 fold increase in Flox mice (15.7 vs 1.9 ng/ml) and 
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8.5 fold increase in FKO mice (19.8 vs 2.3 ng/ml), both p<0.0001, Student’s t-test, data not 
shown). Overall, there was no evidence of an effect of FKO on glucose homeostasis. 
Mean glucose infusion rate was 122.9 µmol/min/kg in Flox mice vs 121.7 µmol/min/kg in 
FKO mice (NS, Student’s t-test, Fig. 5.7D). Mean rate of whole body glucose 
disappearance was 202.5 µmol/min/kg in Flox mice vs 198.8 µmol/min/kg in FKO mice 
(NS, Student’s t-test, Fig. 5.7E). Under clamp conditions of hyperinsulinemia, both groups 
to a similar extent, failed to suppress endogenous glucose production, a measure of 
hepatic gluconeogenesis, 79.6 µmol/min/kg in Flox mice vs 77.2 µmol/min/kg in FKO mice 
(NS, Student’s t-test, Fig. 5.7F). 
Figure 5.7: Adipocyte specific ferroportin deletion does not influence glucose 
homeostasis  
(A + B) Glucose tolerance tests at 0, 15, 30, 60, 120 mins. Mean with 95% confidence intervals. * indicates p<0.05 at a 
single time-point (Student’s t-test) (n = 8-12 per group). (A) Control diet (B) Fast food diet (C-F) Hyperinsulinemic-
euglycemic clamp studies (n= 5 per group). Differences between Flox and FKO groups were all NS (Student’s t-test). C) 
Body weight. (D) Glucose infusion rate. (E) Rate of whole body glucose disappearance. (F) Endogenous glucose 
production. 
 
Fast food diet, but not adipocyte-specific ferroportin deletion, leads to 
steatohepatitis. Fast food diet in both genotypes led to steatohepatitis, characterized, by 
severe (grade 3) steatosis with lobular inflammation and prominent hepatocyte ballooning 
with perisinusoidal and periportal fibrosis. Control diet-fed mice of both genotypes typically 
had simple steatosis with few balloon cells and an absence of lobular inflammation and 
hepatic fibrosis. A summary of the histology findings is shown in Table 5.3 and 
representative liver sections stained with H&E are shown in Fig. 5.8. In both control diet 
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and fast food diet-fed animals, there were no significant differences between genotypes for 
steatosis grade, lobular inflammation, ballooning or fibrosis (all NS, Mann-Whitney tests).  
Increased percentage area of steatosis as quantified by Oil Red O staining was found in 
animals fed fast food diet (p=0.0001), whereas there was no difference between Flox and 
FKO genotypes (NS, both two-way ANOVA, Fig. 5.8E). Hepatic Heme oxygenase-1 
(Hmox1) mRNA, a marker of oxidative stress response [151], was increased by fast food 
diet (p<0.001), but unaffected by genotype (NS, both two-way ANOVA, Fig. 5.8F). Hepatic 
hydroxyproline was significantly increased by fast food diet (p<0.001), but not by FKO (NS, 
two-way ANOVA, Fig. 5.8G). 
Table 5.3: Increased liver injury with fast food diet, but not with Fpn1 deletion.  
NAFLD activity score (NAS). Median score (range) for NAS (score: 0-8), macrovesicular steatosis (grade 0-3), lobular 
inflammation (grade 0-3), ballooning (grade 0-2), fibrosis (grade 0-4). P-value is the result of Mann-Whitney tests 
comparing genotypes for each diet. (n = 8-12 per group) 
       Control diet       Fast Food Diet  
 
 Flox  FKO P   Flox   FKO P 
NAS (0-8) 4(0-6)  2 (0-5) ns  6(5-7) 6(5-7) ns 
Steatosis (0-3) 2.5(0-3)  1.5(0-3) ns  3(3-3) 3(3-3) ns 
Lobular inflammation (0-3) 0(0-1) 0(0-1) ns  1(0-2) 1(0-2) ns 
Ballooning (0-2) 1.5(0-2) 0.5(0-2) ns  2(2-2) 2(2-2) ns 
Fibrosis (0-4) 0(0-1) 0(0-2) ns  2(1-2) 2(2-2) ns 
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Figure 5.8: Fast food diet, but not genotype leads to steatohepatitis.  
(A-D) Light microscopy of representative liver sections stained with Hematoxylin and Eosin (x 200 magnification). (A) 
Flox control diet (B) Flox fast food diet (C) FKO control diet (D) FKO fast food diet (E) Percentage area of liver sections 
stained with Oil Red O. Oil red O staining was increased by fast food diet (p=0.0001), but unaltered by genotype (NS, 
both two-way ANOVA) (F) Liver Hmox1 mRNA. Fast food diet led to increased Hmox1 mRNA (p<0.001), but there was 
no genotype effect (NS, two way ANOVA). (G) Hepatic hydroxyproline. Hydroxyproline was increased by fast food diet 
(p<0.001) but was unaffected by genotype (NS, two-way ANOVA). (n=8-12 per group) 
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Discussion 
 
In this study, we have demonstrated effective adipocyte-specific ferroportin deletion using 
an Adipoq-Cre recombinase model. Our study demonstrates three key findings. Firstly, 
ferroportin deletion did not result in any alteration of adipocyte iron phenotype, glucose 
homeostasis, adipokine regulation or liver injury. Secondly, we have shown that the fast 
food diet is associated with reduced hepatic and splenic iron concentrations with a 
compensatory hepcidin response. Thirdly, we confirm the fast food diet model’s utility as a 
model for NASH and have identified adipose tissue macrophage infiltration which further 
validates this model. 
We did not find an adipocyte iron loading phenotype despite successful Fpn1 deletion in 
FKO mice. There are several possible explanations for this. Firstly, ferroportin may not 
have a significant role in adipocyte iron homeostasis. However, it is not known whether 
iron importers such as the divalent metal transporter-1 (DMT-1) or an unidentified 
alternative export mechanism may have more important roles in the regulation of iron 
content in adipocytes. Secondly, it is possible that the FKO mice would require a longer 
period of dietary iron loading to generate such a phenotype even in the absence of 
adipocyte ferroportin. As such, it may be difficult to determine the importance of adipocyte 
ferroportin to humans who may accumulate iron over many years.  
Gabrielsen et al utilized the AP2-Cre Fpnfl/fl model and reported an iron loading phenotype 
on the basis of reduced quantities of adipocyte Tfr1 mRNA leading to reduced adiponectin 
transcription and insulin resistance [17]. However, data regarding direct iron assay or 
histologic assessment of iron were not presented. Tfr1 mRNA quantity is expected to be 
reduced in iron loaded cells due to a negative feedback mechanism involving iron-
responsive elements in the Tfr1 gene 3’ untranslated region [143]. However Tfr1 mRNA is 
a surrogate that is not well validated as a measure of iron loading and particularly not in 
adipocytes.  
The disparity between the study by Gabrielsen et al and ours could relate to the difference 
in Cre recombinase site. In addition to its expression in adipocytes, the AP2-Cre has been 
reported to have some degree of expression in macrophages [26, 27, 144]. Although 
altered Fpn1 mRNA quantities were not seen in splenic extracts by Gabrielsen et al, the 
Adipoq-Cre has been regarded as a more specific Cre recombinase for adipocytes [17, 
26]. Differences between the two studies may also relate to a difference in mouse strain. 
The strain was reported as either “129/SvEvTac or C57BL6” by Gabrielsen et al. 
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Regardless, it appears that if Cre-lox models of adipocyte ferroportin deletion are to be 
used as models of adipocyte iron loading, then the iron loading phenotype needs to be 
more clearly demonstrated. 
Glucose homeostasis was assessed in this study using intra-peritoneal glucose tolerance 
tests and hyperinsulinemic-euglycemic clamp studies. FKO mice had lower blood glucose 
concentrations at the 120 minute time-point, but not at other time-points or on the AUC 
analysis, suggesting that the significance of this result in isolation is doubtful, particularly 
given the lack of observed change in iron phenotype. Glucose infusion rate and other 
measures in the clamp studies found no difference between genotypes, indicating that 
adipocyte-specific ferroportin knockout does not affect insulin resistance in this model. 
We have demonstrated reduced hepatic and splenic iron concentrations as a result of the 
fast food diet suggesting reduced body iron stores as a consequence of high calorie diet. 
The hormone hepcidin is considered the key regulator of body iron homeostasis [152]. 
Hepcidin production is reported to be raised in individuals with NAFLD [153]. It therefore 
might be expected that low HIC in these mice could be explained by increased Hamp1 
expression leading to reduced intestinal iron absorption following the internalization of 
enterocyte ferroportin [36]. However, Hamp1 expression was markedly decreased in these 
mice suggesting appropriate Hamp1 response to reduced hepatic iron stores and is 
consistent with previous studies [24, 125, 147, 154]. These findings are also in keeping 
with the established association between iron deficiency and obesity in humans [111, 112]. 
Orr et al have shown that a high fat diet led to iron repartitioning with a reduction in HIC 
and an increase in adipocyte iron concentration via an unknown mechanism, although this 
was not seen in our model [24]. In our study, it was not technically possible to accurately 
measure iron concentrations in the stromal vascular fraction of the adipose tissue, due to 
the very low volume of these samples, but this would undoubtedly be very useful 
information if this could be reliably determined in future studies. 
The fast food diet model involves five months of exposure to a high calorie diet and high 
fructose corn syrup in drinking water in mice housed singly to mimic a sedentary lifestyle 
[25]. We have found this to be a reliable model for the generation of a phenotype of 
steatohepatitis and hepatic fibrosis as demonstrated by expert histological assessment 
and supported further by quantification of Oil Red O, Hmox1 mRNA and hepatic 
hydroxyproline. Furthermore, the high residual endogenous glucose production during 
hyperinsulinemic clamp studies suggests profound insulin resistance in this model, which 
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is a highly appropriate feature for a model of human NASH. It was unexpected however 
that our mice fed control diet should develop significant amounts of simple steatosis. This 
may be partly explained by a number of factors including single housing leading to a 
sedentary existence and a relatively advanced age of the mice. 
Adipose tissue macrophage infiltration is a hallmark of obesity and steatohepatitis in 
humans [21, 40]. We have shown that the fast food diet model generates a significant 
increase in adipose tissue macrophage infiltration with crown-like structures. This further 
validates the applicability of the fast food diet model for use in the study of NASH. We had 
considered that an increase in adipocyte iron in FKO mice might create an inflammatory 
state induced by oxidative stress and lead to macrophage infiltration. However, given the 
observed lack of effect of FKO on iron phenotype, it seems unsurprising that genotype did 
not affect macrophage infiltration in this model. In our study, we found that EFP weight 
was lower in FKO mice, although this was only seen in animals fed the control and not the 
fast food diet. In the context of unaltered iron phenotype and lack of effect in fast food diet 
fed mice, the significance of this result remains uncertain. When we studied adipokine 
expression in our model, we found increased adipocyte leptin mRNA and decreased RBP-
4 mRNA with fast food diet. These findings are broadly consistent with human studies of 
NASH, although conflicting reports exist in the literature [16, 155, 156].  
In summary, our findings indicate that the physiological role of ferroportin in adipocytes 
may be limited and other factors involved in iron homeostasis may be more important in 
these cells. As adipocyte iron appears to play a key role in physiological process such as 
appetite regulation and pathophysiological process such as NAFLD and diabetes, a 
greater understanding of iron metabolism in these cells is clearly a target for future studies.  
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Chapter 6 : Iron inhibits the secretion of apolipoprotein E in cultured 
human adipocytes 
 
The previous chapter sought to examine the role of in vivo adipocyte iron loading. In this 
chapter, focus shifts to an in vitro model. As discussed in detail in Chapter 2, there is an 
emerging body of evidence that associates adipose tissue iron with adipose tissue 
dysfunction relevant to NAFLD.[7, 34] In particular, a number of adipokines have been 
shown to be regulated by iron, however the overall effects of iron on the adipocyte 
secretome have not been established.[17, 18] In this chapter, the development of a model 
of iron loading in cultured human adipocytes is described. A proteomic approach to 
explore the effects of iron on the adipocyte secretome relevant to NAFLD is used. 
This chapter is published as an abridged version (Research Letter) with detailed methods 
as supplementary material in Cellular and Molecular Gastroenterology and Hepatology. In 
this chapter the research is presented in its original, conventional manuscript form. The 
abridged version in press with Cellular and Molecular Gastroenterology and Hepatology is 
included as an Appendix, although the content is very similar. 
Britton LJ, Bridle KR, Jaskowski L, He J, Ng C, Ruelcke J, Mohamed A, Reiling J, 
Santrampurwala N, Hill MM, Whitehead JP, Subramaniam VN, Crawford DHG 
Iron inhibits the secretion of apolipoprotein E in cultured human adipocytes 
Cellular and Molecular Gastroenterology and Hepatology 2018 Apr 16;6(2):215-217 
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Abstract 
 
Background & Aims: Non-alcoholic steatohepatitis (NASH) is characterized by adipose 
tissue dysfunction with insulin resistance and the dysregulation of adipokines. Recent data 
indicate increased concentrations of iron in mouse model of obesity and a role for iron in 
the development of adipose tissue dysfunction, however the molecular mechanisms have 
not been established. Methods: To test the hypothesis that iron modulates adipokine 
release, we performed a quantitative proteomics analysis of the human Simpson-Golabi-
Behmel Syndrome (SGBS) adipocyte secretome following 48 hours of treatment with ferric 
ammonium citrate. Results: Treatment with 100 μM iron significantly increased intracellular 
iron concentration, however cellular viability and total protein secretion were not altered. A 
total of 338 proteins were quantified by SILAC (stable isotope labelling with amino acids in 
cell culture). Iron treatment led to differential secretion of 60 of these proteins (>2-fold 
change and p-value <0.05). We focused on iron regulation of apolipoprotein E (ApoE) 
122 
 
secretion as ApoE has been shown to have a protective role in promoting adipogenesis 
and, in mice fed a Western diet, has been shown to protect against steatohepatitis. 
Interestingly, while iron reduced secreted ApoE by 58% (p=0.001) and 76% (p=0.007), as 
measured by SILAC and western blot respectively, iron treatment increased intracellular 
ApoE levels by more than 11-fold (p=0.0005), without causing a significant change in 
mRNA levels. Conclusions: These findings indicate that ApoE secretion is inhibited by iron, 
causing ApoE to accumulate within adipocytes. Identifying the molecular mechanisms of 
iron-induced inhibition of ApoE secretion from adipocytes may reveal novel therapeutic 
strategies for improving adipocyte function in NASH. 
Background 
 
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect over one billion individuals 
worldwide.[1]  It is mostly unclear at present, why some of these individuals develop liver 
failure or liver cancer and yet others do not. Greater insights into disease pathogenesis 
and regulation of liver injury will be essential in order to develop novel effective treatments. 
Much of the pathogenesis of NAFLD has been linked to dysfunctional adipose tissue.[21] 
Inflamed adipose tissue, characterized by macrophage infiltration, predisposes towards 
insulin resistance leading to dysregulated lipolysis of adipose tissue triglyceride by 
hormone sensitive lipase.[21, 42] This in turn increases free fatty acid flux to the liver and 
promotes hepatic steatosis and liver injury.[45, 46] In addition, adipose tissue, as a major 
endocrine organ, is responsible for the secretion of adipokines which are defined as 
“polypeptides that are secreted in the adipose tissue in a regulated manner.”[16] These 
adipokines can have local, paracrine effects on adipose tissue or endocrine effects on 
organs such as the liver. 
Recent data have shown markedly increased adipocyte iron concentration in a high fat diet 
mouse model of obesity.[24] Furthermore, iron has been proposed as a key determinant of 
adipose tissue function and has been linked to the dysregulation of a number of 
adipokines.[17, 19] Of these, the insulin sensitizing and hepato-protective adipokine, 
adiponectin, has been shown in tissue culture and rodent models to be down-regulated at 
a transcriptional level by iron through altered acetylation of the forkhead transcription 
factor, Fox01.[17] Similarly, in a mouse model of dietary iron enrichment, serum 
concentrations of resistin, an adipokine associated with insulin resistance were increased 
via transcriptional up-regulation.[19] Iron has also been shown to increase lipolysis in in 
vitro models using both rat and mouse adipocytes.[92, 93] These effects on adipose tissue 
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biology point towards a potential pathogenic role of iron in the generation of insulin 
resistance and NAFLD.  However, the effect of iron on the majority of proteins in the 
adipocyte secretome has not been studied. 
In order to gain a greater understanding of the role of iron in adipokine dysregulation and 
identify novel treatment targets, we developed an in vitro human adipocyte model of 
cellular iron loading using differentiated Simpson-Golabi-Behmel Syndrome (SGBS) pre-
adipocytes. We utilized stable isotope labelled amino acids in cell culture (SILAC) to 
characterize changes in the adipocyte secretome in response to iron. This technique has 
enabled direct comparison of quantities of individual proteins in the adipocyte secretome in 
response to iron using a proteomics approach. This study, therefore provides a detailed 
analysis of the effect of iron on the human adipocyte secretome as a tool for the 
identification of novel treatment targets in NAFLD. 
Methods 
 
SGBS differentiation and iron treatment 
SGBS pre-adipocytes were a gift from Martin Wabitsch (University of Ulm, Germany) and 
were passaged, proliferated and differentiated at less than 50 generations in 12 well plates 
and 100 mm dishes as previously described.[157, 158] Cells were treated with 90 μg/ml 
heparin and 1 ng/ml fibroblast growth factor-1 (FGF-1) (both Sigma-Aldrich, St Louis, 
Missouri) throughout proliferation and differentiation. After 14 days of differentiation, cells 
were incubated with 0, 25, 100 or 500 μM ferric ammonium citrate (FAC) (Sigma- Aldrich) 
for 24 hrs. After this media was replaced with the same for a further 24 hrs to the end of 
experiment. 
RNA extraction and real-time quantitative PCR (RT-qPCR) 
RNA was extracted from treated SGBS adipocytes using a PureLink RNA mini kit 
(Invitrogen, Carlsbad, California). Complementary DNA was synthesized from 1 µg RNA 
using a Sensifast cDNA synthesis kit (Bioline, London, UK) after treatment with DNase 1 
(Invitrogen). Samples underwent thermal cycling using a ViiA7 real-time PCR machine 
(Invitrogen) with a Sensifast SYBR Lo-ROX Kit (Bioline). The following protocol was used: 
2 min at 95oC, then 40 cycles of 5 sec at 95oC alternating with 20 sec at 63oC, followed by 
a melt curve analysis. Relative mRNA quantities were determined by calibration of Ct 
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values to standard curve of pooled cDNA samples. Results were normalized to Ct values 
of Cyclophillin.  
Iron, cellular viability (MTS) and protein assays. 
Iron levels were quantified using a chromagen reagent method, described by Kohyama et 
al.[159] Cellular viability was assessed using a CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (Promega, Madison, Wisconsin) according to the manufacturer’s 
instructions. Whole cell lysate and secretome samples underwent protein estimation using 
a Pierce BCA protein assay kit (Thermofisher Scientific, Waltham, Massachusetts).  
SILAC proteomics 
For SILAC labelling, SGBS pre-adipocytes were grown in SILAC DMEM: F12 media 
(Thermofisher Scientific) supplemented with dialyzed fetal bovine serum (Thermofisher 
Scientific,) and 22.81mg/L 2H4-Lysine and 36.88mg/L 13C6-Arginine (K4R6) or 22.81mg/L 
13C615N2-Lysine and 36.88mg/L 13C615N4-Arginine (K8R10). Incorporation of labelled amino 
acids was confirmed by liquid chromatography tandem mass spectrometry (LC-MS/MS) on 
tryptic peptides prepared from whole cell lysates. Cell pellets were lysed in 8M urea in 
100mM TEAB (Triethylamonium bicarbonate), and protein concentration estimated using 
Bradford assay (BioRad, Hercules, California). Thirty μg of cell lysate was reduced and 
alkylated by incubating samples for 30 min at 37oC with 2.5mM TCEP (tris(2-
carboxyethyl)phosphine) and then 5mM 2CAA (2-Chloroacetamide). Urea concentration 
was diluted to 1M with 100mM TEAB before adding 0.6 μg of trypsin. Samples were 
incubated overnight then acidified to 1% trifluoroacetic acid (TFA) and cleaned with OMIX 
C18 tips according to the manufacturers’ protocol (Agilent, Santa Clara, California). LC-
MS/MS and database searching was performed as described below. The percentage of 
peptides containing labelled amino acids was then calculated.  
Labelled (>97%) cells underwent differentiation to adipocytes as described above. At day 
14 post differentiation, cells were treated with vehicle (K4R6 cells) or 100 μM FAC (K8R10 
cells) for a further 48 hours using exactly equal volumes of media, replacing the media 
after 24 hrs. Media for secretome analysis was collected from K4R6 and K8R10 cells and 
mixed 1:1 (v/v) before centrifugation at 600 x G at 4oC for 10 min to remove cell debris. 
Supernatant was then concentrated using Amicon Ultra 15ml 10 kDa centrifugal filter units 
(Merck Millipore, Burlington, Massachusetts) in a fixed angle centrifuge at 5000 x G to 
provide approximately 1 ml samples of concentrated mixed secretome. Thirty g of protein 
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was separated on 10% SDS-PAGE gels to 10 mm. Protein visualisation, excision of bands 
and in-gel trypsin digest were performed using a semi-automated method as 
described.[160] A band corresponding to the same molecular weight as transferrin (media 
additive) was removed prior to digestion in order to provide a protein sample exclusively 
secreted from cultured adipocytes. 
Mass spectrometry 
A Q Exactive Plus Orbitrap Mass Spectrometer (Thermofisher Scientific), coupled with 
Easy-nLC 1000 and EASY-spray ion source (both Thermofisher Scientific), was used to 
analyze the digested peptides. Samples were loaded onto an EASY-Spray PepMap RSLC 
C18 2 µm column (50 cm x 75 µm ID), with a Nanoviper Acclaim C18 guard (75 µm x 2 
cm) (both Thermofisher Scientific). A 90 min method was run using a combination of Buffer 
A (0.1% Formic acid) and Buffer B (0.1% Formic acid: Acetonitrile). A two-step gradient 
was run comprising a 60 min gradient from 3% to 25% Buffer B and a 12 min gradient from 
25% to 40% Buffer B. Flow rate was at 250 nL/min. The mass spectrometer was 
programmed to acquire a full mass spectrometry (MS) resolution of 70,000 with an ACG 
target of 3x106 with a maximum injection time of 100 ms. The MS scan range was from 
350 to 1400 m/z. MS/MS was set to acquire a resolution of 17,500 with an ACG target of 
5x105 and maximum injection time of 55 ms. The loop count was set to 20 with a dynamic 
exclusion after 30 sec. 
 
Raw data was processed with Spectrum mill (Rev B.05.00.181 SP1, Agilent). Selected 
modifications included fixed carbamidomethylation of cysteine and SILAC labels (Arg 0-6-
10 Da Lys 0-4-8 Da) and variable oxidized methionine. Results were searched against the 
Human Uniprot database (downloaded 06/01/2015).[161] Trypsin was selected as digest 
enzyme, with two maximum missed cleavages allowed. The precursor mass tolerance was 
set at +/- 20 ppm and product mass tolerance was +/- 20 ppm.  
 
Immunoblotting 
Western blotting using whole cell lysate samples (10 μg) and 5 μL concentrated secretome 
samples was performed as previously described.[147] A 1:500 dilution of primary antibody 
against Apolipoprotein E (ApoE) (sc-53570, Santa Cruz, Dallas, Texas) was applied to the 
membranes. A 1:100,000 dilution of goat anti-mouse horseradish peroxidase antibody 
(Invitrogen) was applied as secondary antibody. ApoE whole cell lysate densitometry was 
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normalized against densitometry using beta-actin as a reference protein (1:2000 primary 
antibody) (Cat No. 4967, Cell Signaling, Danvers, Massachusetts) and 1:20,000 goat anti-
rabbit horseradish peroxidase antibody (Invitrogen). 
Statistical analysis 
For comparisons between the four concentrations of FAC, a one-way ANOVA analysis 
was used. In the event of a p value < 0.05, Dunnett’s multiple comparison test was used to 
compare vehicle (0 μM FAC) with each of 25, 100 and 500 μM FAC treated cells. Mass 
spectrometry proteomic data were analyzed using the online Quantitative Proteomics P-
value Calculator (QPPC) using no normalization and non-adjusted p-values.[162] For 
comparison of mRNA quantities and immunoblot densitometry between two groups, ratio 
paired t-tests were used. For enrichment analysis of significantly iron-regulated proteins, 
one-tailed Fisher’s exact tests were used. All authors had access to the study data and 
have reviewed and approved the final manuscript. 
Results 
 
We first sought to identify a suitable media concentration of FAC that would load iron into 
differentiated adipocytes without compromising cellular viability. We found that compared 
to vehicle both 100 μM and 500 μM FAC caused significant increases in cellular iron 
concentration (p=0.007 and p=0.006 respectively, Figure 6.1(a)). There was no effect of 
iron loading on cellular viability (MTS) assay, total mRNA, total whole cell lysate protein or 
total secretome protein (Figure 6.1 (b-d)). 
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Figure 6.1: Optimization of iron loading in SGBS cells  
(a) Iron assay, p=0.004 (one-way ANOVA), *indicates p<0.01 (Dunnett’s multiple comparisons test compared to 0μM 
FAC, n=2 per group). (b) Total RNA (non-significant (NS) by one-way ANOVA, n=3 per group). (c) Total lysate protein 
(NS by one-way ANOVA, n=3 per group). (d) Total secretome protein (NS by one-way ANOVA, n=3 per group). (e) 
Viability assay (MTS) (NS by one-way ANOVA, n=3 per group). 
 
   
Given these findings, we selected 100 μM FAC as the concentration to compare with 
vehicle in the secretome SILAC proteomic analysis. An overview of the workflow for the 
SILAC experiment is shown in Figure 6.2. A total of 338 proteins were quantified in the 
adipocyte secretome by SILAC proteomics. These are represented graphically as a 
volcano plot in Figure 6.3 and summarized in Table 6.1.  
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Figure 6.2: SILAC workflow 
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Figure 6.3: Volcano plot of relative signal intensity of proteins identified in the 
adipocyte secretome 
The x-axis denotes log 2 of the ratio of iron treated/vehicle treated cells, with proteins to the left of zero representing 
those downregulated by iron and the those to the right representing up-regulation by iron. The y-axis denotes statistical 
significance with a line representing p-value of 0.05. Proteins above this line have p<0.05. Those proteins containing 
signal peptide (as determined by signal peptide annotations on the Uniprot database) are shown in red. Those without 
signal peptide are shown in blue. 
 
Table 6.1: Summary of iron effects on the adipocyte secretome by SILAC 
proteomics.  
Number of proteins with a greater than 2-fold change are shown in parentheses. 
 
 Number of 
proteins down-
regulated 
Number of 
proteins up-
regulated 
Total  
(>2 fold 
change) 
Significant (p<0.05) 61 (53) 11 (7) 72 (60) 
Non-significant (p>0.05) 152 114 266 
Total 213 125 338 
 
To explore the relationships further between proteins that appear to be significantly 
dysregulated in the adipocyte secretome (greater than two-fold change and p<0.05), we 
performed a STRING network interaction analysis. This is represented graphically in 
Figure 6.4. This analysis highlighted central roles for Apolipoprotein E (APOE) and 
Adioponectin (ADIPOQ) which have been shown to have hepatoprotective effects in 
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NAFLD. However, major linked pathways of dysregulation relevant to NAFLD were not 
clearly identified.  
 
Figure 6.4: STRING pathway analysis of secreted proteins.  
STRING pathway network summary of secretome proteins with a greater than two fold change in signal intensity in 
response to iron and p<0.05. Each node represents an individual secretome protein, labelled by gene name (as indicated 
in Table 6.2). Line thickness of network edges indicates the strength of data supporting interactions between individual 
proteins. 
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We then manually reviewed Uniprot database descriptions of the 60 proteins with both a 
greater than two-fold change in response to iron and p-value < 0.05. This generated a list 
of 20 proteins of interest (highlighted in bold in Table 6.2). These proteins of interest and 
their synonyms were then entered into a Pubmed title/abstract search in association with 
NAFLD and its synonyms. This identified three proteins as candidate intermediates for 
iron-induced adipose tissue dysfunction in NAFLD. These proteins were adiponectin, 
apolipoprotein E (ApoE) and annexin A1.  
 
Table 6.2: List of SGBS secretome proteins with significantly altered signal intensity 
in response to iron.  
Proteins shown have a greater than 2-fold change in signal intensity in response to iron, with a p-value <0.05. Proteins 
highlighted in bold represent the 20 proteins of interest after review of Uniprot protein descriptions. 
 
Accession 
number 
Gene 
name 
Protein name Mean signal 
intensity 
ratio 
(iron/vehicle) 
Standard 
deviation 
P value 
Q8IX30 SCUBE3 Signal peptide, CUB 
and EGF-like domain-
containing protein 3 
0.026 0.016 0.001 
P61353 RPL27 60S ribosomal protein 
L27 
0.060 0.005 0.001 
Q9NQH7 XPNPEP3 Probable Xaa-Pro 
aminopeptidase 3 
0.076 0.004 0.001 
P07996 THBS1 Thrombospondin-1 0.083 0.047 0.001 
Q76M96 CCDC80 Coiled-coil domain-
containing protein 80 
0.090 0.031 0.001 
P78539 SRPX Sushi repeat-containing 
protein SRPX 
0.096 0.620 0.001 
Q9UHI8 ADAMTS1 A disintegrin and 
metalloproteinase with 
thrombospondin motifs 
1 
0.114 0.090 0.002 
Q92538 GBF1 Golgi-specific brefeldin 
A-resistance guanine 
nucleotide exchange 
factor 1 
0.118 0.024 0.004 
Q15063 POSTN Periostin 0.121 0.149 0.001 
P08238 HSP90AB1 Heat shock protein HSP 
90-beta 
0.125 0.038 0.004 
P24593 IGFBP5 Insulin-like growth 
factor-binding protein 
5 
0.154 0.069 0.001 
Q15113 PCOLCE Procollagen C-
endopeptidase 
0.155 0.088 0.001 
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enhancer 1 
Q9NTX5 ECHDC1 Ethylmalonyl-CoA 
decarboxylase 
0.158 0.068 0.001 
P25788 PSMA3 Proteasome subunit 
alpha type-3 
0.176 0.442 0.001 
Q12931 TRAP1 Heat shock protein 75 
kDa, mitochondrial 
0.186 0.028 0.018 
P04083 ANXA1 Annexin A1 0.192 0.049 0.001 
P30101 PDIA3 Protein disulfide-
isomerase A3 
0.198 0.059 0.001 
Q99985 SEMA3C Semaphorin-3C 0.199 0.225 0.001 
Q6NZI2 PTRF Polymerase I and 
transcript release factor 
0.210 0.134 0.001 
Q8TAV4 STOML3 Stomatin-like protein 3 0.220 0.084 0.006 
Q9UKZ9 PCOLCE2 Procollagen C-
endopeptidase 
enhancer 2 
0.226 0.030 0.001 
Q05469 LIPE Hormone-sensitive 
lipase 
0.231 0.196 0.023 
Q13642 FHL1 Four and a half LIM 
domains protein 1 
0.263 0.006 0.029 
P02749 APOH Beta-2-glycoprotein 1 0.286 0.310 0.048 
P02462 COL4A1 Collagen alpha-1(IV) 
chain 
0.286 0.351 0.001 
P15311 EZR Ezrin 0.296 0.077 0.003 
P42765 ACAA2 3-ketoacyl-CoA 
thiolase, mitochondrial 
0.308 0.136 0.001 
P68104 EEF1A1 Elongation factor 1-
alpha 1 
0.309 0.215 0.001 
Q9NQC3 RTN4 Reticulon-4 0.312 0.119 0.007 
Q8IY17 PNPLA6 Neuropathy target 
esterase 
0.316 0.028 0.026 
Q92743 HTRA1 Serine protease HTRA1 0.324 0.075 0.001 
P08294 SOD3 Extracellular 
superoxide dismutase 
[Cu-Zn] 
0.339 0.027 0.005 
Q16836 HADH Hydroxyacyl-coenzyme 
A dehydrogenase, 
mitochondrial 
0.348 0.207 0.011 
Q99715 COL12A1 Collagen alpha-1(XII) 
chain 
0.348 0.183 0.001 
P07355 ANXA2 Annexin A2 0.354 0.111 0.001 
P26038 MSN Moesin 0.362 0.110 0.034 
P23284 PPIB Peptidyl-prolyl cis-trans 
isomerase B 
0.374 0.122 0.001 
O94769 ECM2 Extracellular matrix 
protein 2 
0.375 0.060 0.005 
Q9NRN5 OLFML3 Olfactomedin-like 
protein 3 
0.389 0.066 0.002 
P53396 ACLY ATP-citrate synthase 0.389 0.066 0.001 
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Q16363 LAMA4 Laminin subunit alpha-4 0.407 0.091 0.001 
P14625 HSP90B1 Endoplasmin 0.414 0.068 0.025 
Q9BU40 CHRDL1 Chordin-like protein 1 0.419 0.264 0.001 
P02649 APOE Apolipoprotein E 0.421 0.053 0.001 
Q9NS98 SEMA3G Semaphorin-3G 0.425 0.161 0.001 
P02751 FN1 Fibronectin 0.441 0.146 0.001 
P14543 NID1 Nidogen-1 0.442 0.190 0.006 
Q08431 MFGE8 Lactadherin 0.446 0.167 0.026 
Q15848 ADIPOQ Adiponectin 0.449 0.652 0.005 
O75390 CS Citrate synthase, 
mitochondrial 
0.454 0.183 0.012 
Q92626 PXDN Peroxidasin homolog 0.457 0.200 0.001 
P07942 LAMB1 Laminin subunit beta-1 0.484 0.110 0.001 
Q08629 SPOCK1 Testican-1 0.497 0.055 0.014 
O00462 MANBA Beta-mannosidase 2.180 2.560 0.034 
Q13510 ASAH1 Acid ceramidase 2.222 3.135 0.048 
P02794 FTH1 Ferritin heavy chain 2.451 0.769 0.030 
Q02952 AKAP12 A-kinase anchor protein 
12 
2.665 0.572 0.047 
A6NCN2 KRT87P Putative keratin-87 
protein 
4.113 0.011 0.022 
P23468 PTPRD Receptor-type tyrosine-
protein phosphatase 
delta 
10.687 2.199 0.003 
P10586 PTPRF Receptor-type tyrosine-
protein phosphatase F 
11.935 3.955 0.001 
 
Of these candidate proteins, we focused on ApoE for two main reasons. Firstly, the effects 
of iron on ApoE secretion from adipocytes has not to our knowledge previously been 
studied. Secondly, ApoE has been proposed as having a protective role in NAFLD 
pathogenesis.[163] We found a consistently reproducible effect of iron on ApoE by western 
blot in both 12 well plate (non-SILAC) and 100mm plate (SILAC) models. Densitometry of 
secretome ApoE was reduced by 76% (p=0.007), consistent with effect seen with SILAC 
signal intensity analysis of 58% reduction (p=0.001) (Figures 6.5(b) and 6.5(d)). 
Conversely, whole cell lysate samples demonstrated a greater than 11-fold increase in 
intracellular ApoE in response to iron (p=0.0005), without a significant change in ApoE 
mRNA levels (Figures 6.5(a), 6.5(c) and 6.5(e)).  
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Figure 6.5: SBGS ApoE expression following FAC treatment  
(a) ApoE mRNA (NS, ratio paired t-test), (b) Secretome ApoE densitometry (* denotes p=0.001, ratio paired t-test), (c) 
Lysate ApoE densitometry normalized to β-actin (# denotes p=0.0005, ratio paired t-test), (d) Secretome ApoE 
immunoblot, (e) Whole cell lysate ApoE and β-actin immunoblots (n=3 per group) 
 
 
In order to evaluate whether, the effects of FAC were iron-specific or a more generalised 
toxic effect, we examined oxidative stress, inflammatory and endoplasmic reticulum (ER) 
stress responses. We found transcriptional upregulation of anti-oxidant responses with an 
increase in heme-oxygenase-1 (HO-1) (p=0.01) and glutathione peroxidase-1 (GPX-1) 
mRNA (p=0.049). Interleukin-6 (IL-6) mRNA as a marker of inflammation was not 
significantly altered by iron, although there was a trend towards a decrease in IL-6 mRNA 
with iron treatment (43% decrease, p=0.08). (Figures 6.6(a-c)) 
We also examined X-box binding protein (XBP-1) mRNA (spliced and unspliced) which in 
its spliced form is a master regulator of the unfolded protein response caused by 
endoplasmic reticulum (ER) stress.[164] Iron had no effect on quantities of both unspliced 
and spliced XBP-1 mRNA. (Figures 6.6(d) and 6.6(e)) In addition, there was no effect on 
downstream transcriptional targets of spliced XBP-1, such as immunoglobulin binding 
protein (BiP) and ER-degradation-enhancing-α-mannidose-like protein (EDEM). (Figures 
6.6(f) and 6.6(g))  Furthermore, signalling in the ER stress induced apoptosis pathway was 
evaluated by quantifying activating transcription factor 4 (ATF4) and CCAAT/enhancer-
binding protein homologous protein (CHOP) mRNA. (Figures 6.6(h) and 6.6(i)) Again 
these were unaffected by iron.  
Given that a large number of proteins had lower secretome signal intensity in response to 
iron, we hypothesized that iron targets selected mechanisms of protein secretion. To 
investigate the potential secretion pathways regulated by iron, we evaluated two 
characterized protein secretion mechanisms, namely, the classical secretory pathway 
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mediated by signal peptide and vesicle-mediated secretion. The effect of iron on the 
classical secretion pathway was evaluated using signal peptide annotations from the 
Uniprot database.[161] To do this, we performed an enrichment analysis comparing the 61 
significantly down-regulated proteins (p<0.05) with the remaining 277 proteins in the 
adipocyte secretome. Of the 61 significantly downregulated proteins, 62% (38/61) had 
signal peptide, whereas of the remaining proteins only 47% (129/277) had signal peptide 
(Figures 6.3, 6.6(j) and 6.6(k)). One-tailed Fisher’s-exact test showed significant 
enrichment with signal peptide (p=0.02) amongst the significantly downregulated group. In 
contrast, there was no significant enrichment of the exosomal pathway (p=0.51, one-tailed 
Fisher’s-exact test), as 15% (9/61) of significantly down-regulated proteins and 14% 
(39/277) of the remaining secretome proteins had been previously reported in the high 
confidence proteins from the EVpedia database, [165] (Figures 6.6(l) and 6.6(m)). These 
results suggest that iron selectively blocks the classical secretory pathway. 
Figure 6.6: Mechanistic aspects of iron-related dysregulation of protein secretion  
(a) Interleukin-6 (IL-6) mRNA (non-significant (NS), paired t-test, n=3 per group). (b-c) Oxidative stress * indicates 
p<0.05, both n=3 per group (b) Heme-oxygenase (HO-1) mRNA (p=0.01, paired t-test). (c) Glutathione peroxidase 1 
(GPX-1) mRNA (p=0.049, paired t-test). (d-i) Endoplasmic reticulum (ER) stress, all n=3 per group. (d) Unspliced X-box 
binding protein (XBP-1) mRNA (NS, paired t-test). (e) Spliced X-box binding protein (XBP-1) mRNA (NS, paired t-test). 
(f) Immunoglobulin binding protein (BiP) mRNA (NS, paired t-test). (g) ER-degradation-enhancing-α-mannidose-like 
protein (EDEM) mRNA (NS, paired t-test). (h) Activating transcription factor 4 (ATF4) mRNA (NS, paired t-test). (i) 
CCAAT/enhancer-binding protein homologous protein (CHOP) mRNA (NS, paired t-test). (j-m) Enrichment with signal 
peptide and exosome proteins. (j) Proportion of proteins significantly down regulated by iron with signal peptide vs no 
signal peptide. (k) Proportion of proteins not significantly down regulated by iron with signal peptide vs no signal peptide. 
(l) Proportion of proteins significantly down regulated by iron with exosome secretion vs no exosome secretion. (m) 
Proportion of proteins not significantly down-regulated by iron with exosome secretion vs no exosome secretion. Of the 
61 significantly down-regulated proteins, 62% (38/61) had signal peptide, whereas of the remaining proteins only 47% 
(129/277) had signal peptide. One-tailed Fisher’s-exact test showed significant enrichment with signal peptide (p=0.02) 
amongst the significantly down-regulated group. In contrast, there was no significant enrichment of the exosomal 
pathway (p=0.51, one-tailed Fisher’s-exact test), as 15% (9/61) of significantly down-regulated proteins and 14% 
(39/277) of the remaining secretome proteins had been previously reported in the high confidence proteins from the 
EVpedia database.  
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Discussion 
 
In this study, we have identified 72 proteins secreted from human adipocytes which were 
significantly dysregulated in response to iron. Of these, we have identified a number of 
proteins with particular relevance to NAFLD, including ApoE, adiponectin and annexin A1.  
Furthermore, we showed using immunoblotting that ApoE becomes sequestered within 
adipocytes in response to iron. This may be an important pathogenic phenomenon in 
humans with NAFLD, as ApoE appears to protect against steatohepatitis. In a mouse 
model of ApoE knockout, unlike wild type controls, mice fed seven weeks of Western diet 
developed impaired glucose tolerance, steatohepatitis and hepatic fibrosis.[163] ApoE is a 
component of lipoproteins, such as Very Low Density Lipoprotein (VLDL) and High Density 
Lipoprotein (HDL) and promotes VLDL induced adipogenesis.[166] ApoE knockout mice 
also readily develop atherosclerosis on an atherogenic diet and have been widely used as 
models for this condition.[167]  
As ApoE is also synthesized by other tissues, notably the liver, it is important to consider 
the role of ApoE derived from other tissues in the phenotypes seen in global knockout 
models. In order to overcome this issue, Huang et al utilized an AP2 Cre-lox model of 
adipocyte-specific ApoE deletion which demonstrated increased insulin sensitivity 
compared to genetic controls.[168] This suggests that ApoE deficiency in other cells types, 
such as hepatocytes, may offset this benefit in global knockout models. Therefore, in 
future studies, it will be essential to determine whether iron impacts on ApoE secretion in 
other cells, particularly hepatocytes. 
With regards to other cell types, iron has been shown to dysregulate ApoE in primary 
cultured astrocytes and in cortical neurons. This is important, as the ApoEε4 polymorphism 
of the ApoE gene is common and is the strongest genetic risk factor for Alzheimer’s 
disease.[169] In addition, impaired iron homeostasis has been strongly linked to disease 
pathogenesis in this condition.[170] It has recently been shown that in primary cultured 
astrocytes and cortical neurons, iron treatment led to increased intracellular concentrations 
of ApoE and reduced ApoE secretion.[171] Taken together with our data, it seems 
possible that iron may indeed have similar effects on a range of cell types and represents 
a clear target for further investigation.  
Our SILAC analysis showed that iron treatment resulted in an 81% reduction in Annexin 
A1 secretome signal intensity. This is interesting as AnnexinA1 knock-out mice exhibit 
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greater degrees of hepatic lobular inflammation and fibrosis than controls when fed a 
methionine-choline deficient diet.[172] Annexin A1 therefore is potentially an important 
mechanism of iron-related adipocyte dysfunction in NAFLD and a candidate for future 
research. Furthermore, adipocyte iron has previously been shown to down-regulate serum 
adiponectin in a mouse derived adipocytes, 3T3-L1 cells. [17] Our findings support this in a 
human adipocyte cell line with a 55% reduction in adiponectin signal intensity in iron-
treated SGBS cells. 
In order to understand better whether FAC was having an iron-specific effect or a more 
general effect, we examined pathways of oxidative stress, inflammation and ER stress. 
Treatment with iron in our study, demonstrated an upregulation of anti-oxidant responses 
(heme-oxygenase-1 (HO-1) and glutathione peroxidase-1 (GPX-1) mRNA) indicating the 
presence of oxidative stress. However, interleukin-6 (IL-6) mRNA as a marker in 
inflammation was not increased with iron treatment, nor was there any difference among 
multiple markers of endoplasmic reticulum stress. Taken together, our model 
demonstrates oxidative stress responses without any evidence of ER stress or unfolded 
protein responses and no evidence of an impairment of cellular viability. 
We considered whether iron may have a generalized effect on pathways of protein 
secretion, utilized by a variety of proteins. We evaluated the role of iron in the secretion of 
proteins by the classical and exosomal pathways using the Uniprot and EVpedia 
databases respectively. We found enrichment of signal peptide-containing, but not 
exosome-secreted proteins amongst the iron-dysregulated proteins suggesting that iron 
may have a specific effect on proteins secreted via the classical pathway. Further 
investigation is still needed to clarify the mechanistic details of this effect. 
STRING pathway analysis has identified central roles for a number of important proteins in 
relation to dysregulation by iron. No clear unifying pathway was identified however. It is 
worth noting though, that such network analysis is primarily designed for identifying 
intracellular pathway and as such, it may be considered unsurprising that a clear and 
clinically relevant pathway has not been identified.  
Given the lack of quality human data regarding physiological adipocyte iron 
concentrations, a limitation of this study is that it is difficult to determine the physiological 
relevance of the concentrations of iron used. Nonetheless, it is reassuring that there was 
no observed iron-effect on cellular viability, total mRNA, or total protein. 
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This research has characterized the effect of iron on the adipocyte secretome. These data 
provide a platform for multiple avenues for future research. In addition, we have been able 
to show that increased iron results in sequestration of ApoE within adipocytes, which may 
be of key importance in the regulation of insulin resistance and liver injury in NAFLD. 
Further work is required to identify how iron and oxidative stress might regulate this effect 
and whether therapeutic manipulation of adipocyte iron in humans may be of benefit in 
NAFLD. 
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Chapter 7 : Conclusions 
 
The burden of non-alcoholic liver disease (NAFLD) represents a global epidemic.[1] The 
condition can lead to cirrhosis, liver failure and hepatocellular carcinoma.[2] The 
pathogenesis of this condition is not well understood and treatments that are substantially 
and consistently beneficial have not been developed. Dealing with this issue effectively will 
require major societal changes in diet and lifestyle and will almost certainly depend heavily 
upon governmental and public health initiatives. Nevertheless, for the foreseeable future, 
we are faced with an extraordinary burden of disease that urgently requires the 
development of improved medical therapy. 
Given the multifaceted nature of its pathophysiology and the heterogeneous nature of the 
disease, it seems unlikely that a single treatment approach will be effective for the majority 
of people with NAFLD. It may even be that fatty liver disease or steatohepatitis becomes 
regarded as a histologic result of a series of sub-classifications of fatty liver disease, 
including alcohol, insulin resistance and diabetes predominant, other genetic 
predispositions, iron-related, a number of other as yet unknown co-factors and various 
combinations of the above. Given the probable heterogeneity in pathogenesis, NAFLD 
treatment is likely to require a personalised-medicine approach. 
Manipulation of iron homeostasis, by venesection has been used in medicine for 
thousands of years. [173] More recently, venesection has proven to be an effective 
treatment for conditions such as haemochromatosis. Indeed venesection has been 
proposed as a treatment for NAFLD, although no large scale randomised trial has 
convincingly demonstrated effectiveness.[104] It could be argued though, that a 
subpopulation of NAFLD patients with certain iron phenotype may yet benefit from this 
treatment. Alternatively, it may be considered that venesection is too blunt a tool with 
which to benefit patients with NAFLD who may have complex derangements in iron 
homeostasis. Our understanding of cellular and systemic iron homeostasis mechanisms 
including the hepcidin-ferroportin axis have raised the promise of a more sophisticated and 
targeted manipulation of iron homeostasis.[152] Before such treatments might be 
developed for conditions such as NAFLD and possibly type II diabetes, it is essential that 
we more clearly define whether iron really might have an important role and if so, what the 
mechanism and location of iron’s effect might be. 
This thesis has examined the role of iron homeostasis in NAFLD pathogenesis across a 
range of tissues. The effect of subtle changes in enterocyte, and therefore systemic, iron 
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homeostasis in the context of HFE and hepcidin deficiency has been evaluated in an Hfe 
heterozygous knockout mouse model of NAFLD. Focus then shifted to examining the links 
between hepatic iron concentration (HIC) and insulin sensitivity, before evaluating the role 
of adipose tissue iron using in vivo and in vitro models. The key findings from these 
studies are described below. 
In the first of four original research chapters, Chapter 3, describes the use of an animal 
model of heterozygous Hfe deletion fed a high calorie diet as a model for humans with 
heterozygous HFE gene mutations who have co-existent NAFLD. This is a commonly 
encountered clinical scenario, given the high prevalence of both HFE gene polymorphisms 
and NAFLD.[14, 96] Given the observed co-toxic effect of HFE-haemochromatosis and 
NAFLD seen in humans and in mice with homozygous Hfe deletion, it has been important 
to explore the role of heterozygous gene mutations in NAFLD pathogenesis. Indeed it has 
been suggested that functional HFE deficiency itself may play an iron-independent role in 
NAFLD pathogenesis.[15] Human data and meta-analyses have led to conflicting results, 
yet this topic had not previously been studied in an animal model.[14, 96] 
Although increased hepatic iron accumulation with heterozygous Hfe deletion was 
observed, there was no evidence of increased liver injury as a result. It is unclear however 
whether effects may have been seen with a more prolonged exposure high calorie diet. 
Hamp1 (encoding Hepcidin) mRNA / HIC ratios demonstrated an approximate 50% 
decrease in Hfe+/- mice in both dietary groups compared with wild-type littermate controls. 
These findings are consistent with true haploinsufficiency regarding the translation of HFE 
and its interaction with Hamp1.  
The most remarkable finding from the study was the observation of increased serum 
glucose concentrations and HOMA-IR scores in Hfe+/- mice compared with wild-type 
controls. Unfortunately, the experiment was primarily designed to investigate liver injury 
and hepatic lipid metabolism As such, a detailed understanding of the impairment in 
glucose metabolism in this model would only be possible with a repeat study involving the 
use of techniques such as glucose tolerance tests and hyperinsulinaemic-euglycaemic 
clamps. Such a study would be readily achievable and is required to confirm these findings 
and explore the mechanisms by which HFE deficiency and/or mild iron excess can disrupt 
glucose homeostasis. 
In order to explore further the role of iron in glucose homeostasis and insulin resistance, 
Chapter 4 draws upon human data and stored serum samples from a prospective, 
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randomised, controlled trial of venesection in humans with NAFLD.[104] The original 
study, by Adams et al, showed a lack of effect of venesection on hepatic steatosis, serum 
ALT and measures of insulin sensitivity.[104] Nonetheless, given the quality of data 
available and unique access to paired serum samples before and after venesection, this 
was a useful opportunity with which to examine the relationships between iron, insulin 
resistance and adipokines further.  
There is an increasing body of evidence, described in depth in Chapter 2 that links 
alterations in adipocyte iron content to the dysregulation of adipokines implicated in 
NAFLD pathogenesis.[17, 19, 92, 147] Although there is a conspicuous lack of human 
data describing adipocyte iron concentration in NAFLD, a four-fold increase in adipocyte 
iron content was observed in a mouse model of obesity using a high fat diet.[24] This was 
shown to be associated with a reduction in HIC. A repartitioning of iron from the liver to 
adipose tissue was therefore proposed, but a mechanistic explanation remains elusive.[24] 
Chapter 4 describes the effect of venesection on serum concentrations of six key 
adipokines over a six month period, compared to randomised controls in participants with 
NAFLD. In addition, the relationships between, measures of iron homeostasis and insulin 
resistance were explored in depth. 
Venesection had no impact on serum concentrations of the six adipokines; adiponectin, 
leptin, resistin, RBP-4, TNFα and IL-6. There are a number of possible explanations for 
this. These include 1) these six adipokines are not regulated by iron, 2) venesection did 
not significantly mobilise adipose tissue iron, either due to treatment intensity or other 
unknown reasons, or 3) the study was insufficiently powered to detect changes in these 
adipokine concentrations. It should be noted however, that there was no real suggestion of 
a trend towards venesection effect for any of the adipokines studied. 
Further analysis of baseline data did however uncover modest but highly consistent 
associations between multiple surrogates of insulin sensitivity demonstrating an HIC. In 
addition there was a significant positive correlation between HIC and serum adiponectin 
concentration. These results challenge the conventional assumption that increasing HIC in 
the non-haemochromatotic range is associated with insulin resistance and diabetes. 
Indeed, other recently published data indicate that in the non-haemochromatotic range, 
increasing iron may be metabolically advantageous with respect to insulin resistance.[61, 
128] However, causal relationships based on our study cannot be established. This is in 
keeping with the observation of improved glucose tolerance in mice with homozygous Hfe 
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deletion [124]. However, this is seemingly at odds with the observation in Chapter 3 that 
heterozygous Hfe gene deletion is associated with a small increase in HIC, raised fasting 
serum glucose and HOMA-IR scores. The unknown factor though, in the human study and 
in both mouse models is the concentration of iron in adipose tissue and in particular 
adipocytes. This is particularly relevant when one considers the data that show increased 
adipocyte iron concentration in mice fed a high fat diet. [24] 
In order to explore further the relationships between adipose tissue iron and insulin 
resistance in NAFLD pathogenesis, Chapters 5 and 6 utilise in vivo (Chapter 5) and in vitro 
(Chapter 6) models of adipocyte iron loading. In Chapter 5, a model of selective adipocyte 
ferroportin knockout using a Cre-lox system driven by Cre in the promotor region the 
adiponectin gene (Adipoq) was developed. This model convincingly demonstrates effective 
selective knockout of the ferroportin gene (Fpn1) in adipocytes. However, this did not lead 
to increased adipocyte iron levels as measured by multiple means, implying that 
ferroportin may not be a key determinant of mammalian adipocyte iron homeostasis. It was 
then as expected that adipocyte ferroportin deletion did not lead to increased liver injury or 
evidence of altered glucose homeostasis. It remains unclear whether a higher dietary iron 
content would help to expose the desired phenotype or whether ferroportin really does 
have an insignificant role in iron homeostasis in adipocytes.  
In Chapter 6, a proteomic approach was employed in order to identify novel therapeutic 
targets in relation to dysregulation of adipokines by iron. Using stable isotope labelled 
amino acids in cell culture (SILAC), the iron-effect on the human Simpson-Golabi-Behmel 
syndrome (SGBS) adipocyte secretome was characterised. Sixty proteins with a greater 
than two-fold change in secretion and statistical significance of p<0.05 in response to iron 
were identified. Notable proteins that have been implicated in NAFLD pathogenesis were 
highlighted after a literature review relating to these proteins. Of these, adiponectin, 
annexin A1 and apolipoprotein E (ApoE) may be particularly relevant. The findings of a 
reduction in mass spectrometry signal intensity of adiponectin in response to iron replicate 
in human adipocytes, a similar observation, previously only seen in mouse 3T3-L1 
adipocytes. [17] Similarly a knockout model of annexin A1 has previously indicated a 
protective role for this protein in NAFLD pathogenesis. [172] 
The most striking finding from this study relates to ApoE. Immunoblotting of the secretome 
and intracellular protein indicated that iron profoundly inhibits secretion of ApoE causing it 
to become sequestered within adipocytes. There was evidence of transcriptional 
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responses to oxidative stress, without an upregulation of IL-6 or ER stress responses. This 
finding may be of importance in NAFLD given that ApoE appears to have a strongly 
protective effect against diet induced steatohepatitis in mice. [163]  
The research reported in this thesis has described a recurring theme regarding the 
interplay between iron and insulin resistance. Hfe heterozygous knockout in mice was 
associated with modest increases in hepatic iron and serum glucose. In humans however, 
HIC in the non-haemochromatotic range positively correlated with multiple measures of 
insulin sensitivity, including fasting serum glucose. Increasing adipocyte iron has been 
shown in animal and tissue culture models to lead to dysregulation of adipokines that 
typically are associated with increased insulin resistance and hepatic injury, such as 
reduced adiponectin, leptin and increased resistin. [17-19] Some of the discordance 
between these findings may be explained by the proposed repartitioning of iron from the 
liver to adipocytes that is seen in mice fed a high fat diet. [24] If this were the case in 
humans, the association between lower HIC and insulin resistance could, in part, be 
explained by an increase in adipocyte iron with reduced adiponectin transcription and 
increased adipose tissue insulin resistance. 
The missing data that would go some way to evaluating this hypothesis of iron-
repartitioning are human adipocyte iron concentrations in NAFLD. Perhaps unsurprisingly, 
it has been learned during the course of this research that individuals with NAFLD are 
generally reluctant to undergo percutaneous adipose tissue biopsy for ethically approved 
clinical research purposes. One way around this issue would be a cross sectional study of 
patients with NAFLD undergoing elective laparoscopic surgery, such as cholecystectomy. 
Such a study would provide a relatively safe means with which to collect adipose and liver 
tissue samples and correlate with a range of fasting serum parameters including 
adipokines. This is a clear and immediate target for future study. 
The model of adipocyte-specific ferroportin knockout did not lead to a phenotype of 
adipocyte iron overload. The development of a reliable in vivo model of adipocyte-specific 
iron loading would therefore undoubtedly be a hugely valuable tool for research in this 
field. However, the findings indicating that ferroportin may not be a key regulator of 
adipocyte iron homeostasis are in themselves instructive. If adipocyte iron is as important 
as we might imagine in NAFLD and diabetes pathogenesis, then identifying novel iron 
transport mechanisms that are unique to adipocytes may enable the development of 
relatively simple adipocyte-specific treatments targeting iron. 
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Finally, the use of a proteomic approach to analyse the effects of iron on the adipocyte 
secretome has provided a wealth of publicly available data as a platform for future studies. 
To date, there has only been a scratching of the surface of the potential of this data. Other 
than the effects on ApoE which need to be explored in more depth, the dysregulation of a 
number of other proteins may represent novel mechanisms pertaining to adipocyte iron’s 
role in NAFLD pathogenesis.  
In conclusion, multi-faceted links between iron, insulin sensitivity and the dysregulation of 
adipokines have been identified. These findings provide a strong rationale for further 
translational study in this field.  
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Appendix A: Research letter: Iron inhibits the secretion of 
apolipoprotein E in cultured human adipocytes 
 
Below is the abridged version of Chapter 6 that is currently undergoing peer review after 
re-submission with revisions for Cellular and Molecular Gastroenterology and Hepatology. 
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Non-alcoholic steatohepatitis (NASH) is characterized by adipose tissue dysfunction with 
insulin resistance and the dysregulation of adipokines. [21] Recent data indicate 
repartitioning of iron from the liver to adipocytes in obesity and a role for iron in the 
development of adipose tissue dysfunction. [24, 34] However the molecular mechanisms 
have not been established. To test the hypothesis that iron modulates adipokine release, 
we performed a quantitative proteomics analysis of the human Simpson-Golabi-Behmel 
Syndrome (SGBS) adipocyte secretome following 48 hours of treatment with ferric 
ammonium citrate (FAC). We utilized stable isotope labelled amino acids in cell culture 
(SILAC) to characterize changes in the adipocyte secretome in response to iron. This 
technique has enabled direct comparison of quantities of individual proteins in the 
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adipocyte secretome in response to iron using a proteomics approach as a tool for the 
identification of novel treatment targets in NASH. 
We first showed that 100μM FAC causes significant adipocyte iron loading without 
compromising cell viability. We found that compared to vehicle both 100 μM and 500 μM 
FAC caused significant increases in cellular iron concentration (p=0.007 and p=0.006 
respectively, Figure 8.1(a)). There was no effect of iron loading on cellular viability (MTS) 
assay, total mRNA, total whole cell lysate protein or total secretome protein (Figure 8.1 (b-
e)). 
Figure 8.1: Optimization of iron loading in SGBS cells  
(a) Iron assay, p=0.004 (one-way ANOVA), *indicates p<0.01 (Dunnett’s multiple comparisons test compared to 0μM 
FAC, n=2 per group). (b) Total RNA (non-significant (NS) by one-way ANOVA, n=3 per group). (c) Total lysate protein 
(NS by one-way ANOVA, n=3 per group). (d) Total secretome protein (NS by one-way ANOVA, n=3 per group). (e) 
Viability assay (MTS) (NS by one-way ANOVA, n=3 per group). Data are presented as mean and standard error of the 
mean. 
 
Given these findings, we selected 100 μM FAC as the concentration to compare with 
vehicle in the secretome SILAC proteomic analysis. A total of 338 proteins were quantified 
in the adipocyte secretome by SILAC proteomics. These are represented graphically as a 
volcano plot in Figure 8.2 and the proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository 
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(www.proteomexchange.org) with the dataset identifier PXD006341. Iron treatment led to 
significant differential secretion of 60 of these proteins (>2-fold change and p-value <0.05). 
We then manually reviewed Uniprot database descriptions of these 60 proteins. This 
generated a list of 20 proteins of interest (highlighted in bold in Table 8.1). These proteins 
of interest and their synonyms were then entered into a Pubmed title/abstract search in 
association with NASH and its synonyms. This identified three proteins as candidate 
intermediates for iron-induced adipose tissue dysfunction in NASH. These proteins were 
adiponectin, annexin A1 and apolipoprotein E (ApoE). 
Figure 8.2: Volcano plot of relative signal intensity of proteins identified in the 
adipocyte secretome 
The x-axis denotes log 2 of the ratio of iron/vehicle treated cells, with proteins to the left of zero representing those 
downregulated by iron and those to the right representing up-regulation by iron. The y-axis denotes statistical 
significance with a line representing a p-value of 0.05. Proteins above this line have p<0.05. SILAC labelled adipocytes 
generated 338 proteins that were identified in the secretome by mass spectrometry. Of these 213, had reduced signal 
intensity in response to iron, whereas 125 had increased signal intensity. Of the 213 proteins with reduced signal 
intensity, 61 had a statistically significant (p < 0.05) downregulation in response to iron. Of these, 53 had a greater than 
2-fold decrease in response to iron. Of the 125 proteins with increased signal intensity, 11 had a statistically significant (p 
< 0.05) upregulation in response to iron. Of these, 7 proteins had a greater than 2-fold increase response to iron. Those 
proteins containing signal peptide (as determined by signal peptide annotations on the Uniprot database) are shown in 
red. Those without signal peptide are shown in blue. 
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Table 8.1: List of SGBS secretome proteins with significantly altered signal intensity 
in response to iron 
Proteins shown had a greater than 2-fold change in signal intensity in response to iron, with a p-value <0.05. Proteins 
highlighted in bold represent the 20 proteins of interest after review of Uniprot protein descriptions. Data were analyzed 
using the online Quantitative Proteomics P-value Calculator (QPPC) using no normalization and non-adjusted p-values. 
n=3 per group 
 
Accession 
number 
Gene 
name 
Protein name Mean signal 
intensity 
ratio 
(iron/vehicle) 
Standard 
deviation 
P value 
Q8IX30 SCUBE3 Signal peptide, CUB 
and EGF-like domain-
containing protein 3 
0.026 0.016 0.001 
P61353 RPL27 60S ribosomal protein 
L27 
0.060 0.005 0.001 
Q9NQH7 XPNPEP3 Probable Xaa-Pro 
aminopeptidase 3 
0.076 0.004 0.001 
P07996 THBS1 Thrombospondin-1 0.083 0.047 0.001 
Q76M96 CCDC80 Coiled-coil domain-
containing protein 80 
0.090 0.031 0.001 
P78539 SRPX Sushi repeat-containing 
protein SRPX 
0.096 0.620 0.001 
Q9UHI8 ADAMTS1 A disintegrin and 
metalloproteinase with 
thrombospondin motifs 
1 
0.114 0.090 0.002 
Q92538 GBF1 Golgi-specific brefeldin 
A-resistance guanine 
nucleotide exchange 
factor 1 
0.118 0.024 0.004 
Q15063 POSTN Periostin 0.121 0.149 0.001 
P08238 HSP90AB1 Heat shock protein HSP 
90-beta 
0.125 0.038 0.004 
P24593 IGFBP5 Insulin-like growth 
factor-binding protein 
5 
0.154 0.069 0.001 
Q15113 PCOLCE Procollagen C-
endopeptidase 
enhancer 1 
0.155 0.088 0.001 
Q9NTX5 ECHDC1 Ethylmalonyl-CoA 
decarboxylase 
0.158 0.068 0.001 
P25788 PSMA3 Proteasome subunit 
alpha type-3 
0.176 0.442 0.001 
Q12931 TRAP1 Heat shock protein 75 
kDa, mitochondrial 
0.186 0.028 0.018 
P04083 ANXA1 Annexin A1 0.192 0.049 0.001 
P30101 PDIA3 Protein disulfide-
isomerase A3 
0.198 0.059 0.001 
Q99985 SEMA3C Semaphorin-3C 0.199 0.225 0.001 
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Q6NZI2 PTRF Polymerase I and 
transcript release factor 
0.210 0.134 0.001 
Q8TAV4 STOML3 Stomatin-like protein 3 0.220 0.084 0.006 
Q9UKZ9 PCOLCE2 Procollagen C-
endopeptidase 
enhancer 2 
0.226 0.030 0.001 
Q05469 LIPE Hormone-sensitive 
lipase 
0.231 0.196 0.023 
Q13642 FHL1 Four and a half LIM 
domains protein 1 
0.263 0.006 0.029 
P02749 APOH Beta-2-glycoprotein 1 0.286 0.310 0.048 
P02462 COL4A1 Collagen alpha-1(IV) 
chain 
0.286 0.351 0.001 
P15311 EZR Ezrin 0.296 0.077 0.003 
P42765 ACAA2 3-ketoacyl-CoA 
thiolase, mitochondrial 
0.308 0.136 0.001 
P68104 EEF1A1 Elongation factor 1-
alpha 1 
0.309 0.215 0.001 
Q9NQC3 RTN4 Reticulon-4 0.312 0.119 0.007 
Q8IY17 PNPLA6 Neuropathy target 
esterase 
0.316 0.028 0.026 
Q92743 HTRA1 Serine protease HTRA1 0.324 0.075 0.001 
P08294 SOD3 Extracellular 
superoxide dismutase 
[Cu-Zn] 
0.339 0.027 0.005 
Q16836 HADH Hydroxyacyl-coenzyme 
A dehydrogenase, 
mitochondrial 
0.348 0.207 0.011 
Q99715 COL12A1 Collagen alpha-1(XII) 
chain 
0.348 0.183 0.001 
P07355 ANXA2 Annexin A2 0.354 0.111 0.001 
P26038 MSN Moesin 0.362 0.110 0.034 
P23284 PPIB Peptidyl-prolyl cis-trans 
isomerase B 
0.374 0.122 0.001 
O94769 ECM2 Extracellular matrix 
protein 2 
0.375 0.060 0.005 
Q9NRN5 OLFML3 Olfactomedin-like 
protein 3 
0.389 0.066 0.002 
P53396 ACLY ATP-citrate synthase 0.389 0.066 0.001 
Q16363 LAMA4 Laminin subunit alpha-4 0.407 0.091 0.001 
P14625 HSP90B1 Endoplasmin 0.414 0.068 0.025 
Q9BU40 CHRDL1 Chordin-like protein 1 0.419 0.264 0.001 
P02649 APOE Apolipoprotein E 0.421 0.053 0.001 
Q9NS98 SEMA3G Semaphorin-3G 0.425 0.161 0.001 
P02751 FN1 Fibronectin 0.441 0.146 0.001 
P14543 NID1 Nidogen-1 0.442 0.190 0.006 
Q08431 MFGE8 Lactadherin 0.446 0.167 0.026 
Q15848 ADIPOQ Adiponectin 0.449 0.652 0.005 
O75390 CS Citrate synthase, 0.454 0.183 0.012 
152 
 
mitochondrial 
Q92626 PXDN Peroxidasin homolog 0.457 0.200 0.001 
P07942 LAMB1 Laminin subunit beta-1 0.484 0.110 0.001 
Q08629 SPOCK1 Testican-1 0.497 0.055 0.014 
O00462 MANBA Beta-mannosidase 2.180 2.560 0.034 
Q13510 ASAH1 Acid ceramidase 2.222 3.135 0.048 
P02794 FTH1 Ferritin heavy chain 2.451 0.769 0.030 
Q02952 AKAP12 A-kinase anchor protein 
12 
2.665 0.572 0.047 
A6NCN2 KRT87P Putative keratin-87 
protein 
4.113 0.011 0.022 
P23468 PTPRD Receptor-type tyrosine-
protein phosphatase 
delta 
10.687 2.199 0.003 
P10586 PTPRF Receptor-type tyrosine-
protein phosphatase F 
11.935 3.955 0.001 
 
Our SILAC analysis showed that iron treatment resulted in an 81% reduction in Annexin 
A1 secretome signal intensity (p=0.001). This may be important as AnnexinA1 knock-out 
mice exhibit greater degrees of hepatic lobular inflammation and fibrosis than controls 
when fed a methionine-choline deficient diet.[172] Adipocyte iron has also previously been 
shown to transcriptionally down-regulate serum adiponectin in a mouse derived 
adipocytes, 3T3-L1 cells. [17] Our findings now support this in a human adipocyte cell line 
with a 55% reduction in adiponectin signal intensity in iron-treated SGBS cells (p=0.005). 
We next focused on the iron-regulation of ApoE secretion. ApoE appears to protect 
against steatohepatitis in mice. In an ApoE knockout model, unlike wild type controls, 
ApoE KO mice fed seven weeks of a Western diet developed impaired glucose tolerance, 
steatohepatitis and hepatic fibrosis.[163] ApoE is a component of lipoproteins and 
promotes VLDL induced adipogenesis.[166] ApoE knockout mice also readily develop 
atherosclerosis on an atherogenic diet.[167]  
Iron reduced secreted ApoE by 58% (p=0.001) and 76% (p=0.007), as measured by 
SILAC and western blot respectively. Conversely, iron treatment increased intracellular 
ApoE levels by more than 11-fold (p=0.0005), without causing a significant change in 
mRNA levels (Figure 8.3). It therefore appears that iron inhibits the secretion of ApoE from 
adipocytes, causing ApoE to become sequestered intracellularly. 
 
 
153 
 
Figure 8.3: SBGS ApoE expression following FAC treatment  
(a) ApoE mRNA (NS, ratio paired t-test), (b) Secretome ApoE densitometry (* denotes p=0.001, ratio paired t-test), (c) 
Lysate ApoE densitometry normalized to β-actin (# denotes p=0.0005, ratio paired t-test), (d) Secretome ApoE 
immunoblot, (e) Whole cell lysate ApoE and β-actin immunoblots (n=3 per group). Data are presented as mean and 
standard error of the mean. 
 
Similar effects on ApoE secretion have been shown with iron treatment in primary cultured 
astrocytes and cortical neurons. [171] Taken together with our data, it seems possible that 
iron may have similar effects on a range of cell types and represents a clear target for 
further investigation. Treatment with iron in our study, demonstrated an upregulation of 
anti-oxidant responses (heme-oxygenase-1 (HO-1) and glutathione peroxidase-1 (GPX-1) 
mRNA) indicating the presence of oxidative stress. Interleukin-6 (IL-6) mRNA however 
was not increased with iron treatment, nor was there any difference among multiple 
markers of endoplasmic reticulum stress (Figure 8.4 (a-i))  
We considered whether iron may have a generalized effect on pathways of protein 
secretion, utilized by a variety of proteins. We evaluated the role of iron in the secretion of 
proteins by the classical and exosomal pathways using the Uniprot and EVpedia 
databases respectively [161, 165]. We found enrichment of signal peptide-containing 
(p=0.02), but not exosome-secreted proteins (p=0.51) among the iron-dysregulated 
proteins suggesting that iron may have a specific effect on proteins secreted via the 
classical pathway (Figure 8.4(j-m)). 
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Figure 8.4: Mechanistic aspects of iron-related dysregulation of protein secretion 
(a) Interleukin-6 (IL-6) mRNA (non-significant (NS), paired t-test, n=3 per group). (b-c) Oxidative stress * indicates 
p<0.05, both n=3 per group (b) Heme-oxygenase (HO-1) mRNA (p=0.01, paired t-test). (c) Glutathione peroxidase 1 
(GPX-1) mRNA (p=0.049, paired t-test). (d-i) Endoplasmic reticulum (ER) stress, all n=3 per group. (d) Unspliced X-box 
binding protein (XBP-1) mRNA (NS, paired t-test). (e) Spliced X-box binding protein (XBP-1) mRNA (NS, paired t-test). 
(f) Immunoglobulin binding protein (BiP) mRNA (NS, paired t-test). (g) ER-degradation-enhancing-α-mannidose-like 
protein (EDEM) mRNA (NS, paired t-test). (h) Activating transcription factor 4 (ATF4) mRNA (NS, paired t-test). (i) 
CCAAT/enhancer-binding protein homologous protein (CHOP) mRNA (NS, paired t-test). (j-m) Enrichment with signal 
peptide and exosome proteins. (j) Proportion of proteins significantly down regulated by iron with signal peptide vs no 
signal peptide. (k) Proportion of proteins not significantly down regulated by iron with signal peptide vs no signal peptide. 
(l) Proportion of proteins significantly down regulated by iron with exosome secretion vs no exosome secretion. (m) 
Proportion of proteins not significantly down-regulated by iron with exosome secretion vs no exosome secretion. Of the 
61 significantly down-regulated proteins, 62% (38/61) had signal peptide, whereas of the remaining proteins only 47% 
(129/277) had signal peptide. One-tailed Fisher’s-exact test showed significant enrichment with signal peptide (p=0.02) 
amongst the significantly down-regulated group. In contrast, there was no significant enrichment of the exosomal 
pathway (p=0.51, one-tailed Fisher’s-exact test), as 15% (9/61) of significantly down-regulated proteins and 14% 
(39/277) of the remaining secretome proteins had been previously reported in the high confidence proteins from the 
EVpedia database.  
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This research has characterized the effect of iron on the adipocyte secretome. These data 
provide a platform for multiple avenues of future research. In addition, we have been able 
to show that increased iron results in sequestration of ApoE within adipocytes, which may 
be of key importance in the regulation of insulin resistance and liver injury in NASH. 
Identifying the molecular mechanisms of iron-induced inhibition of ApoE secretion from 
adipocytes, particularly relating to the role of oxidative stress, may reveal novel therapeutic 
strategies for improving adipocyte function in NASH. 
Supplementary methods 
 
SGBS differentiation and iron treatment 
SGBS pre-adipocytes were a gift from Martin Wabitsch (University of Ulm, Germany). 
[158, 174] SGBS cells were passaged, proliferated and differentiated at less than 50 
generations in 12 well plates and 100 mm dishes as previously described.[157] Cells were 
treated with 90 μg/ml heparin and 1 ng/ml fibroblast growth factor-1 (FGF-1) (both Sigma-
Aldrich, St Louis, Missouri) throughout proliferation and differentiation. After 14 days of 
differentiation, cells were incubated with 0, 25, 100 or 500 μM ferric ammonium citrate 
(FAC) (Sigma- Aldrich) for 24 hrs. After this media was replaced with the same for a 
further 24 hrs to the end of experiment. 
RNA extraction and real-time quantitative PCR (RT-qPCR) 
RNA was extracted from treated SGBS adipocytes using a PureLink RNA mini kit 
(Invitrogen, Carlsbad, California). Complementary DNA was synthesized from 1 µg RNA 
using a Sensifast cDNA synthesis kit (Bioline, London, UK) after treatment with DNase 1 
(Invitrogen). Samples underwent thermal cycling using a ViiA7 real-time PCR machine 
(Invitrogen) with a Sensifast SYBR Lo-ROX Kit (Bioline). The following protocol was used: 
2 min at 95oC, then 40 cycles of 5 sec at 95oC alternating with 20 sec at 63oC, followed by 
a melt curve analysis. Relative mRNA quantities were determined by calibration of Ct 
values to standard curve of pooled cDNA samples. Results were normalized to Ct values 
of Cyclophillin.  
Iron, cellular viability (MTS) and protein assays. 
Iron levels were quantified using a chromagen reagent method. [159] Cellular viability was 
assessed using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, 
Madison, Wisconsin) according to the manufacturer’s instructions. Whole cell lysate and 
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secretome samples underwent protein estimation using a Pierce BCA protein assay kit 
(Thermofisher Scientific, Waltham, Massachusetts).  
SILAC proteomics 
SILAC incorporates stbale amino acids isotopes, without altering cellular biology, allowing 
direct comparison of the secretome by mass spectrometry between treatment groups. 
[175] SGBS pre-adipocytes were grown in SILAC DMEM: F12 media (Thermofisher 
Scientific) supplemented with dialyzed fetal bovine serum (Thermofisher Scientific,) and 
22.81mg/L 2H4-Lysine and 36.88mg/L 13C6-Arginine (K4R6) or 22.81mg/L 13C615N2-Lysine 
and 36.88mg/L 13C615N4-Arginine (K8R10). Incorporation of labelled amino acids was 
confirmed by liquid chromatography tandem mass spectrometry (LC-MS/MS) on tryptic 
peptides prepared from whole cell lysates. Cell pellets were lysed in 8M urea in 100mM 
TEAB (Triethylamonium bicarbonate), and protein concentration estimated using Bradford 
assay (BioRad, Hercules, California). Thirty μg of cell lysate was reduced and alkylated by 
incubating samples for 30 min at 37oC with 2.5mM TCEP (tris(2-carboxyethyl)phosphine) 
and then 5mM 2CAA (2-Chloroacetamide). Urea concentration was diluted to 1M with 
100mM TEAB before adding 0.6 μg of trypsin. Samples were incubated overnight then 
acidified to 1% trifluoroacetic acid (TFA) and cleaned with OMIX C18 tips according to the 
manufacturers’ protocol (Agilent, Santa Clara, California). LC-MS/MS was performed as 
described below.  
Labelled (>97%) cells underwent differentiation to adipocytes as described above. At day 
14 post differentiation, cells were treated with vehicle (media) (K4R6, medium weight cells) 
or 100 μM FAC (in media) (K8R10, heavy weight cells) for a further 48 hours using exactly 
equal volumes of media, replacing the media after 24 hrs. Media for secretome analysis 
was collected from K4R6 and K8R10 cells and mixed 1:1 (v/v) before centrifugation at 600 
x G at 4oC for 10 min to remove cell debris. Supernatant was then concentrated using 
Amicon Ultra 15ml 10 kDa centrifugal filter units (Merck Millipore, Burlington, 
Massachusetts) in a fixed angle centrifuge at 5000 x G to provide approximately 1 ml 
samples of concentrated mixed secretome. Thirty µg of protein was separated on 10% 
SDS-PAGE gels to 10 mm. Protein visualization, excision of bands and in-gel trypsin 
digest were performed using a semi-automated method as described.[160] A band 
corresponding to the same molecular weight as transferrin (media additive) was removed 
prior to digestion, in order to provide a protein sample exclusively secreted from cultured 
adipocytes. 
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Mass spectrometry 
A Q Exactive Plus Orbitrap Mass Spectrometer (Thermofisher Scientific), coupled with 
Easy-nLC 1000 and EASY-spray ion source (both Thermofisher Scientific), was used to 
analyze the digested peptides. Samples were loaded onto an EASY-Spray PepMap RSLC 
C18 2 µm column (50 cm x 75 µm ID), with a Nanoviper Acclaim C18 guard (75 µm x 2 
cm) (both Thermofisher Scientific). A 90 min method was run using a combination of Buffer 
A (0.1% Formic acid) and Buffer B (0.1% Formic acid: Acetonitrile). A two-step gradient 
was run comprising a 60 min gradient from 3% to 25% Buffer B and a 12 min gradient from 
25% to 40% Buffer B. Flow rate was at 250 nL/min. The mass spectrometer was 
programmed to acquire a full mass spectrometry (MS) resolution of 70,000 with an ACG 
target of 3x106 with a maximum injection time of 100 ms. The MS scan range was from 
350 to 1400 m/z. MS/MS was set to acquire a resolution of 17,500 with an ACG target of 
5x105 and maximum injection time of 55 ms. The loop count was set to 20 with a dynamic 
exclusion after 30 sec. 
Raw data were processed with Spectrum mill (Rev B.05.00.181 SP1, Agilent). Selected 
modifications included fixed carbamidomethylation of cysteine and SILAC labels (Arg 0-6-
10 Da Lys 0-4-8 Da) and variable oxidized methionine. Results were searched against the 
Human Uniprot database (downloaded 06/01/2015).[161] Trypsin was selected as digest 
enzyme, with two maximum missed cleavages allowed. The precursor mass tolerance was 
set at +/- 20 ppm and product mass tolerance was +/- 20 ppm. Data were analyzed using 
the online Quantitative Proteomics P-value Calculator (QPPC) using no normalization and 
non-adjusted p-values.[162] 
Immunoblotting 
Western blotting using whole cell lysate samples (10 μg) and 5 μL concentrated secretome 
samples was performed as previously described.[147] A 1:500 dilution of primary antibody 
against Apolipoprotein E (ApoE) (sc-53570, Santa Cruz, Dallas, Texas) was applied to the 
membranes. A 1:100,000 dilution of goat anti-mouse horseradish peroxidase antibody 
(Invitrogen) was applied as secondary antibody. ApoE whole cell lysate densitometry was 
normalized against densitometry using beta-actin as a reference protein (1:2000 primary 
antibody) (Cat No. 4967, Cell Signaling, Danvers, Massachusetts) and 1:20,000 goat anti-
rabbit horseradish peroxidase antibody (Invitrogen). 
 
159 
 
Appendix B: Ethics committee approvals 
 
 
160 
 
 
 
 
161 
 
References 
 
[1] Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 
2013;10(11):686-90. 
[2] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular 
disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10(6):330-44. 
[3] Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis 
and treatment. Nat Rev Endocrinol 2011;7(8):456-65. 
[4] Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin 
Gastroenterol 2010;26(3):202-8. 
[5] Babitt JL, Lin HY. The molecular pathogenesis of hereditary hemochromatosis. Seminars in 
liver disease 2011;31(3):280-92. 
[6] Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, et al. Steatosis is a 
cofactor in liver injury in hemochromatosis. Gastroenterology 2005;129(6):1937-43. 
[7] Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic 
syndrome: a promising therapeutic target. Journal of hepatology 2011;55(4):920-32. 
[8] Nelson JE, Klintworth H, Kowdley KV. Iron metabolism in Nonalcoholic Fatty Liver Disease. 
Current gastroenterology reports 2012;14(1):8-16. 
[9] Barnette AR, Horbar JD, Soll RF, Pfister RH, Nelson KB, Kenny MJ, et al. Neuroimaging in 
the evaluation of neonatal encephalopathy. Pediatrics 2014;133(6):e1508-17. 
[10] Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 
1998;114(4):842-5. 
[11] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty 
liver disease (NAFLD). Metabolism 2016;65(8):1038-48. 
[12] Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver 
disease. J Clin Endocrinol Metab 2006;91(12):4753-61. 
[13] Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-
overload-related disease in HFE hereditary hemochromatosis. The New England journal of 
medicine 2008;358(3):221-30. 
162 
 
[14] Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes 
and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 
controls. Hepatology 2007;46(4):1071-80. 
[15] Tan TC, Crawford DH, Jaskowski LA, Murphy TM, Heritage ML, Subramaniam VN, et al. 
Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis. 
Am J Physiol Gastrointest Liver Physiol 2011;301(5):G865-76. 
[16] Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50(3):957-69. 
[17] Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, et al. Adipocyte iron 
regulates adiponectin and insulin sensitivity. J Clin Invest 2012;122(10):3529-40. 
[18] Gao Y, Li Z, Gabrielsen JS, Simcox JA, Lee SH, Jones D, et al. Adipocyte iron regulates 
leptin and food intake. J Clin Invest 2015;125(9):3681-91. 
[19] Dongiovanni P, Ruscica M, Rametta R, Recalcati S, Steffani L, Gatti S, et al. Dietary Iron 
Overload Induces Visceral Adipose Tissue Insulin Resistance. Am J Pathol 2013. 
[20] Fernandez-Real JM, Moreno JM, Ricart W. Circulating retinol-binding protein-4 
concentration might reflect insulin resistance-associated iron overload. Diabetes 
2008;57(7):1918-25. 
[21] Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev 
Gastroenterol Hepatol 2011;8(1):35-44. 
[22] Pihan-Le Bars F, Bonnet F, Loreal O, Le Loupp AG, Ropert M, Letessier E, et al. Indicators 
of iron status are correlated with adiponectin expression in adipose tissue of patients with 
morbid obesity. Diabetes Metab 2016;42(2):105-11. 
[23] Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, et al. Increased adipose tissue 
expression of hepcidin in severe obesity is independent from diabetes and NASH. 
Gastroenterology 2006;131(3):788-96. 
[24] Orr JS, Kennedy A, Anderson-Baucum EK, Webb CD, Fordahl SC, Erikson KM, et al. 
Obesity alters adipose tissue macrophage iron content and tissue iron distribution. Diabetes 
2014;63(2):421-32. 
[25] Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, et al. Fast food 
diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and 
high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 
2011;301(5):G825-34. 
163 
 
[26] Lee KY, Russell SJ, Ussar S, Boucher J, Vernochet C, Mori MA, et al. Lessons on 
conditional gene targeting in mouse adipose tissue. Diabetes 2013;62(3):864-74. 
[27] Eguchi J, Wang X, Yu S, Kershaw EE, Chiu PC, Dushay J, et al. Transcriptional control of 
adipose lipid handling by IRF4. Cell Metab 2011;13(3):249-59. 
[28] Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty 
liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J 
Gastroenterol Hepatol 2007;22(6):778-87. 
[29] Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency 
and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. 
Gastroenterology 2011;141(4):1249-53. 
[30] Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural 
history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. 
Alimentary Pharmacology and Therapeutics 2011;34(3):274-85. 
[31] Khan FZ, Perumpail RB, Wong RJ, Ahmed A. Advances in hepatocellular carcinoma: 
Nonalcoholic steatohepatitis-related hepatocellular carcinoma. World journal of hepatology 
2015;7(18):2155-61. 
[32] Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation 
to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 
2014;26(1):100-7. 
[33] Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver 
iron overload with normal transferrin saturation. Lancet 1997;349(9045):95-7. 
[34] Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab 2013;17(3):329-41. 
[35] Watt RK. The many faces of the octahedral ferritin protein. Biometals : an international 
journal on the role of metal ions in biology, biochemistry, and medicine 2011;24(3):489-500. 
[36] Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci 2009;66(20):3241-61. 
[37] Fleming DJ, Jacques PF, Tucker KL, Massaro JM, D'Agostino RB, Sr., Wilson PW, et al. 
Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete 
population with a high prevalence of elevated iron stores. Am J Clin Nutr 2001;73(3):638-
46. 
[38] Fleming RE, Ponka P. Iron overload in human disease. The New England journal of 
medicine 2012;366(4):348-59. 
164 
 
[39] Takamura T, Misu H, Ota T, Kaneko S. Fatty liver as a consequence and cause of insulin 
resistance: lessons from type 2 diabetic liver. Endocr J 2012;59(9):745-63. 
[40] Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is 
associated with macrophage accumulation in adipose tissue. J Clin Invest 
2003;112(12):1796-808. 
[41] Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the 
metabolic movers. J Gastroenterol Hepatol 2010;25(4):672-90. 
[42] Carmen GY, Victor SM. Signalling mechanisms regulating lipolysis. Cell Signal 
2006;18(4):401-8. 
[43] Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of 
fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty 
liver disease. J Clin Invest 2005;115(5):1343-51. 
[44] Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing 
links. Cell 2012;148(5):852-71. 
[45] Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent 
hepatocyte lipoapoptosis. J Biol Chem 2006;281(17):12093-101. 
[46] Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic 
reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol 
Endocrinol Metab 2006;291(2):E275-81. 
[47] Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem 
Pharmacol 2013;86(11):1517-24. 
[48] Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of 
nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52(1):59-69. 
[49] Frazier TH, DiBaise JK, McClain CJ. Gut microbiota, intestinal permeability, obesity-
induced inflammation, and liver injury. JPEN J Parenter Enteral Nutr 2011;35(5 Suppl):14S-
20S. 
[50] Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, et al. Activation and 
dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. 
Gastroenterology 2008;134(2):568-76. 
[51] Zhang XQ, Xu CF, Yu CH, Chen WX, Li YM. Role of endoplasmic reticulum stress in the 
pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20(7):1768-76. 
165 
 
[52] Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and 
mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol 
2014;20(39):14205-18. 
[53] Bohinc BN, Diehl AM. Mechanisms of disease progression in NASH: new paradigms. Clin 
Liver Dis 2012;16(3):549-65. 
[54] Huang J, Gabrielsen JS, Cooksey RC, Luo B, Boros LG, Jones DL, et al. Increased 
glucose disposal and AMP-dependent kinase signaling in a mouse model of 
hemochromatosis. J Biol Chem 2007;282(52):37501-7. 
[55] Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. 
Diabetes Care 1999;22(12):1978-83. 
[56] Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of 
type 2 diabetes in apparently healthy women. Jama 2004;291(6):711-7. 
[57] Montonen J, Boeing H, Steffen A, Lehmann R, Fritsche A, Joost HG, et al. Body iron stores 
and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer 
and Nutrition (EPIC)-Potsdam study. Diabetologia 2012;55(10):2613-21. 
[58] Orban E, Schwab S, Thorand B, Huth C. Association of iron indices and type 2 diabetes: a 
meta-analysis of observational studies. Diabetes/metabolism research and reviews 
2014;30(5):372-94. 
[59] Huth C, Beuerle S, Zierer A, Heier M, Herder C, Kaiser T, et al. Biomarkers of iron 
metabolism are independently associated with impaired glucose metabolism and type 2 
diabetes: the KORA F4 study. Eur J Endocrinol 2015;173(5):643-53. 
[60] Podmore C, Meidtner K, Schulze MB, Scott RA, Ramond A, Butterworth AS, et al. The 
Association of Multiple Biomarkers of Iron Metabolism and Type 2 Diabetes: The EPIC-
InterAct Study. Diabetes Care 2016. 
[61] Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution 
of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. 
Hepatology 2004;39(1):179-87. 
[62] Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. 
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in 
patients with nonalcoholic fatty liver disease. Hepatology 2012;55(1):77-85. 
[63] Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, et al. A simple clinical 
scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting 
166 
 
steatohepatitis in nonalcoholic fatty liver disease. Journal of gastroenterology 
2011;46(2):257-68. 
[64] Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, et al. HFE 
genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic 
fatty liver disease. Gastroenterology 2010;138(3):905-12. 
[65] Chandok N, Minuk G, Wengiel M, Uhanova J. Serum ferritin levels do not predict the stage 
of underlying non-alcoholic fatty liver disease. Journal of gastrointestinal and liver diseases 
: JGLD 2012;21(1):53-8. 
[66] Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, et al. HFE mutations, 
hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with 
fibrotic severity. Hepatology 2002;36(1):142-9. 
[67] Kim CW, Chang Y, Sung E, Shin H, Ryu S. Serum ferritin levels predict incident non-
alcoholic fatty liver disease in healthy Korean men. Metabolism 2012;61(8):1182-8. 
[68] Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation 
and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J 
Clin Invest 2004;113(9):1277-87. 
[69] Minamiyama Y, Takemura S, Kodai S, Shinkawa H, Tsukioka T, Ichikawa H, et al. Iron 
restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. 
Am J Physiol Endocrinol Metab 2010;298(6):E1140-9. 
[70] MacDonald GA, Bridle KR, Ward PJ, Walker NI, Houglum K, George DK, et al. Lipid 
peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs 
predominately in acinar zone 3. J Gastroenterol Hepatol 2001;16(6):599-606. 
[71] Fujita N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Kobayashi Y, et al. Iron overload is 
associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer 
Epidemiol Biomarkers Prev 2009;18(2):424-32. 
[72] Nakashima T, Sumida Y, Furutani M, Hirohama A, Okita M, Mitsuyoshi H, et al. Elevation of 
serum thioredoxin levels in patients with nonalcoholic steatohepatitis. Hepatol Res 
2005;33(2):135-7. 
[73] Messner DJ, Rhieu BH, Kowdley KV. Iron overload causes oxidative stress and impaired 
insulin signaling in AML-12 hepatocytes. Digestive diseases and sciences 2013;58(7):1899-
908. 
167 
 
[74] Maliken BD, Nelson JE, Klintworth HM, Beauchamp M, Yeh MM, Kowdley KV. Hepatic 
reticuloendothelial system cell iron deposition is associated with increased apoptosis in 
nonalcoholic fatty liver disease. Hepatology 2013. 
[75] Chen L, Xiong S, She H, Lin SW, Wang J, Tsukamoto H. Iron causes interactions of TAK1, 
p21ras, and phosphatidylinositol 3-kinase in caveolae to activate IkappaB kinase in hepatic 
macrophages. J Biol Chem 2007;282(8):5582-8. 
[76] Handa P, Morgan-Stevenson V, Maliken BD, Nelson JE, Washington S, Westerman M, et 
al. Iron overload results in hepatic oxidative stress, immune cell activation, and 
hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese 
mice. Am J Physiol Gastrointest Liver Physiol 2016;310(2):G117-27. 
[77] Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, Watters DJ, et al. Ferritin 
functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear 
factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 2009;49(3):887-
900. 
[78] Tan TC, Crawford DH, Jaskowski LA, Subramaniam VN, Clouston AD, Crane DI, et al. 
Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse 
model of alcohol and high-fat diet-induced liver injury. Lab Invest 2013;93(12):1295-312. 
[79] Graham RM, Chua AC, Carter KW, Delima RD, Johnstone D, Herbison CE, et al. Hepatic 
iron loading in mice increases cholesterol biosynthesis. Hepatology 2010;52(2):462-71. 
[80] George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased 
hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased 
fibrosis. Gastroenterology 1998;114(2):311-8. 
[81] Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, et al. 
Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk 
for nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96(8):2448-55. 
[82] Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, et al. Non-
alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in 
non-alcoholic steatohepatitis. Journal of hepatology 1999;31(3):421-9. 
[83] Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, et al. Relationship 
between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty 
liver disease. Hepatology 2011;53(2):448-57. 
168 
 
[84] Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, Cummings OW, et al. Design and 
validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 
2005;41(6):1313-21. 
[85] Cildir G, Akincilar SC, Tergaonkar V. Chronic adipose tissue inflammation: all immune cells 
on the stage. Trends Mol Med 2013;19(8):487-500. 
[86] Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and 
disease. Nature 2013;496(7446):445-55. 
[87] Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, 
fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. 
Nat Med 2009;15(8):930-9. 
[88] Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al. CD8+ effector T 
cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat 
Med 2009;15(8):914-20. 
[89] Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 
2006;444(7121):881-7. 
[90] Wlazlo N, van Greevenbroek MM, Ferreira I, Jansen EH, Feskens EJ, van der Kallen CJ, et 
al. Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: 
the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 
2013;36(2):309-15. 
[91] Pihan-Le Bars F, Bonnet F, Loreal O, Le Loupp AG, Ropert M, Letessier E, et al. Indicators 
of iron status are correlated with adiponectin expression in adipose tissue of patients with 
morbid obesity. Diabetes Metab 2015. 
[92] Rumberger JM, Peters T, Jr., Burrington C, Green A. Transferrin and iron contribute to the 
lipolytic effect of serum in isolated adipocytes. Diabetes 2004;53(10):2535-41. 
[93] Chirumbolo S, Rossi AP, Rizzatti V, Zoico E, Franceschetti G, Girelli D, et al. Iron primes 
3T3-L1 adipocytes to a TLR4-mediated inflammatory response. Nutrition 2015;31(10):1266-
74. 
[94] Deugnier Y, Turlin B. Pathology of hepatic iron overload. Seminars in liver disease 
2011;31(3):260-71. 
[95] McLaren GD, Gordeuk VR. Hereditary hemochromatosis: insights from the 
Hemochromatosis and Iron Overload Screening (HEIRS) Study. Hematology Am Soc 
Hematol Educ Program 2009:195-206. 
169 
 
[96] Hernaez R, Yeung E, Clark JM, Kowdley KV, Brancati FL, Kao WH. Hemochromatosis 
gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Journal 
of hepatology 2011;55(5):1079-85. 
[97] Nelson JE, Brunt EM, Kowdley KV, Nonalcoholic Steatohepatitis Clinical Research N. 
Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease 
patients with C282Y HFE mutations. Hepatology 2012;56(5):1730-40. 
[98] Valenti L, Rametta R, Dongiovanni P, Motta BM, Canavesi E, Pelusi S, et al. The A736V 
TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver 
disease. PLoS One 2012;7(11):e48804. 
[99] Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, 
Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-
cell function. Diabetes 2002;51(4):1000-4. 
[100] Facchini FS. Effect of phlebotomy on plasma glucose and insulin concentrations. Diabetes 
Care 1998;21(12):2190. 
[101] Houschyar KS, Ludtke R, Dobos GJ, Kalus U, Broecker-Preuss M, Rampp T, et al. Effects 
of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a 
randomized clinical trial. BMC Med 2012;10:54. 
[102] Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant 
patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 
2002;122(4):931-9. 
[103] Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, et al. A 
randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and 
hyperferritinemia. World J Gastroenterol 2014;20(11):3002-10. 
[104] Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, et al. The impact of 
phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. 
Hepatology 2015;61(5):1555-64. 
[105] Adams PC. The (II)logic of iron reduction therapy for steatohepatitis. Hepatology 
2015;62(3):668-70. 
[106] Senates E, Yilmaz Y, Colak Y, Ozturk O, Altunoz ME, Kurt R, et al. Serum levels of 
hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolic syndrome 
and related disorders 2011;9(4):287-90. 
170 
 
[107] Dongiovanni P, Lanti C, Gatti S, Rametta R, Recalcati S, Maggioni M, et al. High fat diet 
subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS One 
2015;10(2):e0116855. 
[108] Hoki T, Miyanishi K, Tanaka S, Takada K, Kawano Y, Sakurada A, et al. Increased 
duodenal iron absorption through up-regulation of divalent metal transporter 1 from 
enhancement of iron regulatory protein 1 activity in patients with nonalcoholic 
steatohepatitis. Hepatology 2015;62(3):751-61. 
[109] Otogawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, et al. 
Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, 
inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the 
pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007;170(3):967-80. 
[110] Wang H, Li H, Jiang X, Shi W, Shen Z, Li M. Hepcidin is directly regulated by insulin and 
plays an important role in iron overload in streptozotocin-induced diabetic rats. Diabetes 
2014;63(5):1506-18. 
[111] Coimbra S, Catarino C, Santos-Silva A. The role of adipocytes in the modulation of iron 
metabolism in obesity. Obes Rev 2013. 
[112] Siddique A, Nelson JE, Aouizerat B, Yeh MM, Kowdley KV, Network NCR. Iron deficiency 
in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, 
and low serum hepcidin. Clin Gastroenterol Hepatol 2014;12(7):1170-8. 
[113] Fleming DJ, Tucker KL, Jacques PF, Dallal GE, Wilson PW, Wood RJ. Dietary factors 
associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. 
Am J Clin Nutr 2002;76(6):1375-84. 
[114] Bowers K, Yeung E, Williams MA, Qi L, Tobias DK, Hu FB, et al. A prospective study of 
prepregnancy dietary iron intake and risk for gestational diabetes mellitus. Diabetes Care 
2011;34(7):1557-63. 
[115] Qiu C, Zhang C, Gelaye B, Enquobahrie DA, Frederick IO, Williams MA. Gestational 
diabetes mellitus in relation to maternal dietary heme iron and nonheme iron intake. 
Diabetes Care 2011;34(7):1564-9. 
[116] Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL, et al. How 
common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local 
differences? J Gastroenterol Hepatol 2007;22(6):788-93. 
171 
 
[117] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural 
history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. 
Alimentary pharmacology & therapeutics 2011;34(3):274-85. 
[118] Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of 
hemochromatosis: 2011 practice guideline by the American Association for the Study of 
Liver Diseases. Hepatology 2011;54(1):328-43. 
[119] Chen H, Su T, Attieh ZK, Fox TC, McKie AT, Anderson GJ, et al. Systemic regulation of 
Hephaestin and Ireg1 revealed in studies of genetic and nutritional iron deficiency. Blood 
2003;102(5):1893-9. 
[120] Fuqua BK, Lu Y, Darshan D, Frazer DM, Wilkins SJ, Wolkow N, et al. The multicopper 
ferroxidase hephaestin enhances intestinal iron absorption in mice. PLoS One 
2014;9(6):e98792. 
[121] Leavens KF, Birnbaum MJ. Insulin signaling to hepatic lipid metabolism in health and 
disease. Crit Rev Biochem Mol Biol 2011;46(3):200-15. 
[122] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis 
model assessment: insulin resistance and beta-cell function from fasting plasma glucose 
and insulin concentrations in man. Diabetologia 1985;28(7):412-9. 
[123] Rong Y, Bao W, Rong S, Fang M, Wang D, Yao P, et al. Hemochromatosis gene (HFE) 
polymorphisms and risk of type 2 diabetes mellitus: a meta-analysis. Am J Epidemiol 
2012;176(6):461-72. 
[124] Huang J, Jones D, Luo B, Sanderson M, Soto J, Abel ED, et al. Iron overload and diabetes 
risk: a shift from glucose to Fatty Acid oxidation and increased hepatic glucose production 
in a mouse model of hereditary hemochromatosis. Diabetes 2011;60(1):80-7. 
[125] Sonnweber T, Ress C, Nairz M, Theurl I, Schroll A, Murphy AT, et al. High-fat diet causes 
iron deficiency via hepcidin-independent reduction of duodenal iron absorption. J Nutr 
Biochem 2012;23(12):1600-8. 
[126] Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol 
Diabetes 1999;107(2):119-25. 
[127] Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the 
indifferent? Diabetes 2005;54 Suppl 2:S114-24. 
172 
 
[128] Laine F, Ruivard M, Loustaud-Ratti V, Bonnet F, Cales P, Bardou-Jacquet E, et al. 
Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A 
randomized controlled study in 274 patients. Hepatology 2017;65(2):465-74. 
[129] Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, et al. 
Complex non-invasive fibrosis models are more accurate than simple models in non-
alcoholic fatty liver disease. J Gastroenterol Hepatol 2011;26(10):1536-43. 
[130] van Rijnsoever M, Galhenage S, Mollison L, Gummer J, Trengove R, Olynyk JK. 
Dysregulated Erythropoietin, Hepcidin, and Bone Marrow Iron Metabolism Contribute to 
Interferon-Induced Anemia in Hepatitis C. J Interferon Cytokine Res 2016;36(11):630-4. 
[131] Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, et al. Association 
between Serum Hepcidin-25 and Primary Resistance to Erythropoiesis Stimulating Agents 
in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. LID - 
10.1111/nep.12815 [doi]. 2016(1440-1797 (Electronic)). 
[132] Litton E, Baker S, Erber WN, Farmer S, Ferrier J, French C, et al. Intravenous iron or 
placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial : 
A randomized trial of IV iron in critical illness. 2016(1432-1238 (Electronic)). 
[133] House MJ, Gan EK, Adams LA, Ayonrinde OT, Bangma SJ, Bhathal PS, et al. Diagnostic 
performance of a rapid magnetic resonance imaging method of measuring hepatic 
steatosis. PLoS One 2013;8(3):e59287. 
[134] St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. 
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic 
resonance. Blood 2005;105(2):855-61. 
[135] Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M. Effect of metformin 
therapy on plasma adiponectin and leptin levels in obese and insulin resistant 
postmenopausal females with type 2 diabetes. Georgian Med News 2007(145):52-5. 
[136] Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of 
adipose tissue insulin resistance on metabolic parameters and liver histology in obese 
patients with nonalcoholic fatty liver disease. Hepatology 2012;55(5):1389-97. 
[137] Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance 
testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22(9):1462-70. 
[138] Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early 
hemochromatosis and determination of the critical iron level associated with fibrosis. 
Hepatology 1986;6(1):24-9. 
173 
 
[139] Pippard MJ. Measurement of iron status. Prog Clin Biol Res 1989;309:85-92. 
[140] Ryan JD, Armitage AE, Cobbold JF, Banerjee R, Borsani O, Dongiovanni P, et al. Hepatic 
iron is the major determinant of serum ferritin in NAFLD patients. Liver Int 2018;38(1):164-
73. 
[141] Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, et al. Increased adipose tissue 
expression of hepcidin in severe obesity is independent from diabetes and NASH. 
Gastroenterology 2006;131(3):788-96. 
[142] Green A, Basile R, Rumberger JM. Transferrin and iron induce insulin resistance of glucose 
transport in adipocytes. Metabolism 2006;55(8):1042-5. 
[143] Casey JL, Hentze MW, Koeller DM, Caughman SW, Rouault TA, Klausner RD, et al. Iron-
responsive elements: regulatory RNA sequences that control mRNA levels and translation. 
Science 1988;240(4854):924-8. 
[144] Wang ZV, Deng Y, Wang QA, Sun K, Scherer PE. Identification and characterization of a 
promoter cassette conferring adipocyte-specific gene expression. Endocrinology 
2010;151(6):2933-9. 
[145] Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. The iron exporter 
ferroportin/Slc40a1 is essential for iron homeostasis. Cell metabolism 2005;1(3):191-200. 
[146] Brunt EM. Nonalcoholic fatty liver disease: What the pathologist can tell the clinician. 
Digestive Diseases 2012;30(SUPPL. 1):61-8. 
[147] Britton L, Jaskowski L, Bridle K, Santrampurwala N, Reiling J, Musgrave N, et al. 
Heterozygous Hfe gene deletion leads to impaired glucose homeostasis, but not liver injury 
in mice fed a high-calorie diet. Physiol Rep 2016;4(12). 
[148] Xirouchaki CE, Mangiafico SP, Bate K, Ruan Z, Huang AM, Tedjosiswoyo BW, et al. 
Impaired glucose metabolism and exercise capacity with muscle-specific glycogen 
synthase 1 (gys1) deletion in adult mice. Mol Metab 2016;5(3):221-32. 
[149] Bridle KR, Sobbe AL, de Guzman CE, Santrampurwala N, Jaskowski LA, Clouston AD, et 
al. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in 
evolving and established fibrosis in Mdr2(-)/(-) mice. Liver Int 2015;35(4):1451-63. 
[150] Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines 
macrophage localization and function in adipose tissue of obese mice and humans. J Lipid 
Res 2005;46(11):2347-55. 
174 
 
[151] Lickteig AJ, Fisher CD, Augustine LM, Cherrington NJ. Genes of the antioxidant response 
undergo upregulation in a rodent model of nonalcoholic steatohepatitis. J Biochem Mol 
Toxicol 2007;21(4):216-20. 
[152] Rishi G, Wallace DF, Subramaniam VN. Hepcidin: regulation of the master iron regulator. 
Biosci Rep 2015;35(3). 
[153] Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: 
diagnostic implications. Clin Chem 2011;57(12):1650-69. 
[154] Chung J, Kim MS, Han SN. Diet-induced obesity leads to decreased hepatic iron storage in 
mice. Nutrition research (New York, NY) 2011;31(12):915-21. 
[155] Wolfs MG, Gruben N, Rensen SS, Verdam FJ, Greve JW, Driessen A, et al. Determining 
the association between adipokine expression in multiple tissues and phenotypic features 
of non-alcoholic fatty liver disease in obesity. Nutr Diabetes 2015;5:e146. 
[156] Alkhouri N, Lopez R, Berk M, Feldstein AE. Serum retinol-binding protein 4 levels in 
patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2009;43(10):985-9. 
[157] Luo X, Hutley LJ, Webster JA, Kim YH, Liu DF, Newell FS, et al. Identification of BMP and 
activin membrane-bound inhibitor (BAMBI) as a potent negative regulator of adipogenesis 
and modulator of autocrine/paracrine adipogenic factors. Diabetes 2012;61(1):124-36. 
[158] Wabitsch M, Brenner RE, Melzner I, Braun M, Moller P, Heinze E, et al. Characterization of 
a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes 
Relat Metab Disord 2001;25(1):8-15. 
[159] Kohyama M, Ise W, Edelson BT, Wilker PR, Hildner K, Mejia C, et al. Role for Spi-C in the 
development of red pulp macrophages and splenic iron homeostasis. Nature 
2009;457(7227):318-21. 
[160] Ruelcke JE, Loo D, Hill MM. Reducing the cost of semi-automated in-gel tryptic digestion 
and GeLC sample preparation for high-throughput proteomics. J Proteomics 2016;149:3-6. 
[161] The UniProt C. UniProt: the universal protein knowledgebase. Nucleic Acids Res 
2017;45(D1):D158-D69. 
[162] Chen D, Shah A, Nguyen H, Loo D, Inder KL, Hill MM. Online quantitative proteomics p-
value calculator for permutation-based statistical testing of peptide ratios. J Proteome Res 
2014;13(9):4184-91. 
175 
 
[163] Schierwagen R, Maybuchen L, Zimmer S, Hittatiya K, Back C, Klein S, et al. Seven weeks 
of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-
alcoholic steatohepatitis with liver fibrosis. Sci Rep 2015;5:12931. 
[164] Oslowski CM, Urano F. Measuring ER stress and the unfolded protein response using 
mammalian tissue culture system. Methods Enzymol 2011;490:71-92. 
[165] Kim DK, Lee J, Kim SR, Choi DS, Yoon YJ, Kim JH, et al. EVpedia: a community web 
portal for extracellular vesicles research. Bioinformatics 2015;31(6):933-9. 
[166] Chiba T, Nakazawa T, Yui K, Kaneko E, Shimokado K. VLDL induces adipocyte 
differentiation in ApoE-dependent manner. Arterioscler Thromb Vasc Biol 2003;23(8):1423-
9. 
[167] Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N. Apolipoprotein E 
knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid 
Res 2009;50 Suppl:S178-82. 
[168] Huang ZH, Reardon CA, Getz GS, Maeda N, Mazzone T. Selective suppression of adipose 
tissue apoE expression impacts systemic metabolic phenotype and adipose tissue 
inflammation. J Lipid Res 2015;56(2):215-26. 
[169] Caselli RJ, Beach TG, Knopman DS, Graff-Radford NR. Alzheimer Disease: Scientific 
Breakthroughs and Translational Challenges. Mayo Clin Proc 2017;92(6):978-94. 
[170] Castellani RJ, Moreira PI, Perry G, Zhu X. The role of iron as a mediator of oxidative stress 
in Alzheimer disease. Biofactors 2012;38(2):133-8. 
[171] Xu H, Perreau VM, Dent KA, Bush AI, Finkelstein DI, Adlard PA. Iron Regulates 
Apolipoprotein E Expression and Secretion in Neurons and Astrocytes. J Alzheimers Dis 
2016;51(2):471-87. 
[172] Locatelli I, Sutti S, Jindal A, Vacchiano M, Bozzola C, Reutelingsperger C, et al. 
Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in 
mice. Hepatology 2014;60(2):531-44. 
[173] Parapia LA. History of bloodletting by phlebotomy. Br J Haematol 2008;143(4):490-5. 
[174] Fischer-Posovszky P, Newell FS, Wabitsch M, Tornqvist HE. Human SGBS cells - a unique 
tool for studies of human fat cell biology. Obes Facts 2008;1(4):184-9. 
[175] Ong SE, Mann M. A practical recipe for stable isotope labeling by amino acids in cell 
culture (SILAC). Nat Protoc 2006;1(6):2650-60. 
176 
 
 
 
